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Introduction: The Harvard Medical Practice (Study II) identified medications as the most 
common source of injury resulting from medical care. The subsequent Institute Of Medicine 
(IOM; now renamed as the National Academy of Medicine) report “To Err Is Human: 
Building a Safer Health System” brought considerable national and international attention to 
the problem of errors in hospitals. Given that medication errors and error-related adverse drug 
events (ADEs) are overall much more common in ambulatory care, primary care and home 
(henceforth collectively referred to as community) settings than in hospital settings, it is also 
important to focus on these hitherto neglected sectors. There is, however, very limited 
research on the frequency of medication errors and error-related ADEs in Saudi Arabia’s 
(SA’s) community settings.  
Aims: To estimate the incidence and prevalence of medication errors and associated ADEs in 
community settings, and to identify the risk factors for these outcomes, with an emphasis on 
those that are potentially modifiable. 
Methods:  I have undertaken a phased programme of work. In Phase 1, I undertook a 
systematic review of the existing research on the epidemiology of medication errors and error-
related ADEs, and their risk factors in community settings. Phase 2 was a feasibility study to 
identify the ambulatory settings and electronic database, evaluate the feasibility of data 
extraction and data collection from electronic health records (EHRs) and to check the 
availability and assess the reliability of key outcome measures. Phase 3 was a pilot, 
retrospective cohort study using clinically important errors in medicine management that were 
extracted from EHRs. This third phase also focused on assessing the sample size calculations 
for undertaking a larger cohort study. A random sample of 200 records was selected; a list of 
all patients who visited the Family Medicine department two weeks before data collection was 
generated. Each record was given a code number and EHRs were selected using a random 
number table that was generated using the ‘simple random sample without replacement’ 
function in STATA. The final study, Phase 4 was a larger retrospective cohort study to 
estimate the period prevalence of clinically important errors in medicine management, 
identify risk factors associated with patients at risk of clinically important errors in medicine 
management and to compare the estimates from this SA-based study with QRESEARCH 
analysis of secular trends in the United Kingdom (UK). A random sample of 2000 records 
was selected using a similar process to Phase 3. All research participants were adults aged 
 2 
≥18 years. Phases 2-4 were based on the methods used by Avery et al. (2012).  Phases 3 and 4 
were undertaken in randomly selected samples of 200 and 2000 patients, respectively. 
Statistical analyses in Phases 3 and 4 were undertaken using STATA (version 14) statistical 
software.   
Results: For Phase 1, I identified a total of 15,302 potentially eligible studies, of which 60 
met the inclusion criteria: 53 studies focused on medication errors, three on error-related 
adverse events and four on risk factors only. None of these studies was undertaken in SA. The 
prevalence of prescribing errors was reported in 46 studies with prevalence estimates ranging 
widely from 2.0-94.0%. Inappropriate prescribing was the most common type of error 
reported. 
Only one study reported the prevalence of monitoring errors, finding that incomplete 
therapeutic/safety laboratory-test monitoring occurred in 73.0% of patients. The incidence of 
preventable ADEs was estimated as 15/1000 person-years, the prevalence of drug-drug 
interaction (DDI)-related adverse drug reactions (ADR) as 7.0% and the prevalence of 
preventable ADE as 0.4%. A number of patients, healthcare professionals and medication-
related risk factors were identified, including the number of medications used by the patient, 
increased patient age (≥75 years), the number of multi-morbidities, the use of anticoagulants, 
cases where more than one physician was involved in patients’ care and care being provided 
by family physicians/general practitioners (GP). 
 
For Phase 2, I selected the EHRs of King Faisal Specialist Hospital & Research Centre 
(KFSH&RC) Family Medicine and Polyclinics, Riyadh, SA and the findings confirmed that 
the pilot study was feasible and likely to yield random samples. More specifically, all 
information needed for the outcome measures were available in one electronic system and 
were useable in Phases 3 and 4.  
In Phase 3, a random sample of 200 records was selected. The overall period prevalence of 
patients with at least one medication error over 15 months was 10.0% (95% confidence 
interval (CI) 5.8 to 14.2). The overall period prevalence of medication errors over 15 months 
was 16.0% (95% CI 8.2 to 23.8). Risk factors that significantly predicted the overall patients 
at risk of medication errors were patient’s age of ≥65 years and using over-the-counter (OTC) 
medications. 
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In Phase 4, a random sample of 2000 records was selected using a similar process to Phase 3. 
The overall period prevalence of patients with at least one medication error over 15 months 
was 5.85% (95% CI 4.8 to 6.9). The overall period prevalence of medication errors over 15 
months was 8.1% (95% CI 6.5 to 9.7). The overall period prevalence estimate of the first 12 
clinically important errors in medicine management in the cohort study was more compared to 
the QRESEARCH analysis of secular trends. This may reflect the different types of healthcare 
services provided and the different methods of data extraction between both countries. Risk 
factors that significantly predicted the overall patients at risk of errors were patient’s age of 
≥65 years, male gender, Saudi nationality and taking five or more concurrent drugs 
(polypharmacy).  
In both Phases 3 and 4, the highest risk of prescribing errors was found to be for ‘Outcome 
2a: patients with asthma who had been prescribed a β-blocker’. For monitoring errors, the 
highest risk was in ‘Outcome 7: patients receiving lithium for at least three months who had 
not received a recorded check of their lithium concentrations in the previous three months’. 
 
Conclusions: This is the first study to investigate medication errors in community settings in 
SA. This research has revealed that clinically important medication errors are common with a 
period prevalence estimate of 8.1% and are seen both in relation to the prescribing and 
monitoring of drugs. Future research should replicate this work in different community 
contexts in SA and other countries, in order to investigate in greater depth the error-related 




Medication errors are mistakes made during the patient’s treatment stages, starting from the 
time the doctor chooses and writes the prescribed drug until the drug is dispensed by the 
pharmacist to the patient. In addition, patients/or their caregivers sometimes, make mistakes 
in the medication they brought themselves. Patient’s treatment stage is complex. Mistakes can 
happen at any stage along this complex pathway. Sometimes patients can be harmed by these 
mistakes. When a medication error leads to harm, it is called a preventable adverse drug event 
(ADE). ADEs have been identified as one of the most common causes of preventable error-
related harm in hospital care. It is important to also study the safety of the drugs consumed 
outside the hospital because more medications are very frequently used outside of hospitals 
and with less supervision compared to inside the hospital.  
In Saudi Arabia (SA), only a limited number of research studies on medication errors have 
been conducted outside of hospital settings, i.e. in the community. I, therefore, aimed to 
estimate how common are medication errors and preventable ADEs that occur in community 
settings in SA and understand their risk factors. 
 
I undertook a phased programme of work. In Phase 1, I reviewed the literature on existing 
research on the rates of occurrence of medication errors and preventable ADEs, and the 
factors that increase the chance of developing those errors in community settings. The 
literature review also helped me to identify studies that could serve as a template for my 
fieldwork in SA. After reviewing this body of literature, I selected and used a list of 21 pre-
defined clinically important medication errors in the following research phases based on the 
methods used by Avery and colleagues (2012). Phase 2 involved a study to choose the 
ambulatory settings and electronic database and to measure the ability to successfully 
complete the next two phases of work. Phase 3 was a pilot or small scale study using the list 
of predefined medication errors. Information from electronic health records (EHRs) was 
extracted, in order to focus on assessing the sample size calculations for undertaking a larger 
cohort study. Finally, Phase 4 was a larger cohort study to look at the rate of occurrence of 
medication errors in a community setting. 
 
The literature review revealed a very wide variation in the medication errors and error-related 
adverse events rates that were reported in studies; this variation may have been due to the 
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different populations studied, the different study designs and different outcomes. This review 
identified important limitations in these studies, as well as gaps in the literature on this topic. 
For Phase 2, I selected the outpatient clinic in King Faisal Specialist Hospital & Research 
Centre (KFSH&RC), Riyadh, SA and found that it was feasible to extract and collect the 
research data from that source. I was able to frame the method of sampling and I was able to 
successfully complete the next two phases. A pilot study conducted in Phase 3 showed that 
the prevalence rate was 10% or in other words, a total of 10 outpatients in 100 patients may 
experience at least one medication error during the study period. A patient’s age ≥65 years 
and using medication the patients brought for themselves increased the chances of medication 
errors. Therefore, I continued to Phase 4, cohort study, which showed that the prevalence rate 
was 6% meaning on average 6 outpatients in 100 patients experienced at least one medication 
error during the study period. A patient’s age of ≥65 years, male patients, Saudi nationality 
and using five or more drugs were all factors identified to increase the chance of patients 
experiencing a medication error. 
 
In conclusion, this is the first study looking at medication errors in community settings in SA. 
This study shows that clinically important medication errors are common in SA. These 
findings now need to be built on with a focus on developing and evaluating interventions to 
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Chapter One: Medication Errors and Adverse Drug Events 
1.1 Introduction   
The 1990 Harvard Medical Practice (Study II) identified medication as the most common 
source of injury resulting from medical care.(1) The subsequent report from the Institute Of 
Medicine (IOM; now named as the National Academy of Medicine), titled “To Err Is Human: 
Building a Safer Health System” brought considerable national and international attention to 
the problem of errors in hospitals in 2000.(2) In the report, the authors estimated that in the 
United States of America (USA) some 44,000-98,000 deaths per year were caused by medical 
errors.(2) Of those deaths, approximately 7,000 were believed to be the result of medication 
errors occurring either in or outside of hospital.(2) The World Health Organization (WHO) 
has subsequently identified medication errors as one of the key areas on which to focus 
attention in order to enhance the safety of ambulatory, primary care, and home settings.(3)  
In this chapter, I will introduce the concepts of: a) medication errors, b) error-related adverse 
drug events (ADEs) or preventable ADEs, and c) adverse drug reactions (ADRs). The 
definitions of these terms are summarised in Table 1-1. Medication error is the inadvertent 
inappropriate use of a drug that may or may not result in harm,(4) while ADEs have been 
defined by Bates et al. (1990) as an “injury resulting from medical intervention related to a 
drug”.(5) The majority of ADEs are predictable and dose dependent while a smaller number 
of ADEs are unpredictable and idiosyncratic or an allergic reaction to a drug; in other words 
ADRs.(6) ADR or non-preventable reaction “is an injury due to a medication where there is 
no error in the medication process”.(7) My focus is confined to medication errors and error-
related ADEs or preventable ADEs since as ADRs occur with the appropriate use of a drug 
they are not due to, or the result of, an error. Table 1-1 below lists the detailed definitions of 
ADE, ADR, and medication error. 
Medication errors and error-related ADEs are common and are responsible for considerable 
patient harm.(8) In 2007 in the USA, an estimated one medication error per hospitalised 
patient occurred daily(9) and 1.5 million preventable ADE occurred annually.(9) More 
specifically, ADEs can lead to morbidity, hospitalisation, increased healthcare costs and, in 
some cases, death.(8, 10) The cost of drug-related morbidity and mortality has been estimated 
to be $177.4 billion annually in the USA alone.(11) Since the release of “To Err Is Human: 
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Building a Safer Health System” by the IOM,(2) which focused on acute care settings, most 
patient safety research has been conducted in hospital settings.(12, 13) International and 
national policy drivers are however for patients to be increasingly managed in ambulatory, 
primary care and home settings, in order to realise the goals of more accessible, patient-
centred and efficient healthcare.(14) In addition, given that the shift from health worker 
management to self-management, most medications are now consumed outside of hospital 
settings, with the patients or a family member in charge of medications administration. 
Therefore, a more substantial understanding of error occurrence in community care contexts 




























 Definition  
Adverse drug 
event (ADE) 
“Injury resulting from medical intervention related to a drug”(5) 
 
As defined by the WHO, an ADE is an event that is “noxious and 
unintended and occurs at doses used in man for prophylaxis, 
diagnosis, therapy, or modification of physiologic functions”. Note 
that this definition does not include mistakes in prescribing, 
providing, or administering drugs unless injury results.(15)  
 Preventable ADE:  
1- “Is harm caused by the use of a drug as a result of an error. 
Medication related harm due to error” National Coordinating Council 
for Medication Error Reporting and Prevention (NCC-MERP).(16) 
 
2- “Is an injury that is the result of an error at any stage in the 
medication use—for example, a coma due to an overdose of a 
sedative”(7) 
 
Non-preventable ADE:  
1- “Is drug-induced harm occurring with appropriate use of 
medication. Medication related harm not due to error ”(NCC-
MERP).(16) 
2- “Is an injury due to a medication where there is no error in the 
medication process—for example, an allergic reaction in a patient 
not previously known to be allergic to the medication. These are 
also known as adverse drug reactions, or non-preventable 
reactions due to side effects or allergic reactions”(7) 
3- Adverse drug reaction (ADR) “Response to a drug which is 
noxious and unintended and which occurs at doses normally used 
in man for prophylaxis, diagnosis, or therapy of disease or for the 
modification of physiologic function”. (WHO, 2002) 
Medication error  “Any preventable event that may cause or lead to inappropriate 
medication use or patient harm, while the medication is in the control 
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 Definition  
of the health care professional, patient, or consumer. Such events may 
be related to professional practice, health-care products, procedures, 
and systems, including prescribing; order communication; product 
labelling, packaging, and nomenclature; compounding; dispensing; 
distribution; administration; education; monitoring; and use”. (NCC-
MERP)(17)  
Table 1-1. Definitions of adverse drug event, adverse drug reaction and medication 
error. 
 
1.2 Relationship between medication errors and adverse drug events  
Not all medication errors harm the patient. Studies have found that only between 1-10% of 
medication errors contribute to patient harm.(2, 6, 18, 19)  Figure 1-1 shows the relationship 
between medication errors and ADEs.  
If an ADE results from an error, it is described as a ‘preventable ADE’; if an ADE does not 





Figure 1-1. Relationship between medication errors and adverse drug events.(7) 
 
1.3 Medication error types 
Medication errors can occur at any point in the medicines’ management process i.e. during 
prescribing, transcription, dispensing, administering and monitoring.(7, 20) Medication errors 
also occur when transferring patients between care settings.(9) 
A series of studies has identified that medication errors can occur in the following settings:  
• Hospital [Bates et al. (1995) and Kaushal et al. (2001)](6, 21) 
• Outpatient [Gandhi et al. (2000)](22)  
• Ambulatory and primary care [Gandhi et al. (2003)](23)  
• Nursing and home care [Field et al. (2001)](24)  
• Transition of care from hospital to home [Martin (2012)](25)  
• After discharge [Forster (2005) and Kripalani (2012)](26, 27) 
• Home or community dwelling [Sorensen et al. (2006) and Walsh (2008)].(10, 28) 
My research focus is on ambulatory, primary care and home sites (henceforth collectively 
referred to as community) settings. 
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1.4 Medication error causes  
James Reason proposed the “Swiss Cheese Model” of system accidents. This model explains 
how human and/or organisational structures can potentially prevent, or cause, medication 
errors. According to this model, a series of barriers are in place to prevent errors from causing 
harm to humans. However, each barrier has its unintended and random weaknesses, or holes, 
just like Swiss cheese.(29)  
In a landmark systems analysis of ADEs by Leape et al. (1995)(30) the following factors were 
identified as proximal causes of medication errors: “lack of knowledge of the drug, lack of 
information about the patient, rule violations, slip and memory lapses, transcription errors, 
faulty drug identity checking, faulty interaction with other services, faulty dose checking, 
infusion pump and parenteral delivery problem, inadequate monitoring, drug stocking and 
delivery problems, preparation errors, and lack of standardization”,(30) which occur across 
multiple stages. The term proximal cause is defined as “the apparent reason the error was 
made”. A single proximal cause can result in a variety of types of errors. Conversely, one type 
of error can result from several different proximal causes. 
Figure 1-2Figure 1-2 below is a model offered by Avery et al. (2002),(20) of why and how 
adverse events occur in primary care. The model, as a whole, shows that different types of 









1.5 Medication error risk factors and outcomes 
The different risk factors that increase the risk of medication error occurrence include the 
following: lack of knowledge, age, polypharmacy (which can be defined as five or more 
concurrent drugs)(31) or using multiple medications, cognitive status, using high alert 
medication which are “drugs that bear a heightened risk of causing significant patient harm 
when used in error”(32) or medication with narrow therapeutic index, the latter being “drugs 
with small differences between therapeutic and toxic doses”.(33)  
The outcomes of medication errors are several, including patient harm, which may manifest as 
patient discomfort, side-effects, and a temporary or permanent decline in health status, 
increase in emergency department (ED) attendance, outpatient clinic visit, hospital admissions 
and death.(2, 7, 34) Children and adults who suffer from multiple long-term conditions with 
associated complex drug regimens are particularly at risk.(35-37) 
1.6 Chapter summary 
Many patients are inadvertently and unintentionally harmed by the medical care they receive. 
Medication errors are a particularly common cause of iatrogenic harm. These errors can occur 
at any stage of the medicines’ management process. The majority of research conducted in 
this area has been undertaken in hospitals in European, North American, and Australian 
contexts with a smaller number of studies in community settings and fewer still in the Middle 
Eastern region.  
The available evidence suggests that most of these medication errors are preventable. 
Understanding the underlying causes of such errors can help in both error prevention and 
improving medication management processes. 
The following chapter will give a brief overview of the Saudi healthcare system, as well as 
some wider context to the country. 
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Chapter Two: Saudi Arabia: a Country Profile 
2.1 Introduction 
The original work in this PhD was undertaken in Riyadh, the capital and largest city of Saudi 
Arabia (SA).  In order to contextualise this work, I will in this chapter provide an overview of 
both the healthcare system of SA and the medical services available in the ambulatory setting. 
To achieve this goal, it is also important to consider aspects of SA culture and religious 
traditions that shape the nature of SA; particularly because SA, within the Arabian Peninsula 
in the Middle East is the birthplace of Islam. 
This chapter provides an insight into SA’s population, history, and economy and highlights 
how Islam shapes notions of health and the healthcare system. Aspects of the Saudi healthcare 
system that may have a bearing on medication safety will be explained in this chapter. These 
include the care provided by Saudi physicians to non-Saudi patients and by non-Saudi 
physicians to Saudi patients,(38) unrestricted access through community pharmacies to 
medications that are, in many other countries, not available over-the-counter (OTC),(39) and 
the problem of buying prescribed medication as non-prescribed medication in the community 
settings.(40) Considering these aspects during my data collection can help facilitate an 
understanding of patient practice and the risks of medication errors. 
SA is undertaking a major redevelopment of its healthcare system, moving from a primarily 
hospital-based system to a more integrated care system with a strong primary care-based 
health system. After the Alma-Ata Declaration, a ministerial decree was issued to establish 
Primary Healthcare (PHC) centres. The move to the PHC system resulted in an increase in the 
number of PHC centres and the improvement of free care provided, including preventive and 
curative services.(41) In recent years, SA has been progressively developing its PHC system 
to increase the availability and accessibility of its health services to the entire population. 
Given the dearth of global studies looking at medication error in the community, and the 
global and particular shift in SA from secondary and tertiary care to community-based care, 
the focus of my work is important and timely. I plan to do the first in-depth work looking at 
medication errors in Riyadh, the capital and largest city in SA.(41) 
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2.2 Geography  
SA is the largest nation in the Middle East, with a land area of about 2,250,000 square 
kilometres consisting mostly of desert. It shares a border with Iraq, Jordan, and Kuwait to the 
north, the Sultanate of Oman and Yemen to the south, the Bahrain, Persian Gulf, Qatar and 




                           
Figure 2-1. Map of SA.(42) 
 
2.3 History 
Prophet Mohammad peace be upon him (PBUH), who is believed by Muslims to be the 
Messenger of Allah (God), was born in Makkah, which is in the west of SA. His main 
objective was to call upon people to believe in monotheism and spread the message of Islam.  
Prophet Muhammad PBUH moved to the city of Madinah in 571 CE, where later the Hejri 
(lunar) Calendar was developed. Islam’s most sacred scripture is the Holy Qur’an (which the 




The history of the region was dominated by the rise and spread of the Ottoman Empire from 
the 13th Century onwards with increasing coalescing of different power bases occupying 
territories in the area including Najd, Hejaz, Hassa, Assir areas and North Yemen.  In 1745, 
Prince Muhammad bin Saud from the Najd and Sheikh Muhammad Ibn Abdul Wahab 
launched a religious movement calling for the purification of Islam by spreading the original 
message of Allah and Prophet Mohammed PBUH. 
With the flair-up of World War I, the British found neighbourhood partners in the Hijazi 
Hashemites and the Al Saud family, both eager to assert their freedom from the Ottomans; 
thereby aiming to ensure Arab independence.(43)   
After World War I, the Arabian Peninsula divided into two empires: Hashemite Emara of 
Makkah which related to Governor of Makkah Sharif, Husayn Ben Ali; and the Najd area.(43) 
The history of SA, in its current form as a state, began with its foundation in 1932 by King 
Abdulaziz Al Saud. After his death in 1953, his son King Saud succeeded him to the throne. 
With the rise of a new global economy requiring an energy source for expansion, the oil rich 
lands of SA provided the nation with not only economic prosperity, but also a great deal of 
political leverage in the international community. Despite the abundant oil wealth, 
extravagant spending ultimately led to governmental deficits and foreign borrowing in the 
1950s.(43) Since then, SA has initiated major reforms in education and health, as well as in 
science and technology related research. In January 2015, Salman bin Abdulaziz Al Saud 
(Prime Minister of SA and Custodian of the Two Holy Mosques) was crowned the seventh 
king of SA. 
2.4 Population 
As of 2018, SA’s population according to the Central Department of Statistics & Information 
(CDSI) of the Kingdom is 33,413,660 people with a total average life expectancy of 74.8 
years: 73.5 years for males and 76.1 years for females. Non-Saudi residents make up 37.8% of 












Table 2-1. Population estimates in SA, 2018.(44)  
 
2.5 Economy   
SA’s economy is oil based, with the nation holding 18% of the world’s petroleum 
reserves.(45) Since the discovery of oil in the 1930’s, SA has gone through a major and rapid 
transition from an agricultural subsistence land to a major economic power. SA is an 
important member of the Organization of the Petroleum Exporting Countries (OPEC).(45) 
The Saudi economy depends mainly on oil demand and is shaped by external pricing.(46) 
The oil and gas sectors account for about 50% of Gross Domestic Product (GDP), and about 
70% of export earnings.(45) The service sector accounts for 43% of the economy, while 
agriculture accounts for 5% of the economy.(47) The proven crude oil and natural gas 
reserves according to OPEC are 266,260 million barrels and 8,715 billion cubic metres, 
respectively.(45) The total expenditure on health was 4.7% of GDP, which equates to $2,466  
per person in 2014.(48)  
Understanding the global battle on oil and the reasons for the price reductions are beyond the 
scope of this PhD. However, recognising the impact that the shifting price will have on the 
national budget and consequently on the budget allocated for healthcare is important.  
Apart from petroleum, the Kingdom’s other natural resources include iron, gold, silver and 
copper. The national currency is the Saudi Riyal.(45)  
The rapidly growing Saudi populations, in addition to providing free services for all Saudi 
nationals, have been key factors in the rise of health expenditures in SA.(49)  
Age/Gender Male Female Total 
Young (< 15 years old) 4,186,398 4,034,482 8,220,880 
Adult (15-64 years old) 14,486,665 9,630,263 24,116,928 
Elderly (≥ 65 years old) 567,893 507,959 1,075,852 
Total 19,240,956 14,172,704 33,413,660 
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Table 2-2. Statistical data and indicators on Saudi human resources for 2018 (first 
quarter).(50) 
 
2.6 Health profile  
2.6.1 Disease burden 
According to the most recent data available, the leading causes of death in SA in 2016 were 
ischemic heart disease, road injury, cerebrovascular disease, chronic kidney diseases, lower 
respiratory tract infections, Alzheimer’s disease, diabetes mellitus, congenital defects, liver 
cancer and falls.(51) Table 2-3 shows the leading 10 causes of years lived with disability 
(YLD) in SA.(52)  
Table 2-3. Leading 10 causes of years lived with disability (YLD) with ratio of observed 
YLD to YLD expected on the basis of Socio-demographic Index in SA, 2016.(52) 
 




Employment rate (15 years and above) 93.9 96.6 79.0 
Unemployment rate (15 years and above) 6.1 3.4 21.0 
Saudi employment rate (15 years and above) 87.1 92.4 69.1 












































2.6.2 Health services  
SA provides the following health services: in-patient, emergency, outpatient care and primary 
care which include maternal and neonatal, haemodialysis and organ transplant, medical 
rehabilitation, medical commissions, mental health, nutrition, forensic medicine, dental 
services, ophthalmology, dedicated health services during pilgrimage (Hajj) season and home 
healthcare.(53, 54) Table 2-4 below shows developments in the healthcare services of SA 
over the last 90 years. 
Year  Evolution of services Number  
1926 Establishment of a Health Directorate in Jeddah and 
the opening of Ajyad Hospital in Mecca and Bab 
Shareef Hospital in Jeddah 
- 
1927 The Directorate was renamed the Directorate of 
General Health and Ambulances 
- 
1951 The Directorate became the Ministry of Health 
(MOH) 




40-fold increase in oil revenues led to much greater 
capital investment in healthcare infrastructure 
- 
1970 First 5-year National Development Plan was instituted 
by the Saudi government to promote development in a 
number of areas, including healthcare system(47) 
Increase in number of hospitals 
74 hospitals and 9,039 
beds 
1978 According to the Alma-Ata Declaration, the Saudi 
MOH decided to activate and develop the preventive 
health services by adopting the PHC approach(41) 
 
- 
1980 A ministerial decree was issued to establish PHC 
centres(41)  
Establish suitable premises for primary care 
throughout the country(41) 
- 
1985-1987 Real expansion of healthcare system begins  65 new hospitals and 




Year  Evolution of services Number  
1990 Increase in private health sector - 
2002 Increase in number of hospitals 331 hospitals and 
47,242 beds  
2009  82% of client visits to PHC centres MOH facilities 
(41) 
408 hospitals providing 
55,932 beds 
Table 2-4. The history and evolution of healthcare services in SA.(41, 47, 55) 
 
2.6.3 Health and Islam  
At this point in this background chapter on SA, it is important to consider religious issues and 
their impact on health. Islam is the national religion in SA, which as stated above, is based on 
the Holy Qur’an and Sunnah. Muslims believe that health, illness, and death all come from 
Allah. Though Islamic belief indicates that those who are unwell should seek medical advice, 
the belief that illnesses originate from Allah may lead some patients not to seek healthcare. 
Jabir ibn Abdullah (a prominent companion of Prophet Muhammad PBUH) reported Allah's 
Messenger Prophet Mohammad PBUH as saying: “There is a remedy for every malady, and 
when the remedy is applied to the disease it is cured with the permission of Allah, the Exalted 
and Glorious”.(56)  
The Islamic faith encourages regular exercise, moderate eating and drinking, no alcohol, 
personal cleanliness and other constructive practices that promote health and well-being such 
as meditation, fasting, and breastfeeding.(57) For example, as regards diet, Allah said in The 
Holy Qur’an “O children of Adam, take your adornment at every Mosque, and eat and drink, 
but be not excessive. Indeed, He likes not those who commit excess”. (Al-A’raf 31)  
The Prophet Mohammad PBUH encouraged asceticism in life and eating and drinking 
without excess as he said: “No man fills a container worse than his stomach. A few morsels 
that keep his back upright are sufficient for him. If he has to, then he should keep one-third 
for food, one-third for drink and one-third for his breathing”.(58)  
Muslins should fast in the month of Ramadan and are encouraged to fast on Monday and 
Thursday. Pork and alcohol are prohibited according to Islam. Islam discourages the use of 
any substances that may harm or change the body or disrupt the mind. 
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Even though exercise is not mentioned directly in the Holy Qur’an, Muslims are encouraged 
to follow Prophet Mohammad’s lifestyle and they will be rewarded for following him. 
Walking to the Mosque, starting the day early, the movement involved in the daily 
performance of prayer, the performance of Hajj and visiting Makkah (Umrah) are acts of the 
Prophet PBUH, which require physical effort and are considered good for health.  
Physical activities such as swimming, archery and horse riding were advocated by the Prophet 
Mohammad PBUH as being of value. He said, “Any action without the remembrance of Allah 
is either a diversion or heedlessness excepting four acts: Walking from target to target 
[during archery practice], training a horse, playing with one’s family, and learning to swim”.  
Although Islam advocates for moderation in diet, 28.7% of Saudi’s population (aged 15 years 
or older) have obesity resulting in the main from negative health-related behaviours.(59) 
Several factors are attributed to the increase in the incidence of obesity in SA. These factors 
include increasing sedentary lifestyles in both children and adults. In children, behaviours 
such as low levels of physical activity, spending large amounts of time watching television, 
sleeping for less than seven hours have all been found to be associated with obesity.(60) Saudi 
women have limited physical activity due, in part, to their dependence on house-maids. Food 
intake together with the pattern of diet have been identified as major reasons for obesity, 
including skipping breakfast, and the frequent use of soft drinks,(60) a high daily per capita 
energy supply and fat intake (during the period 1971-2005) was estimated to be present in 
60% of SA’s population.(60)  
Within the Qur’anic tradition particular attention to care of the body, especially cleanliness is 
emphasised. The Qur’an advocates washing all the exposed areas of the body before prayer, 
hands, feet, face, mouth, nostrils, etc., five times a day (ablution). Allah said in The Holy 
Qur’an “O you who have believed, when you rise to [perform] prayer, wash your faces and 
your forearms to the elbows and wipe over your heads and wash your feet to the ankles”. (Al-
Ma’idah 6) 
This supportive health activity is now emphasised globally in healthcare to prevent the spread 
of disease; in particular, hand washing and personal hygiene, are a core part of Islamic life. 
The Prophet Muhammad PBUH stressed brushing teeth as part of a Muslim’s daily routine. 
There is therefore value in understanding the way in which the health routines of those living 
in SA are shaped by Islamic beliefs and also value in understanding whether such 
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articulations of beliefs will be able to shed light on strategies to reduce medication errors, on 
self-management and on decision making in community settings.    
Islam and pilgrimage 
SA has a unique position in the Islamic world, as the nation contains the two holiest cities of 
Islam: Mecca and Medina. In the pilgrimage (Hajj) season, about two million pilgrims from 
all over the world perform the Hajj annually, which is a major challenge that requires planned 
and organised efforts to ensure adequate healthcare services are available.(41) Free medical 
services are provided during the Hajj.  
Islam and healthcare  
Islam has shaped the structural healthcare system in SA in several ways. Hospitals in SA have 
separate wards for men and women, a female nurse is assigned for the care of women when 
female patients are examined by a male physician, especially in the areas of obstetrics and 
gynaecology care.(61) If gender-specific care is impossible, a male nurse caring for women 
should always be joined by either a female staff member or one of the patient’s adult relatives. 
Islam  allows for Muslim healthcare professionals to manage or care.(57) If the patients can 
fast during Ramadan, healthcare providers can adjust the time of medication administration 
after breaking their fast. Drug products that contain alcohol or pork are not allowed to be 
given to Muslim patients.  
In hospitals, prayer areas and rest rooms should be available for the performing of personal 
ablutions; and the sound of the prayer should be heard inside and around hospitals.(61)  
2.7 Healthcare system 
Until the end of the 1970s, the health services in SA were predominantly curative focusing on 
treatment of existing health diseases. Then after the Alma-Ata Declaration 1978, a ministerial 
decree was issued to establish PHC centres, with an agreement to achieve ‘health for all by 
the year 2000’ as shown in Table 2-4Table 2-4.(38, 41)  Establishment of a PHC strategy and 
applying a referral system has helped to reduce the number of visits to outpatient clinics.(41) 
The most up-to-date rating of SA’s healthcare system according to the WHO was in the year 
2000, when it was rated at 26th of 190 health systems globally.(62)  
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Healthcare is provided free to all Saudi citizens by the MOH, which “is responsible for the 
country’s health system. It has a well-defined, decentralized organisational and 
administrative structure. Its functions include: strategic planning, formulating specific health 
policies, supervising all health service delivery programs, as well as monitoring and 
controlling all other health related activities”.(63) The MOH serves as a national health 
service for the Saudi population.(46)  
Foreign non-Saudi workers who represent 80.5% of the whole non-Saudi population 
according to the CDSI of the Kingdom in the first quarter of 2018,(50) can use the MOH 
facilities only in an emergency.(46) The majority of foreign workers and their dependents 
receive healthcare through employment-based or self-paid insurance.(55) Health insurance is 
provided through The Council of Cooperative Health Insurance, which was established in 
1999. This insurance facility is applicable to Saudis and non-Saudis in the private sector 
where their employers pay the health costs.(41) 
2.7.1 Pharmaceutical services 
Until 2007, the MOH was the primary pharmaceutical regulatory authority in SA. In 2007, via 
Royal Decree, the Saudi Food and Drug Authority (SFDA) took over the function of MOH. 
Established in 2003, the SFDA is responsible for developing and enforcing a regulatory 
system for the pharmaceutical sector.(64)  
Each hospital has pharmaceutical services with community pharmacies, which stock a full 
range of medicines included in the MOH Drug Formulary.(65) The governmental central 
medical stores are responsible for distribution of pharmaceuticals to the public and private 
sectors hospitals.(64) 
In all governmental health services, all Saudis can receive medicines free of charge.(64) Non-
Saudis are eligible for services and medications through their insurance policy.(64, 66) 
According to one report, about 48.8% prescription medications were dispensed without a 
prescription.(40) In April 2018, the MOH warned against selling antibiotics without 
prescriptions and stated “violators will face legal actions which include a fine of up to 100 
thousand riyals, abolition of the license and imprisonment for up to six months”.(67) In SA, a 
number of prescription medications are also available as OTC; the exceptions being narcotics, 
psychotropic substances and antibiotics. The Food and Drug Administration (FDA) defines 
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OTC drugs as “drugs that have been found to be safe and appropriate for use without the 
supervision of a health care professional such as a physician, and they can be purchased by 
consumers without a prescription”.(68) 
Currently in SA, there are nine public and private pharmacy schools. The first College of 
Pharmacy was established in King Saud University (KSU), Riyadh, in 1959. The pharmacy 
education in SA is a five year programme, for a Bachelor of Pharmacy degree.(69) 
2.7.2 Delivery of health services in Saudi Arabia 
Health services in SA are delivered and provided by three main sectors:(41) 
1. The government sector, the MOH, is the owner and provider of healthcare services, 
which account for over 62% of all inpatient care.   
2. Other governmental sector healthcare providers, which deliver primary, secondary, 
and tertiary care and which are funded outside the budget of the MOH include: 
• Armed Forces Hospital 
• King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh 
• KFSH&RC, Jeddah 
• Ministry of Education (school health units) 
• Ministry of Higher Education (University Hospitals)  
• Ministry of Interior Medical Services 
• National Guards Medical Services 
• Red Crescent Society 
• Royal Commission Hospitals in Jubail and Yanbu 
• University Hospitals and Medical Centres in the Kingdom. 
3. The private sector: provides all level of healthcare services and charges a fee. 
The government’s and other governmental sector healthcare providers have a decentralised 
healthcare delivery system.(70) The MOH is responsible for advising other government 
agencies and the private sector on ways to achieve the government’s health objectives.(63) 
Table 2-5 summarises the health resources in SA offered by the three healthcare sectors. 
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The total number of physicians in 2016 was 75,740, increasing to 82,375 physician in 
2017.(71) 
 
 Health resources 
at the MOH 
Health resources within 
other governmental 
sectors 
Health resources in the 





Free health services 
to all Saudi 




restricted to legal 




Employees and their 
families and dependents of 
the different governmental 
body  
The Ministry of Higher 
Education (University 
hospitals): 
A- Saudis: all are eligible 
B-non-Saudis: Eligibility 
is restricted to legal 
residents who are under 
individual affiliations. 
The Ministry of 
Education: government 
school children  
Red Crescent: emergency 
services  
All  
Finance  By the MOH By the Ministry of 
Finance through their 
respective ministries and 
agencies. 





and tertiary care 
through healthcare 
centres, hospitals, 
medical & dental 
Primary, secondary and 
tertiary care through 
healthcare centres, 
hospitals, medical & 
dental services, and 
Primary, secondary and 
tertiary care. 
Different private practices 




 Health resources 
at the MOH 
Health resources within 
other governmental 
sectors 
Health resources in the 





medical education and 
training programmes, and 
they also conduct health 
research in collaboration 
with other research centres 
health services according 
to the size of the practice. 
B- Dispensaries and pharmacies (total number) 
Pharmacies   8,114 private pharmacies, 
representing a rate of one 
pharmacy per 3,912 
individuals(54) 
C- Health manpower (total number: Saudi and non-Saudi)(71) 
Physicians  42,609 16,346 23,420 
Dentists 3,996 1,283 10,420 
Nurses 103,990 35,808 45,895 
Pharmacists 3,853 2,304 22,155 
Allied health 
professionals  
59,646 30,214 22,001 
Table 2-5. Health resources in SA by the three healthcare providers: Ministry Of 











2.7.3 Structure of healthcare levels in Saudi Arabia 
The MOH supplies and provides its public healthcare services at three levels: primary, 
secondary, and tertiary. In SA, there are 20 health regions, each led by a Regional Director 
General of Health Services who is directly responsible to the Deputy Minister of Health for 
Executive Affairs. The directorate is responsible for staff supervision and evaluation, 
recruitment and welfare, and training.(63) 
 
A. Primary healthcare (PHC) centres 
Primary care provides both preventive and curative healthcare services. Primary care involves 
“basic health services for all members of the community, and represents the first level of 
community contact with the health services”.(72)  
In recent years, SA has been progressively developing the primary care system to increase 
availability and accessibility of its health services to the entire population.(41)  
Data from a nationally representative multistage survey on healthcare utilisation of 
individuals aged 15 years or older, shows that most Saudi nationals do not use the PHC 
centres for general health examination despite their free cost and local availability.(73)  
Male and female healthcare providers are available in the PHC centres; the patient has the 
right to decide on having a male or female medical professional, and the waiting areas are 
separated between male and female patients.(74)  
The PHC centres emphasise an eight element approach to health: “educating the population 
concerning prevailing health problems and the methods of preventing and controlling them, 
provision of adequate supply of safe water and basic sanitation, promotion of food supply and 
proper nutrition, provision of comprehensive maternal and child healthcare, immunization of 
children against major communicable diseases, prevention and control of locally endemic 
diseases, appropriate treatment of common diseases and injuries, and provision of essential 
drugs”.(41) 
The number of the healthcare centres in the 20 regions that provide PHC from the MOH in 
SA was 2,259 centres in 2013,(53) which increased to 2,325 centres in 2016.(54) 
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For the referral system between different levels of care, the PHCs are linked to general 
hospitals, which, in turn, are linked to tertiary care in all MOH facilities. Primary care 
physicians fill in a predesigned standardised referral form with the relevant clinical and social 
information. Services in secondary care require a referral from a PHC, except in emergency 
cases.(75, 76) Patients can access secondary care directly through an ED. Services in tertiary 
care need a referral from PHC, except in emergency cases.(75) Patients cannot access tertiary 
care directly. 
The services provided by PHC centres are: “Maternal health, child health, immunization, 
management of chronic disease (e.g. hypertension and diabetes), dental health, provision of 
essential drugs, environmental health (e.g. water and sanitation), food hygiene, health 
education, disease control”.(63) 
B. Secondary healthcare (General hospitals)  
General hospitals accept patients who need additional advanced care via a process of referral 
from the PHC centre. In 2016, there were 470 general hospitals in SA with 70,844 beds.(54) 
Cases including cardiovascular diseases, obesity, diabetes, hypertension, and asthma and 
chronic obstructive pulmonary disease (COPD) are referred to these secondary healthcare 
facilities. Services include “Obstetrics and gynaecology, medical, surgical, paediatric, dental, 
emergency service. Some are affiliated to medical college for undergraduate and 
postgraduate clinical training. Antenatal care is provided at the primary care health centres 
with two referrals to the secondary care hospital, at 16-18 weeks for ultrasound scan and at 
34-36 weeks for a final check-up”.(63) 
C. Tertiary healthcare (Specialised hospitals)  
The government provides and finances tertiary care services. Cases that need more complex 
levels of care are transferred to the tertiary central or specialised hospitals (e.g. KFSH&RC 
and King Khalid Eye Specialist Hospital).(41) Examples of cases referred to the specialised 
hospitals include pituitary tumours and congenital malformations. 
2.7.4 Health information system  
The variation in healthcare systems and providers in SA has led to differences in the ways the 
healthcare facilities are provided, including differences in the information system used across 
the healthcare system. As a result, patient information/records have become distributed in 
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different healthcare facilities without a provider having the patients’ complete 
information/record except in rare cases where the patient chooses to receive healthcare from 
one provider at all times. As a consequence, patients may be given different medications 
which may affect patient safety.(77)  
According to the Country Cooperation Strategy for WHO and SA 2012-2016, the health 
information system is described as following: 
“The Ministry of Health is promoting the use of information technology in order to improve 
the quality of data and evolve towards paperless management. Hospital facilities are using 
International Classification of Diseases, Tenth Revision (ICD-10) in order to code causes of 
morbidity and mortality. The only long established medical scientific research centre is 
located at the KFSH&RC, which receives its budget from the government”.(46) 
Use of the electronic health record (EHR) system is gradually moving into MOH facilities, 
which were not previously connected to each other or to other private organisations.(41) The 
KFSH&RC and the National Guard Health Affairs (NGHA) have implemented the EHRs and 
electronic information.(41, 77) 
2.7.5 Access and barriers to health services in Saudi Arabia 
A recent systematic review aimed at providing an overview of the quality of PHC centres and 
identifying barriers to access quality healthcare in SA identified that there were good levels of 
access to immunisation (83-94%), maternal care (67-95%), and screening and treatment of 
epidemic diseases, while the access was lower than the targets for health education, chronic 
illnesses e.g. hypertension, and low referral rates for diagnostic purposes and specialised care 
(38) Another study showed that: “in order to improve access to services, 90% of primary care 
centres established appointment systems, registers, and follow-up systems”.(47) 
Furthermore, there is a shortage of services for some groups of patients such as the elderly, 
adolescents, and individuals with special needs.(41) Large sections of the population, 
especially those living in remote areas, do not have the ability to easily access healthcare 
facilities.(41)  
Physicians have noted that it is difficult to understand some patients due to low levels of 
education in the community and lack of a common language with which to communicate.(38) 
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An estimated 40% of patients experience language barriers; a problem directly related to the 
high number of non-Saudi national primary care professionals serving at the PHC level who 
do not have Arabic or English as their first language.(38) 
2.7.6 Medication safety in Saudi Arabia  
Given the increasing importance of patient safety, it is important to focus on the issues of 
medication safety and medication errors. Medication safety is still a new concept in SA that 
was first initiated by the SFDA. However, some MOH hospitals and other sectors have started 
implementing the concept.(78) Some studies were conducted in SA focusing on medication 
errors, (79-83) mainly in hospital settings. It was found that only 30% of hospitals in SA had 
a medication committee, and only 9% had a medication safety officer.(81)  
In a study done in 2010, 65 different healthcare professionals were divided into nine groups to 
join round-table discussions. The objective was to explore their perspectives on medication 
safety in hospitals and community settings in SA and to improve medication safety 
practice.(39) The study addressed the factors related to medication safety problems; 
unrestricted public access to medications from various hospitals and community pharmacies, 
communication gaps between healthcare institutions, limited use of important technologies 
such as computerised provider order entry (CPOE), and the lack of medication safety 
programmes in hospitals.(39) 
2.8 Chapter summary 
Until oil was discovered, SA was a poor country with limited resources, an underdeveloped 
infrastructure, and subsistence agrarian living for many members of its more rural population. 
Its healthcare system has been only relatively recently developed and much investment is 
currently taking place to improve the system’s quality standards and increase the availability 
of services. SA is going through a rapid transition to increase the reach and quality of its PHC 
services and to refocus continuity of care from hospital to primary health settings. 
Improving healthcare has been challenging due to the need to provide high quality healthcare 
for the rapidly growing population at an affordable cost, the need to improve the 
implementation of electronic health record systems, and the majority of health workers are 
foreigners. This latter point, together with the large number of non-Saudi residents in the 
country frequently gives rise to difficulties in ensuring effective communication between 
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health providers and their patients. In view of the recent healthcare reforms in SA involving 
the building up of primary care services, my thesis focuses on the issue of medication safety 
in the community and primary care context. There is an urgent need to understand more about 
medication safety in SA especially, at the primary care level. 
The following chapter will present the aims and objectives of my PhD and provide an 
overview of the methods employed.
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Chapter Three: Aims, Objectives, and Overview of Methods 
3.1 Introduction  
There is limited understanding of the frequency of medication errors and error-related ADEs 
in community settings in SA. This chapter details the aims and objectives of my PhD and 
provides an overview of the methodology and methods that were used to gather and analyse 
data. This PhD involved undertaking a four phased programme of work: Phase 1 was a 
systematic review; Phase 2 was a feasibility study; Phase 3 was a pilot retrospective cohort 
study; and Phase 4 was a retrospective cohort study. 
It should be noted that Phase 1 of this research focused on both medication errors and error-
related ADEs, but Phases 2, 3 and 4 focused solely on medication errors. 
 
3.2 Aims  
The main aims of the research were to investigate the epidemiology of medication errors and 
error-related ADEs. More specifically, I sought to:  
1. Estimate the incidence and prevalence of medication error and associated ADEs in 
community (i.e. ambulatory, primary care and home) settings  
2. Identify risk factors for medication errors and error-related ADEs with an emphasis on 
those that were potentially modifiable. 
 
3.3 Objectives 
The specific objectives of the overall PhD are detailed below:  
In Phase 1, I sought to: 
1. Estimate the incidence/prevalence of medication errors in community settings   
2. Estimate the incidence/prevalence of error-related ADEs in community settings 
3. Identify risk factors associated with medication errors and error-related ADEs. 
 
In Phase 2, in the context of Riyadh, SA, I sought to: 
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1. To identify the ambulatory setting and electronic database  
2. To evaluate the feasibility of data extraction and data collection from EHRs  
3. To check the availability and assess the reliability of key primary, secondary, 
composite secondary and revised updated outcome measures 
4. To inform plans for the pilot retrospective cohort study (Phase 3). 
 
In Phase 3, in the context of Riyadh, SA, I sought to:  
1. Pilot the study procedures 
2. Inform sample size calculations for undertaking the larger retrospective cohort study  
3. Inform plans for undertaking a definitive large retrospective cohort study 
4. Estimate the period prevalence of clinically important errors in medicine management 
5. Identify risk factors associated with patients at risk of clinically important errors in 
medicine management. 
 
In Phase 4, in the context of Riyadh, SA, I sought to:  
1. Estimate the period prevalence of clinically important errors in medicine management 
2. Identify risk factors associated with patients at risk of clinically important errors in 
medicine management 
3. Compare the QRESEARCH analysis of secular trends in the United Kingdom (UK) 
with the estimates I obtained in SA.(84) 
  
3.4 Overview of methods 
My research was conceptualised as a phased programme of work (Figure 3-1). Phase 1, 
involved undertaking a systematic review of the existing research and evidence on the 
epidemiology of medication errors and error-related ADEs in community settings. Phase 2 
was a feasibility study. Phase 3 was a pilot retrospective cohort study using clinically 
important errors in medicine management and extracting data from EHRs, which was 
undertaken in KFSH&RC, Riyadh. The focus was on assessing the feasibility of, and 
informing sample size calculations for, undertaking a larger cohort study. Finally, Phase 4 
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was a larger retrospective cohort study undertaken in adults (≥ 18 years old) based on a study 





Figure 3-1. PhD phased programme overview.
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Chapter Four: Phase 1: Investigating the Epidemiology of Medication Errors and 
Error-related Adverse Drug Events in Adults in Primary Care, Ambulatory Care 
and Home Settings: a Systematic Review 
4.1 Introduction 
In order to determine the epidemiology of medication errors and error-related ADEs and risk 
factors in the community settings, I had undertaken Phase 1, a systematic review of the 
literature. The rationale was to identify, select and critically appraise all relevant evidence in 
order to gather existing knowledge, understanding, and update on the previous studies done. 
Systematic review method will give an unbiased and replicable representation of current 
knowledge with reference to my topic compared to the literature review, which is mainly 
descriptive, and have a source of selection bias. Prior to undertaking further primary work in 
this area, it is important to take stock of the current evidence base, reflect on the quality of the 
evidence, distil key findings that have the potential to provide both estimates on the frequency 
of medication errors and error-related ADEs, and understand the factors underpinning this 
important source of preventable harm. The aim of this systematic review was to investigate 
the epidemiology of medication errors, error-related adverse events as well as risk factors for 
errors in adults managed in community care contexts (i.e. primary care, ambulatory care and 
home settings. It should be noted that this phase focused on both medication errors and error-
related ADEs, but Phases 2, 3 and 4 focused solely on medication errors. 
The study protocol was developed following Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines, and was registered in PROSPERO.(86, 
87) The detailed systematic review protocol has also been published and detailed in Appendix 
3.(88) There follows the full paper of this systematic review.  
 






























































































4.3 Chapter summary 
The aim of my systematic review was to critically review previous studies conducted in the 
community of the incidence/prevalence of medication errors and associated adverse events 
and to identify the main risk factors. We identified 60 studies carried out in various countries 
providing a comprehensive assessment of the available evidence on the epidemiology of 
medication errors and error-related ADEs in community settings. 
No relevant studies on the incidence of medication errors in these settings were found. The 
reported point or period prevalence of medication errors in community settings had a very 
wide range (i.e. 2.0-94.0%). This wide range appears, at least in part, to be due to the 
inconsistency in the definitions of the medication errors used in the studies, differences in 
populations studied, methodologies employed for error detection, and different outcome 
measures. More than half (37 studies) of the resulting medication errors studies were 
regarding the prescription of inappropriate drugs within the prescribing error stage in an 
elderly age group using different criteria. The comparison of those criteria is challenging due 
to the difference in medication use, consumption and availability of those medications to 
patients between countries. Further work is needed to review errors occurring at 
administration and dispensing stages of the medicines’ management process. 
 
As for preventable ADEs, which may in some cases occur as a result of medication errors, 
only one study reported error-related adverse events incidence, measured as 15/1000 person-
years.(89) The prevalence of preventable ADE was further reported in five other studies and 
varied according to the medication error type that resulted in the adverse event. 
 
The most common patient-related risk factors for both medication errors and preventable 
ADEs mentioned were the number of medications used by the patient and the increased age of 
patients. The most common healthcare professional-related risk factors for medication error 
was when more than one practitioner was involved in the care of patients and care being 
provided by family medicine and GP specialities. 
 
Most of the studies were conducted on elderly populations in economically-developed 
countries. There is therefore clearly a need to extend this work to low- and middle-income 
countries, particularly given the WHO’s recent launch of a Global Patient Safety 
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Challenge.(90, 91) My systematic review did not find a validated method for detecting all 
classes of medication errors. Bearing this in mind and the fact that most of the preventable 
ADEs are as a result of prescribing errors and/or medication monitoring errors,(92) Avery et 
al. (2012), in the Pharmacist-led information technology-based intervention to reduce rates of 
clinically important errors in primary care (PINCER) trial for medication errors in the UK, 
developed a list of clinically important errors in prescribing and monitoring in primary care. 
The feasibility of doing a pilot retrospective cohort study (Phase 2), based on the baseline 




Chapter Five: Phase 2: Feasibility Study to Inform the Development of a Pilot 
Retrospective Cohort Study Investigating the Epidemiology of Medication Errors 
in Adults Using Electronic Health Records in Riyadh, Saudi Arabia 
5.1 Introduction  
In Phase 1, the systematic literature review identified 60 different original studies looking at 
medication errors, of which only six measured ADEs as an outcome. In the earliest study 
identified, Field (2007) used EHRs for detecting ADEs through computer generated signals of 
possible drug-related incidents and then identified the events related to patient medication 
errors.(93) Gandhi (2010) used ADE monitoring triggers (or rules) that were programmed and 
then run against data in the EHR to detect ADEs.(89) The other four studies looked at ADEs 
resulting from discrepancies (between the medications described by the patients and 
caregivers with the drugs listed by their GP), drug-drug interaction- related adverse drug 
reaction (DDI-related ADR) and the use of potentially inappropriate medicine (PIM). (94-97) 
My systematic review revealed that identification of ADEs could most efficiently be carried 
out by using either computer-generated signals of possible drug-related incidents or trigger 
tools based on abnormal laboratory values and prescriptions for antidotes.(89, 93) Identifying 
signals included elevated drug levels, abnormal laboratory results, the use of medications 
considered to be antidotes, and diagnoses that could reflect an ADE. Computer-generated 
signals or trigger tools have been used to study ADEs (ADEs; ADR and medication errors 
that cause harm). However, the use of these two tools has several limitations. For example, 
they may not detect whether the reported errors were directly related to the medications or to 
the disease itself; they may require an intensive chart review and may be prone to subjective 
interpretation.  
Previous work has been done on prescribing indicators in general practice, which have been 
defined as “statements describing prescribing events that put the patient at risk of harm” used 
to monitor prescribing patterns.(98, 99) Investigating prescribing patterns and quality is not 
included in the aims or objectives of my thesis.   
According to the literature review, several methods can be applied to measure and identify the 
incidence and prevalence of medication errors in the community context. There is no single 
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approach that is considered to be a gold standard for medication errors detection. Detection of 
medication errors depends on the setting, the expected type of medication error and the cost of 
detection.(100)  
The provisional plan for the method of this PhD research was to carry out a prospective 
cohort study, using a telephone survey adapted from Gandhi et al. study,(23) in adults from a 
randomly selected sample of the community pharmacies within the five regions of the Riyadh 
city, Saudi Arabia. However, after the completion of Phase 1 and considering the available 
time and resources, I modified my plans. The systematic review did not identify a validated 
method for detecting all classes of medication errors. According to the systematic review and 
previous work, most of the preventable ADEs occur as a result of prescribing and/or 
medication monitoring errors.(88, 92)  
Following discussion with other researchers, I identified a validated tool for measuring 
medication errors developed by Avery et al. (2012) in the PINCER trial in the UK. The 
PINCER trial is one of the world’s first randomised studies aiming to reduce the risk of 
medication errors in general practices, which focused on a pre-specified list of clinically 
important errors in prescribing and monitoring.(85) This list was developed through a series 
of steps involving a systematic review of the literature, and epidemiological, consensus  
exercise and pilot work.(92, 101, 102) This present research investigates the epidemiology of 
clinically important errors in medicine management as defined by the PINCER trial.(85) 
Hence, I used a method which has been established by previous research in the current 
context.(85) In order to investigate the relevant outcome measures in a future retrospective 
cohort study, I first established the feasibility and reliability of using data extraction from the 
EHRs of KFSH&RC Family Medicine and Polyclinics, Riyadh, SA. Choosing EHR screening 
for this feasibility and pilot study was the most compatible option to fit with the imposition 
set by the Saudi Cultural Bureau, which specified a maximum of three months for a 
postgraduate student to undertake data collection or fieldwork. Furthermore, the interest is the 
epidemiology of clinically important errors in medicine management, rather than the adverse 
events themselves, so Phases 2, 3 and 4 of my research focused only on the medication errors. 
Given the global dearth of studies looking at medication errors in the community, the 
transition across the world from secondary and tertiary care to community-based care, 
particularly in SA, as well as the absence of studies carried out in the kingdom, this work was 
both important and timely.  
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In Phase 2, the feasibility study, I sought to; a) identify the ambulatory setting and electronic 
database; b) evaluate the feasibility of data extraction and data collection from EHRs; c) 
check the availability and assess the reliability of key outcome measures; and d) inform the 
development of Phase 3, a pilot retrospective cohort study that focused on assessing the 
feasibility of doing a larger Phase 4 study, based on the baseline method developed in the 
PINCER trial by Avery et al. (2012).(85) 
It should be noted that Phase 1 of this research focused on both medication errors and error-
related ADEs, but Phases 2, 3 and 4 focused solely on medication errors. 
 
5.2 Methods  
A feasibility study is an initial part of a research done before the main study to answer the 
question ‘Can this study work?’. The National Institute for Health Research (NIHR) 
Evaluation, Trials and Studies Coordination Centre has helpfully explained the rationale for a 
feasibility study stating that it “focuses on conducting research to examine whether the study 
can be done”. Thus, feasibility studies are conducted first, followed by pilot studies.(103)  
A feasibility study focuses on the process and its rationale is to a) identify the ambulatory 
setting and electronic database, b) check the procedure of recruitment, c) assess the data 
collection procedure, d) know sample’s characteristics, e) check the availability of outcome 
measures, and f) evaluate the ability to implement the study.(103) 
 
5.2.1 Setting and electronic database 
I tried to identify a potential healthcare setting in which there was access to longitudinal EHR 
data. To choose the setting of the fieldwork, five ambulatory care centres in Riyadh, SA, were 
contacted by Email communications and phone calls, namely: 
1. KFSH&RC Family Medicine and Polyclinics Centre. There were several reasons for 
carrying out this study at KFSH&RC. Firstly, usually, patients choose to receive 
healthcare from KFSH&RC because of the high-quality care provided. Secondly, 
greater populations were covered by this hospital compared to the following four 
settings, which allowed a more complete and accurate picture of medication error 
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rates. The centre serves a population of 35,000 Saudi and non-Saudi employees and 
their dependents of all ages. It has a well-developed electronic system Integrated 
Clinical Information System (ICIS), which includes reporting of medication errors. In 
2015, the Family Medicine provision has been awarded Healthcare Information and 
Management Systems Society (HIMSS) 7 accreditation. The KFSH&RC Family 
Medicine-Riyadh city, SA became the first ambulatory care service outside the USA 
to achieve HIMSS 7 status.(104) Several meetings and discussions were conducted 
with Dr Abdullah Alkenizan (AK) from KFSH&RC regarding the collaboration work, 
the applicability of the method and ethical considerations. 
2. King Khalid University Hospital ambulatory care, this setting was subsequently 
discarded as it had a new electronic System for Integrated Health Information (eSiHi) 
launched only in May 2015 and thus the potential for having missing data and 
inaccurate coding was high. 
3. NGHA, this setting was not considered suitable as the institution is specifically for 
employees of this governmental body, together with their families and dependents.  
4. Prince Sultan Military Medical City, this setting was not considered suitable for the 
same reason of the NGHA setting and it did not have an EHR system for ambulatory 
care. 
5. Security Forces Hospital, this setting was not considered suitable for the same reason 
of the NGHA setting.  
KFSH&RC, located in the capital of SA, Riyadh, is a 1086-bed tertiary care facility that 
provides the highest level of specialised healthcare in an integrated educational and research 
setting. The Department of Family Medicine and Polyclinics is comprised of two sections, 
namely Family Medicine and Polyclinics. “The Section of Family Medicine is responsible for 
the healthcare needs of hospital employees and their eligible dependents of all age groups 
(approximately 35,000). Family Medicine provides services that include screening, diagnosis, 
management and prevention of physical and psychosocial conditions, as well as providing 
health education and medical counselling, occupational and infection control services 
including assessment of pre-employment, needle stick injuries and tuberculosis (TB) 
surveillance. The Section of Polyclinics serves as an initial assessment and referral clinic to 
determine a patient's eligibility for tertiary care services at KFSH. It is also an ambulatory 
care facility for tertiary care patients who need special additional management of their 
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chronic diseases.  In addition, Polyclinics provides back up support to the Emergency Room 
for cases, which need urgent follow-up.  Polyclinics are comprised of Medical, Pediatrics and 
Orthopedic Clinic”.(105) 
 
5.2.2 Methods  
Inclusion/exclusion criteria:  
Patients’ records were considered eligible if they were for adults of 18 years and over, 
recorded to be receiving at least one prescribed/OTC medication and had been registered with 
the Family Medicine and Polyclinic department for at least 15 months prior to data extraction. 
The 15 months retrospective duration was chosen as that period was specified in the 
QRESEARCH outcomes.(85) Records were excluded if they related to patients who were 
under 18 years, had no medications recorded at any point in time over the study period, if 
their outcome measures occurred during hospitalisation or ED visits, or if they were lost to 
follow-up; specifically, if the patient had not attended the clinic, had left the clinic or had 
died. 
Sampling: 
For sampling in the feasibility phase, I used a systematic random sample from each 
KFSH&RC Family Medicine clinic during the period from 14 May 2017 to 18 May 2017. 
Systematic sampling is “The procedure of selecting according to some simple, systematic 
rule, such as all persons whose names begin with specified alphabetic letters, born on certain 
dates, or located at specified points on a master list”.(106) The reason for choosing a 
systematic random sample in this phase was because it was convenient, and sampling was 
undertaken before I had received the ICIS training.  
Outcome measures: 
Patients records were then reviewed to obtain one positive outcome measure (medication 
error) of each of the outcome measures listed (Box 5-1). For the outcome measures: a) the 
numerator of each of the outcome measures listed in Error! Reference source not found. is 
considered positive if the patient had a potential medication error; and b) the denominator of 
each of the outcome measures listed is considered positive if the patients had a potential risk 
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of medication error. The maximum number of patients reviewed in the feasibility phase 
considering the time period was 500. If some outcome measures had not been observed after 
500 records had been reviewed, such outcome measures were classed as ‘rare’ and were 
considered for exclusion from the pilot and cohort study phases. 
5.2.3 Training on the ICIS  
I received training on the ICIS and I was able to ask specific questions that helped in data 
collection e.g. how to develop a list of patients visiting the Family Medicine and Polyclinics 
in a specific period. No training was needed for the secondary data extractor Salma Al-khani 
(SK) as she worked in KFSH&RC and she was familiar with the system.  
5.2.4 Availability and reliability of key outcome measures 
The outcome measures used in the feasibility study consisted, initially, of three primary 
outcomes, seven secondary outcomes and an additional two composite secondary outcome 
measures, taken from the original PINCER trial.(85) In addition, another nine outcome 
measures were taken from the revised updated PINCER outcomes.(107) See Box 5-1. In a 
study by Spencer (2014) that aimed to identify and update a set of prescribing indicators for 
assessing the safety of prescribing in general practice, it was considered by a panel of 
healthcare professionals that 13 of these indicators were associated with high risk and three 
with extreme risk to patients.(99) The medicines’ management processes involved in these 
outcomes were prescribing (contraindication and dosing error) and monitoring errors. Details 
of each error stage, ADEs and risk are given in Appendix 7. In this phase, the availability of 
the necessary data and outcome measures were sought.  
A working definition of reliability was that “a measurement is reliable when it is stable; i.e. 
when repetition of an experiment or measurement gives the same results”.(106)  
 
Primary outcomes 
1. Patients with a history of peptic ulcer who have been prescribed a non-selective 
non-steroidal anti-inflammatory drug (NSAID) without co-prescription of a 
proton-pump inhibitor (PPI) 
2. (2a) Patients with asthma who have been prescribed a beta-blocker (β-blocker) 
89 
 
3. Patients aged 75 years and older who have been prescribed an angiotensin 
converting enzyme (ACE) inhibitor or a loop diuretic long-term who have not had 
a computer-recorded check of their renal function and electrolytes in the previous 
15 months 
Secondary outcomes 
(2b) Patients with asthma [and no history of coronary heart disease (CHD)] who 
had been prescribed a β-blocker 
4. Proportion of women with a past medical history of venous or arterial thrombosis 
who had been prescribed the combined oral contraceptive pill 
5. Patients receiving methotrexate for at least 3 months who had not had a full blood 
count recorded (5a) or liver function test (5b) in the previous 3 months 
6. Patients receiving warfarin for at least 3 months who had not had a recorded check 
of their International Normalised Ratio (INR) in the previous 12 weeks 
7. Patients receiving lithium for at least 3 months who had not had a recorded check 
of their lithium concentrations in the previous 3 months 
8. Patients receiving amiodarone for at least 6 months who had not had a thyroid 
function test in the previous 6 months 
9. Patients receiving prescriptions of methotrexate without instructions that the drug 
should be taken every week 
10. Patients receiving prescriptions of amiodarone for at least 1 month who are 
receiving a dose of more than 200 mg per day 
Composite secondary outcome measures 
11. Patients with at least one prescription problem (a combination of outcome 
measures 1, 2, or 4) 
12. Patients with at least one monitoring problem (a combination of outcome measures 
3, 5, 6, 7, or 8) 
Additional revised updated outcome measures  
13. Prescription of an oral NSAID, without co-prescription of an ulcer-healing drug, to 
a patient aged ≥ 65 years 
14. Prescription of an anti-platelet drug, without co-prescription of an ulcer-healing 
drug, to a patient with a history of peptic ulceration 
15. Prescription of warfarin or New Oral Anti-Coagulant (NOAC) in combination 
with an oral NSAID 
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16. Prescription of warfarin or NOAC and an anti-platelet drug in combination 
without co-prescription of an ulcer-healing drug 
17. Prescription of aspirin in combination with another anti-platelet drug without co-
prescription of an ulcer-healing drug 
18. Prescription of a long-acting beta-2 agonist inhaler (excluding combination 
products with inhaled corticosteroid) to a patient with asthma who is not also 
prescribed an inhaled corticosteroid 
19. Prescription of an oral NSAID to a patient with heart failure 
20. Prescription of antipsychotics for >6 weeks in a patient aged ≥ 65 years with 
dementia but not psychosis 
21. Prescription of an oral NSAID to a patient with estimated Glomerular Filtration 
Rate (eGFR) < 45 
Box 5-1. Outcome measures from the PINCER trial and the revised updated PINCER 
outcomes.(85, 107) 
 
5.2.5 Feasibility and practicability of data extraction and data collection from EHRs 
The transition from paper medical files to EHR systems has facilitated the development of 
electronically extracted data from the EHRs, which may be perceived as large health 
information databases. These databases, therefore, can serve as clinical research resources. 
The researcher must be able to demonstrate that the electronically extracted data are of 
sufficient quality.(108) Because of the lack of technical capacity to ensure accuracy and 
quality, and to avoid the delay that would be necessary for generating the required 
anonymised data electronically from the electronic medical records department in 
KFSH&RC, collecting data from the EHRs was undertaken manually by reviewing individual 
EHR. This method of data collection is distinct from the data extraction approach in the 
PINCER trial, (84, 85) which was undertaken electronically. A paper-based data collection 
form was developed for the feasibility study (See Appendix 10). For validity “An expression 
of the degree to which a measurement measures what it purports to measure”,(106) the data 





5.2.6 Ethics  
According to the KFSH&RC guidelines and the policy of the research ethics committee 
(REC), the retrospective chart review method did not require a subject’s consent and 
KFSH&RC may waive that consent (see Section 6.2.9).(109) I submitted the research 
protocol to KFSH&RC on 28 March 2017. The research protocol, data collection sheet and 
waiver of informed consent (in place of an individual’s informed consent) were approved by 
the REC in KFSH&RC, Riyadh, SA (project # 2171 060) (Appendix 9). The confidentiality 
of the data was maintained by giving each EHR a code number to preserve patient privacy, I 
did not record any patient identifier information e.g. (names, addresses and medical record 
number) that could be used to link data to participants. 
After the research approval was obtained, I had access to the ICIS as the research coordinator 
and a secondary data extractor (SK), had access to ICIS because she is an employee of 
KFSH&RC.  
5.3 Results  
Of the five ambulatory settings reviewed, the EHR database at KFSH&RC was selected on 
the grounds that it was possible to: access longitudinal EHR data; construct a suitable 
sampling frame; and extract relevant outcome variables. 
An average of 200 patients were seen daily by physicians in the Family Medicine and 
Polyclinics. I retrospectively reviewed a total of 500 records fulfilling the inclusion criteria 
from 01 February 2016 to 31 May 2017 (15 months prior to data extraction). 
Analysis to achieve objectives  
5.3.1 Availability of necessary data in the EHR 
All the necessary information from each patient’s EHR was available in one system (ICIS), 
including baseline characteristics, medications, diagnosis using coding of the International 
Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-
10),(110) together with laboratory results, including urea and electrolytes, blood count, liver 
function, INR, thyroid function, drug level and surgical pathology report for biopsy to detect 
peptic ulcer. In detail, the following variables were available: 
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• All the patients’ visits to Family Medicine and Polyclinics could be seen 
under document viewing, along with the visiting dates. 
• Diagnosis could be seen in Problems and diagnosis, and under document 
viewing, as well as in the indication of each prescribed medication. 
• The medication was noted under the medication list. 
• All laboratory results, with their dates, were recorded in the flowsheet with 
specifying the study duration i.e. before 15 months or more. 
The availability of drugs under the following drug classes in KFSH&RC were sought through 
reviewing the KFSH&RC formulary: ACE inhibitors, anti-platelets, antipsychotics, β-
blockers, gastro-protective agents, long-acting beta-2 agonist inhaler, loop diuretics, NOACs, 
NSAIDs and oral contraceptives. Details of the medications available under each class are 




Class Drug generic name  Restricted drug (specialty other than Family Medicine 
physician can prescribe the drug) 
Antipsychotic agent ChlorproMAZINE 
 
 
OLANZapine- Family Medicine physicians are 
authorised to renew prescriptions of olanzapine.  
 
RisperiDONE- Family Medicine physicians are 





ARIPiprazole- Prescribing restricted to psychiatrists. 
 
CloZAPine- Prescribing restricted to psychiatry and neurology 
consultants. 
 
OLANZapine- Prescribing oral form restricted to psychiatrists, 
neurologists for treatment of schizophrenia and bipolar mania, 
Family Medicine physicians are authorised to renew prescriptions 
of olanzapine.  
 
Pimozide- Prescribing restricted to neurologists for the treatment 
of Tourette's disorder and psychiatrists for schizophrenia. 
 
Haloperidol- Adult haematology/oncology for management of 
chemotherapy-associated nausea or vomiting. 
 
RisperiDONE- Prescribing oral form restricted to psychiatrists 
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and neurologists for use as a second-line agent for patients who 
do not respond to, or are intolerant to, traditional neuroleptics. 
 
QUEtiapine- Prescribing restricted to psychiatrists, neurologists 
and adult intensive care unit (ICU) physicians. 
 
Ziprasidone- Prescribing restricted to psychiatrists. 
NOAC  Rivaroxaban- Prescribing restricted to the approved indications as 
per guidelines. 
 
Argatroban- Prescribing restricted to haematology consultants for 
patient with Heparin induced thrombocytopenia (HIT). Adult ICU 
consultants and cardiac ICU consultants may initiate therapy for 
24 hours until a hematology consultation is obtained. Subsequent 
doses require haematology approval. 
 
Fondaparinux- Prescribing restricted to adult cardiology 
physicians and adult haematology/thromboembolism services 
according to guidelines. 










Dipyridamole- Prescribing injection form restricted to 
cardiologists. 
 
Ticagrelor- Prescribing restricted to adult cardiology and 
emergency physicians. 
NSAID Aspirin  
Diclofenac 


















Dorzolamide and Timolol  
Timolol  
Propranolol  
Sotalol [FR]- Family Medicine and Internal 
Medicine Consultants may prescribe sotalol for 
maintenance therapy. 
Sotalol [FR]- Prescribing restricted to cardiologists and adult 
intensivists for initiation of therapy. 
Long Acting Beta 2 
Agonist  
Budesonide and Formoterol  
Fluticasone and Salmeterol  
 





























































KFSH uses lower potency estrogen component 
oral contraceptives. Norethisterone = 
norethindrone 









 Esomeprazole [FR] - Prescribing restricted to adult 
gastroenterology consultants for the treatment of 50 patients per 
year only. 
Omeprazole [FR] - Prescribing intravenous form restricted to 
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Table 5-1. Medications available in the KFSH&RC and their restrictions. 





Misoprostol - Prescribing restricted to obstetrics and gynaecology 
and gastroenterology physicians. 
Gastro-protective 
H2 receptor antagonist 
Ranitidine (double dose) 
 
Dementia drugs  
Donepezil 
Memantine 





Methotrexate -Prescribing Ebetrexate® prefilled syringe restricted 
to adult and pediatric rheumatologists for treatment of juvenile 





Amiodarone-Oral tablets are not restricted. 
Amiodarone- Prescribing injectable amiodarone restricted to 




All the outcomes were identified at least once after reviewing 500 records in the feasibility 
phase apart from the following three outcomes: 
• Outcome 7: patients receiving lithium for at least three months who had not had a 
recorded check of their lithium concentrations in the previous three months 
• Outcome 8: patients receiving amiodarone for at least six months who had not had 
a thyroid function test in the previous six months 
• Outcome 10: patients receiving prescriptions of amiodarone for at least one month 
who were receiving a dose of more than 200 mg per day. 
The following single outcome was not seen as an error in this phase: 
Outcome 9: Patients receiving prescriptions of methotrexate without instructions that 
the drug should be taken every week. 
The instruction for taking methotrexate every week is specified on the medication 
label as (every seven days). 
5.3.2 Feasibility and practicability of data extraction and data collection from EHRs 
The data collection form was tested and reviewed on 10 electronic records. It was also 
double-checked independently by the secondary data extractor (SK) (See Appendix 10).  
5.4 Chapter summary 
This phase of work was designed to identify the ambulatory setting and electronic database 
and to assess the feasibility of using EHRs to conduct epidemiological research on a pre-
specified list of clinically important errors in medicine management (Box 5-1). I selected the 
EHRs of KFSH&RC Family Medicine and Polyclinics, Riyadh, SA. All the outcomes were 
seen at least once in a total of 500 patients, apart from Outcomes 7, 8, 9 and 10 for 
amiodarone, methotrexate and lithium. However, none of the outcome measures were 
excluded from the pilot phase (Phase 3), because it was considered possible that Outcomes 7, 
8 and 10 could appear when screening a higher number of records. 
The following three points were confirmed in this feasibility phase: the secondary data 
extractor and I were able to access the EHRs, I could construct the sampling framework for 
the pilot study through simple random sampling, and all outcome measures were identified 
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apart from four outcomes for amiodarone, methotrexate and lithium (as detailed above) and 
they could all be used in the following phases. 
The findings from this phase of my research suggested that the pilot phase is feasible, likely 
to provide random sample and all information needed for the outcome measures was available 




Chapter Six: Phase 3: A pilot Retrospective Cohort Study Investigating the 
Epidemiology of Medication Errors in Adults Using Electronic Health Records in 
Riyadh, Saudi Arabia 
6.1 Introduction 
Phase 2 of this study was initiated to identify and select the ambulatory setting and electronic 
database and to test the feasibility of using data from EHRs of KFSH&RC Family Medicine 
and Polyclinics, Riyadh, SA. The findings from Phase 2 indicated that the pilot phase would 
be feasible. The reason for undertaking this pilot retrospective cohort study was to inform 
sample size calculations and to inform plans for undertaking a larger retrospective cohort 
study, based on the methods developed for baseline assessments in the PINCER trial.(85) 
Given the limited research team and time period for this PhD, Phases 3 and 4 focused only on 
medication errors, which was in contrast to the systematic review (Chapter 4) in which I 
focused on both medication errors and error-related ADEs.   
The research design, sampling, variables, data collection, statistical analysis and results of the 
pilot study are discussed in this chapter along with a discussion of changes to methods that 
were carried forward into the main study (Chapter 7).  
6.2  Methods  
A pilot study is “A small-scale test of the methods and procedures to be used on a larger 
scale if the pilot study demonstrates that these methods and procedures can work”(106) and is 
often used by researchers to pre-test a research instrument and/or approach (Baker, 
1994).(111) 
A random sample of patients visiting the Family Medicine and Polyclinics in KFSH&RC was 
selected. Patients using this service would be managing their medication through the 
outpatient clinic and using medication by themselves and/or with the assistance of a caregiver 
at home. A retrospective cohort was constructed and patients records were then manually 
reviewed. Manual data collection was carried out to avoid the delay that would be necessary 
for generating the required anonymised large number of data electronically from the 
electronic medical records department at KFSH&RC and because of the lack of 
informaticians available to provide the data in my timeframe. 
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6.2.1 Study design  
The pilot study sought to build on the feasibility study by providing a clearer focus on 
outcomes, rather than processes.(103) Conducting a pilot study prior to the main study should 
enhance the success of the main study and help to identify and resolve any potential sources 
of problems in the main study.  
The pilot retrospective cohort study was designed to measure period prevalence of the 
primary, secondary, composite secondary and revised updated outcome measures and risk 
factors. Period prevalence was defined as “the proportion of individuals with the condition at 
any time during a specified time period or interval”.(106)  
  
6.2.2 Participants and sampling  
Subjects were selected from the Family Medicine and Polyclinics at KFSH&RC. Sampling 
was undertaken over one month in 2017; the follow-up was carried out retrospectively, over 
the 15 months prior to the data extraction from 01 February 2016 to 31 May 2017. The pilot 













Number of all patients at 
sampling n=1253 Excluding < 18 years old patients 
n=40 
Number of ≥ 18 years old 
patients n=1213 
Random sample of 255 
Number of patients’ records 
included n=200 
 N=200 
Excluding registered for <15 months 
n= 45 
Excluding patients not on medications 
n=6 
Died, left the clinic, did not attend 
n=4 
Total exclusion: n=55 
 
Number of ≥ 18 years old 
patients n=1103 














Figure 6-1. Pilot study flowchart outlining population and sample enrolment. 
Inclusion criteria: 
1. Saudi and non-Saudi adults aged 18 years or over. 
2. Patients recorded to be receiving at least one prescribed/OTC medication. These 
medications were checked against the SFDA list of human medications and were 
subsequently classified into prescription or OTC medications.(112)  
3. Patients who had been registered with the Family Medicine and Polyclinics at 
KFSH&RC for at least 15 months prior to data extraction. 
 
Exclusion criteria: 
1. Patient aged less than 18 years. 




3. Patients whose primary and secondary outcomes occurred during hospitalisation or 
ED visits. 
4. Those lost to follow-up due to not attending the Family Medicine and Polyclinics 
appointment, having left the clinic or having died. 
 
Method of sampling:  
After attending the training course on the ICIS system, I was able to generate a list of patients 
visiting the Family Medicine and Polyclinics and to perform sampling. Simple random 
sampling was chosen to reduce selection bias. Simple random sampling is one type of 
probability or random sampling in which “each person has an equal chance of being selected 
out of the entire population”.(106) A list of all patients who visited the Family Medicine 
department two weeks before data collection (31 May 2017) was generated. Two weeks was 
specified because the maximum duration that could be specified by the ICIS for generating a 
patient list was two weeks, which yielded around 1,500 records. Each person was assigned a 
number. I excluded paediatric patients. Then, numbers were selected at random, from a table 
of random numbers, until the desired sample size was attained.(106) 
Electronic records were randomly selected using a random number table generated via the 
‘simple random sample without replacement’ function in STATA (version 14) to avoid 
including the same patient twice. 
 
6.2.3 Variables  
Baseline characteristics:  
The baseline characteristic variables recorded were age, gender, nationality (Saudi, 
non-Saudi), diagnosis or underlying conditions and OTC recorded at any point during 
the 15 months, and polypharmacy (taking five or more medications at any point during 
the 15 months). 
Exposures:  
1. Prescribed medications and/or OTC drugs.  




Outcome variables:  
1. Period prevalence of the primary, secondary, composite secondary and revised 
updated outcome measures. 
For the primary, secondary, composite secondary and revised updated outcome measures see 
Box 5-1.(85, 107) 
 
6.2.4 Data sources/measurement 
Identification of outcomes 
After selecting a random sample from the Family Medicine and Polyclinics, the secondary 
data extractor (SK) and I undertook in-depth screening of EHRs (i.e. assessing diagnosis, 
medication list and laboratory data fields). This screening was done in order to investigate the 
period prevalence of clinically important errors, and risk factors associated with patients at 
risk of clinically important errors in medicine management (age, gender, nationality, ≥5 
regularly scheduled medications and using OTC). The presence, or absence, of the primary, 
secondary, composite secondary and revised updated outcome measures (the numerator) and 
the denominator for each outcome measures were recorded. During the EHR review, we 
focused on the outcomes detailed in Box 5-1. This method was taken from the baseline 
method developed in the PINCER trial by Avery et al. (2012).(85, 107) 
To identify factors predicting patients who would be at risk of experiencing errors during the 
follow-up period, I conducted a binary logistic regression analysis. The literature suggests that 
increased age, female gender, using ≥ 5 concurrent medications (polypharmacy) and using 
OTC medications, may be associated with medication errors.(113) Therefore, my model 
incorporated the following independent variables: a) age, b) gender, c) nationality, d)  ≥5 
regularly scheduled medications and e) using OTC. Information including age, gender, 
nationality, regularly scheduled medications and diagnosis was abstracted from EHRs. 
Development of a data collection tool: 
Manual data extraction from the EHRs was independently undertaken by two extractors (GA 
and SK) to minimise the risk of errors in data extraction. A paper-based data collection form 
was used to complete an extensive summary description of all relative information available 
in the EHRs to gather the patient’s demographics and outcome measures (see Appendix 10). 
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Any discrepancy or disagreement was checked by me and discussed/resolved by independent 
double-checking the records or through arbitration by a third reviewer (AK) if a decision 
could not be reached. This approach was adopted because inter-rater reliability requires 
completely independent rating of the same event by two or more raters.(114, 115)  
The paper data collection forms were stored in a secure location in the clinic (i.e. locked 
office). 
The information in the paper-based data collection tool was transferred to an electronic data 
sheet using an Excel spreadsheet for the analysis. The electronic data sheet was stored in a 
password-protected computer and no patient identifying information was recorded. 
 
6.2.5 Bias  
Bias is the “systematic deviation of results or inferences from truth”.(106)  
Bias in sampling method:  
To reduce the risk of selection bias in sampling, simple random sampling was employed.  
Bias in study design: 
Selection and information bias are particular problems with retrospective cohort studies where 
exposure and outcomes have already occurred at the time of subject enrolment.(116) This 
type of bias cannot be avoided when employing a retrospective study design. Documentation 
bias may occur within a retrospective review because the investigator must rely on 
information provided only in the electronic records to identify or assess the outcome.  
 
6.2.6 Study size 
A sample size of 10% or more of the major study size is commonly deemed adequate for a 
pilot study,(117) so up to 200 patient records were required in the pilot study. Related 




The original intention was to identify the sample size required to detect the period prevalence 
and the lowest strength of association odds ratio (OR) between risk factors and outcomes of 
interest. However, because of the large number of variables and the lack of informaticians 
available to provide the data in my timeframe that resulted me in choosing the manual method 
for data extraction, each record needs a maximum of 15 minutes to scan and extract data. 
Therefore, the largest sample size that was feasible considering the time available, resources 
and research team size was 2000 records. 
 
6.2.7 Data access and cleaning methods  
The electronic data sheet was checked for errors in data entry, outliers and missing data. 
For each of the outcome measures, a number of data checks were used to ensure that:(84) 
• The ages of the included patients fulfilled the criteria for being included in the relevant 
outcome measure. 
• The drugs fulfilled the criteria for the relevant outcome measure. 
• Cases labelled as numerators fulfilled the criteria for being numerators. 
• Cases labelled as non-numerators were correctly labelled as non-numerators, whilst also 
fulfilling the criteria for being denominators. 
 
For monitoring outcome measures, a number of data checks were used to help ensure that: 
• The dates of the latest relevant monitoring codes (where available) were used correctly to 
assign the patient to being either a numerator or denominator. 
• In relation to the combined hormonal contraceptive outcome measure (Outcome 4), all 
patients were female.  
• In relation to the methotrexate dosing instructions outcome measure (Outcome 9), only 
those patients that had dosing instructions recorded were included (i.e. records with blank 
dosage instructions fields were excluded). 
For composite Outcome measure 11: 
• Data from Outcomes 1, 2 and 4 (see Box 5-1) were combined, ensuring that they were not 
double counted, thus identifying patients who appeared one or more times as numerators 
in order to calculate the proportion of patients with one or more prescribing problems 
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from those at risk of one or more prescribing problems*. For example, if a patient 
appeared as a numerator in any of Outcomes 1, 2 and 4, they would appear as a numerator 
in the composite outcome measure. 
*Patients at risk were patients with a positive denominator for Outcomes 1, 2 and 4.  
For composite Outcome measure 12: 
• Data from Outcomes 3, 5, 6, 7 and 8 (see Box 5-1) were combined, ensuring that they 
were not double counted, thus identifying patients who appeared one or more times as 
numerators in order to calculate the proportion of patients with one or more monitoring 
problems from those at risk of one or more monitoring problems*.(84) 
* Patients at risk were patients with a positive denominator for Outcomes 3, 5, 6, 7 
and 8.  
An inventory of medical record numbers and patients’ code number was used to ensure 
patients were not included in the dataset more than once. 
 
6.2.8 Statistical methods 
Period prevalence calculations: 
Microsoft Excel and STATA (version 14) were used to manage and analyse the data.  
The overall period prevalence of patients with at least one medication error was calculated as: 
the number of patients experiencing one or more medication error at any time during the 15 
month period (numerator)/the total number of patients in the study population 
(denominator).(118)  
The overall period prevalence of medication errors was calculated as: the number of 
medication errors at any time during the 15 month period (numerator)/the total number of 
patients in the study population (denominator). 
The prevalence of each primary and secondary outcome measure listed below was described 
using numerators, denominators and percentages, at patient level.  
Primary outcome measures: 
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• Patients with a history of peptic ulcer prescribed an NSAID (excluding aspirin) without a 
PPI (numerator)/ Patients with a history of peptic ulcer without a PPI (denominator) 
• Patients with asthma prescribed a β-blocker (numerator)/Patients with asthma 
(denominator) 
• Patients aged ≥75 on long term ACE inhibitors or diuretics without urea and electrolyte 
monitoring in the previous 15 months (numerator)/Patients aged ≥75 on long term (15 
months) ACE inhibitors or loop diuretics (denominator). 
Secondary outcome measures: 
• Patients with asthma and not CHD who are prescribed a β-blocker (numerator)/Patients 
with asthma and not CHD (denominator) 
• Female patients with a history of venous or arterial thromboembolism and arterial 
thrombosis prescribed combined oral contraceptives (numerator)/Female patients with a 
history of venous or arterial thromboembolism and arterial thrombosis (denominator) 
• Patients prescribed methotrexate for ≥three months without a full blood count in the last 
three months (numerator)/Patients prescribed methotrexate for ≥ three months 
(denominator) 
• Patients prescribed methotrexate for ≥ three months without a liver function test in the last 
three months (numerator) / Patients prescribed methotrexate for ≥ three months 
(denominator) 
• Patients prescribed warfarin for ≥ three months without an INR in the last three months 
(numerator) /Patients prescribed warfarin for ≥ three months (denominator) 
• Patients prescribed lithium for ≥ three months without a lithium level in last three months 
(numerator) / Patients prescribed lithium for ≥ three months (denominator) 
• Patients prescribed amiodarone for ≥ six months without a thyroid function test in the last 
six months (numerator) / Patients prescribed amiodarone for ≥ six months (denominator) 
• Patients prescribed methotrexate without instructions to take weekly (numerator) / 
Patients prescribed methotrexate (denominator) 
• Patients prescribed amiodarone for ≥ one month at a dose >200 mg/day (numerator) / 
Patients prescribed amiodarone for ≥ one month (denominator). 
 
Composite outcome measures: 
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• Number of patients with at least one prescribing problem (numerator) / Number of 
patients at risk of at least one prescribing problem (denominator) 
• Number of patients with at least one monitoring problem (numerator) / Number of 
patients at risk of at least one monitoring problem (denominator). 
 
Revised updated outcome measures:(107)  
• Patients aged ≥ 65 years prescribed an oral NSAID (excluding aspirin) without co-
prescription of an ulcer-healing drug (numerator) /Patients aged ≥ 65 years without co-
prescription of an ulcer-healing drug (denominator) 
• Patients aged ≥ 18 years with a history of peptic ulceration prescribed an anti-platelet drug 
without co-prescription of an ulcer-healing drug (numerator) /Patients aged ≥ 18 years 
with a history of peptic ulceration without co-prescription of an ulcer-healing drug 
(denominator) 
• Patients aged ≥ 18 years prescribed warfarin or NOAC in combination with an oral 
NSAID (excluding aspirin) (numerator) / Patients aged ≥ 18 years prescribed warfarin or 
NOAC (denominator) 
• Patients aged ≥ 18 years prescribed warfarin or NOAC and an anti-platelet drug in 
combination without co-prescription of an ulcer-healing drug (numerator) / Patients aged 
≥18 years prescribed warfarin or NOAC without co-prescription of an ulcer-healing drug 
(denominator) 
• Patients aged ≥18 years prescribed aspirin in combination with another anti-platelet drug 
without co-prescription of an ulcer-healing drug (numerator)/Patients aged ≥ 18 years 
prescribed aspirin without co-prescription of an ulcer-healing drug (denominator) 
• Patients aged ≥ 18 years with asthma prescribed a long-acting beta-2 agonist inhaler not 
also prescribed an inhaled corticosteroid (numerator) / Patients aged ≥18 years with 
asthma prescribed a long-acting beta-2 agonist inhaler (denominator) 
• Patients aged ≥ 18 years who have a diagnosis of heart failure prescribed an oral NSAID 
(excluding aspirin) (numerator)/ Patients aged ≥ 18 years who have a diagnosis of heart 
failure (denominator) 
• Patients aged ≥ 65 years with a Read code for dementia but no Read code for  psychosis 
prescribed antipsychotic drugs for >6 weeks (numerator)/ Patients aged ≥ 65 years with a 
Read code for dementia but no Read code for  psychosis (denominator) 
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• Patients aged ≥18 years with an eGFR <45 prescribed an oral NSAID (excluding aspirin) 
(numerator) / Patients aged ≥18 years with an eGFR <45 (denominator). 
Descriptive statistics:  
To illustrate patients’ demographic characteristics and diagnosis, descriptive statistics in terms 
of frequency counts and proportions were used.  
For each record, the medication list during the study period was checked against the SFDA 
list of human medications and each medication was subsequently classified as either a 
prescription or OTC medication. If the patient’s record showed that the patient had used OTC 
medication at any point during the 15 months, this was recorded in the data collection sheet as 
‘yes’. If the patient’s record showed that the patient was using ≥ five concurrent medications 
at any point during the 15 months, this was also recorded in the data collection sheet as ‘yes’. 
Risk factors: 
A regression technique allows the identification and description of the relationships that exist 
between variables. Regression is” the relation of mean values of a dependent or regressand 
variable to independent or regressor variables (covariates)”.(106) 
Several types of regression techniques exist. Two of the most widely used in research are: a) 
linear regression, which analyses continuous outcomes (dependent variable), and b) logistic 
regression, which analyses categorical outcomes (dependent variable).(119) 
As a result, logistic regression was used to evaluate the strength and direction of the 
association between risk factors and outcome because I had categorical dependent variables 
(i.e. patients at risk outcome (Y): yes or no coded as 1 or 0) and independent variables (x) with 
2 or more categories.(120)  
Logistic regression is “(Syn: logistic regression model) a statistical model for the probability 
that a binary variable Y equals 1 as a function of a covariate x, typically used when Y is an 
individual’s disease indicator and x is the value of a risk factor or risk indicator”. (106) 
Basic assumptions that must be met for logistic regression include independence of errors, the 
absence of multi-collinearity, and lack of strongly influential outliers. Additionally, there 
should be an adequate number of events per independent variable to avoid an overfit model, 
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with commonly recommended minimum ranging from 10 to 20 events per independent 
variable.(119)  
The result of the regression analysis was presented in terms of OR; 95% confidence interval 
(CI). Significance measures of P <0.05 and 95% CI were used. CI is “a range constructed 
around the sample statistic in such a way that the population parameter is included with a 
specified probability”.(121) 
Each logistic regression involved the entry of a single dependent variable and a single 
independent variable. For the logistic regression modelling, the dependent variable was 
defined as the presence/absence of the outcome i.e. the presence/absence of patients at risk of 
medication error. The independent variables were age in years, gender, nationality, taking five 
or more drugs (polypharmacy) and using OTC medications.  
For the interpretation of ORs with their 95% CIs, OR greater than 1 corresponds to ‘positive 
effects’ because they increase the odds. Those between 0 and 1 correspond to ‘negative 
effects’ because they decrease the odds. ORs of exactly 1 corresponds to ‘no 
association’.(119) 
A CI containing 1.0 for an OR means that we are less than 95% sure that a significant 
difference exists; a significance test of the difference would thus give P > 0.05. A confidence 
interval not including 1.0 for an OR means that we are more than 95% sure that a significant 
difference exists; a significance test of the difference would thus give P < 0.05. An interval 
bounded at one end by exactly 1.0 will give P= 0.05.(121) 
Agreement between two data extractors: 
For the categorical variable, Kappa coefficient is commonly used to determine the coefficient 
of agreement between the two independent data extractors. 
A Kappa score: is “a measure of the degree of nonrandom agreement between observers or 
measurements of the same categorical variable. Kappa coefficients are measures of 




The number of positive (error or risk) in the pilot study dataset is 196 in 200 patients. To be 
able to calculate the Kappa coefficient, the data were entered as a two-way table. For details 
on the Kappa coefficient method for calculation see Appendix 8.  
For the interpretation of the Kappa coefficient, Landis and Koch suggested a Kappa value of 
less than 0.40 is considered poor-to-fair agreement, 0.41-0.60 is moderate agreement, 0.61-
0.80 is felt to be substantial agreement, and 0.81-1.00 is considered almost perfect 
agreement.(122) Discrepancies were resolved by discussion between the two data extractors 
and by double-checking the records. 
Using a retrospective cohort, missing data are common. I reported the number of, and reasons 
for, missing values, where possible. Removing subjects with missing data may produce biased 
results, unless the subjects with missing data are few. If there is a large proportion of missing 
data, a suitable multiple imputation technique can be used to reduce bias.  
 
6.2.9 Ethics and regulatory approvals 
I was aware of the ethical considerations in my study and the responsibility of dealing with 
data. The WHO’s report ‘Ethical issues in patient safety research’ states in the privacy and 
confidentiality guideline that “every precaution must be taken to protect the privacy of 
research subjects and the confidentiality of their personal information”.(123)  
Confidentiality and privacy of the data were maintained throughout this study. To ensure 
anonymity of participants, all participants’ personal data or identifiers were treated 
confidentially by giving each participant a code number, thus anonymising the data in any 
future publications.  
An inventory of medical record numbers mapping identifiers to patient’s code number was 
also stored as a hard copy in a secure location in the clinic (i.e. locked office).  
Regarding EHR searching, patients were not contacted, and I did not record any patient 
identifier information such as names, addresses, and medical record numbers that could be 
used to link data to participants. According to the KFSH&RC guidelines and policy of the 
REC, the research method does not require a subject’s consent. As stated in the ‘Research that 
may be exempt from REC review’ section:  
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“It is important to note that the study of existing data (retrospective chart reviews) or 
the use of discards of tissue taken for clinical reasons can ONLY be exempted from 
REC review IF the information is recorded in such a manner that the subjects cannot 
be identified, either directly or through a code linked to the subject (i.e., the identity of 
the subject is NOT or may NOT be readily ascertained by the investigator or 
associated with the information). It is also important to note that the types of research 
that can be exempted must pose NO risks to the subjects”.(109)  
The data collected from the EHRs were used for the research purpose only. Research 
protocols that may be eligible for exemption from REC review must be submitted to the 
Office of Research Affairs for registration and approval by the research advisory council (i.e., 
the Clinical Research Committee or Basic Research Committee). Each protocol must also 
contain a statement that justifies the request for exemption.(109)  
I simultaneously received ethical approval for Phases 2 and 3 of my research programme from 
the Clinical Research Committee and the REC of the institution’s Office of Research Affairs, 
KFSH&RC, Riyadh, SA (see Section 5.2.6). (Appendix 9) 
 
6.2.10 Reporting 
The methodology of the Phase 3 pilot retrospective cohort study was reported using the 
STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist 
(124) and the REporting of studies Conducted using Observational Routinely-collected health 
Data (RECORD) statement.(125) (see Appendix 11). 
 
6.3 Results 
At sampling, the number of all patients who visited the Family Medicine department two 
weeks before data collection was 1,253. I and SK collected the required information from 200 
electronic records after excluding patients who were aged under 18 years, registered for less 
than 15 months, not on medications, or who had died, left the clinic or did not attend (see Box 
5-1). The pilot retrospective study was conducted over a 15-month period between 01 
February 2016 and 31 May 2017. 
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The percentages of adults in the age range 18-64 and 65 years or over were 83.0% and 17.0%, 
respectively. The majority of the study population was of Saudi nationality (74.0%). Table 
6-1 summarises the data relating to the adults’ characteristics. 
The agreement between the two independent data extractors was substantial (Kappa 0.69). All 
discrepancies were resolved by discussion and by double-checking the records. For details on 
the Kappa coefficient result see Appendix 8.  
In the pilot study stage, no missing data were found. 
Variable Mean (years; 95% CI) 
Age (50.1; 95% CI 47.9 to 52.4) 
Variable  Count (%) 
Age  18-64 years 166 (83.0%) 
≥ 65 years 34 (17.0%) 
Gender  Male 72 (36.0%) 
Female 128 (64.0%) 
Nationality   Saudi 148 (74.0%) 
Non-Saudi  52 (26.0%) 
Polypharmacy  Yes: ≥ 5 medications  119 (59.5%) 
No: 1-4 medications 81 (40.5%) 
OTC medicines Yes: using OTC 186 (93.0%) 
No: not using OTC 14 (7.0%) 
Diagnosis  Cardiac and vascular disorder  Gastrointestinal disorder 
Cardiac arrhythmias 2 (1.0%) Ulcer 1 (0.5%) 
Dyslipidaemia 79 (40%) Gastritis 9 (4.5%) 
Essential hypertension 85 (42.5%) History of H. pylori  6 (3.0%) 
Heart failure 5 (2.5%) Renal disorder  
Ischemic heart disease 9 (4.5%) Chronic kidney disease  8 (4.0%) 
Pulmonary disorder Arthritic disorder  
Asthma 27 (13.5%) Osteoarthritis 27 (13.5%) 
COPD 1 (0.5%) Osteoporosis 2 (1.0%) 
Rhinitis 20 (10.0%) Endocrine disorder  
Psychiatric disorder  Hypo/hyperthyroidism  34 (17.0%) 
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Table 6-1. Pilot study demographic characteristics. 
 
6.3.1 Proportions of errors in patients at risk of each outcome measure 
We reviewed the electronic record of each patient and extracted the relevant data 
retrospectively within the study period. 
For each record and for each of the outcomes of interest, we identified whether a particular 
patient was at risk and whether a relevant prescribing or monitoring error had been made. The 
details are shown in Table 6-2. 
Outcome measures  Numerators Denominators Proportion of 
errors in 
patients at risk 
(%); 95% CI 
Primary outcomes 
1. Patients with a history of peptic 
ulcer who had been prescribed a non-
selective NSAID without co-
prescription of a PPI 
0 1 0 
(2a) Patients with asthma who had 
been prescribed a β-blocker 
3 4 75.0; 95% CI -
4.6 to 154.6 
3. Patients aged 75 years and older 
who had been prescribed an ACE 
inhibitor or a loop diuretic long-term 
who had not had a computer-recorded 
check of their renal function and 
electrolytes in the previous 15 months 
0 1 0 
Secondary outcomes 
(2b) Patients with asthma [and no 4 24 16.7; 95% CI 
Depression  13 (6.5%) Diabetes mellitus  73 (36.5%) 
Bipolar  1 (0.5%) 
Dementia  3 (1.5%)   
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Outcome measures  Numerators Denominators Proportion of 
errors in 
patients at risk 
(%); 95% CI 
history of CHD] who had been 
prescribed a β-blocker 
0.6 to 32.7 
4. Proportions of women with a past 
medical history of venous or arterial 
thrombosis who had been prescribed 
the combined oral contraceptive pill 
0 1 0 
5. Patients receiving methotrexate for 
at least 3 months who had not had a 
full blood count recorded (5a), or liver 
function test (5b), in the previous 3 
months 
0 0 Not calculable  
6. Patients receiving warfarin for at 
least 3 months who had not had a 
recorded check of their INR in the 
previous 12 weeks 
0 2 0.0 
7. Patients receiving lithium for at 
least 3 months who had not had a 
recorded check of their lithium 
concentrations in the previous 3 
months 
1 1 100.0 
8. Patients receiving amiodarone for at 
least 6 months who had not had a 
thyroid function test in the previous 6 
months 
0 0 Not calculable 
9. Patients receiving prescriptions of 
methotrexate without instructions that 
the drug should be taken every week 
 
0 0 Not calculable 
10. Patients receiving prescriptions of 0 0 Not calculable 
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Outcome measures  Numerators Denominators Proportion of 
errors in 
patients at risk 
(%); 95% CI 
amiodarone for at least 1 month who 
are receiving a dose of more than 200 
mg per day 
Composite secondary outcome measures 
11. Patients with at least one 
prescription problem (a combination 
of outcome measures 1, 2, and 4) 
 
7 30 23.3; 95% CI 
7.3 to 39.4 
12. Patients with at least one 
monitoring problem (a combination of 
outcome measures 3, 5, 6, 7, and 8) 
 
1 4 25.0; 95% CI -
54.6 to 104.6 
Additional revised updated outcomes measures 
13. Prescription of an oral NSAID, 
without co-prescription of an ulcer-
healing drug, to a patient aged  ≥ 65 
years 
6 27 22.2; 95% CI 
5.5 to 38.9 
14. Prescription of an anti-platelet 
drug without co-prescription of an 
ulcer-healing drug, to a patient with a 
history of peptic ulceration 
0 1 0.0 
15. Prescription of warfarin or NOAC 
in combination with an oral NSAID 
0 5 0.0 
16. Prescription of warfarin or NOAC 
and an anti-platelet drug in 
combination without co-prescription 
of an ulcer-healing drug 
3 4 75.0; 95% CI -
4.6 to 154.6 
17. Prescription of aspirin in 
combination with another anti-platelet 




Outcome measures  Numerators Denominators Proportion of 
errors in 
patients at risk 
(%); 95% CI 
drug without co-prescription of an 
ulcer-healing drug 
18. Prescription of a long-acting beta-
2 agonist inhaler (excluding 
combination products with inhaled 
corticosteroid) to a patient with 
asthma who is not also prescribed an 
inhaled corticosteroid 
0 0 Not calculable 
19. Prescription of an oral NSAID to a 
patient with heart failure 
2 5 40.0; 95% CI -
28.0 to 108.0 
20. Prescription of antipsychotics for 
> 6 weeks in a patient aged ≥ 65 years 
with dementia but not psychosis 
1 3 33.3; 95% CI -
110.1 to 176.8 
21. Prescription of an oral NSAID to a 
patient with eGFR < 45 
0 5 0 




16.0; 95% CI 
8.2 to 23.8 
Period prevalence  Total of 20 
patients with at 
least one error  
200 total 
patients 
10.0; 95% CI 
5.8 to 14.2  
Table 6-2. Pilot study proportion of errors in patients at risk of each primary, 
secondary, composite and revised updated outcome measure described using 




Outcome 1: Proportion of patients prescribed a NSAID (excluding aspirin), without a 
PPI among patients with a history of peptic ulcer  
Only one patient had a history of peptic ulcer without PPI. This patient was not on any 
NSAID.  
Outcome 2a: Proportion of β-blocker users among patients with asthma 
Four patients had a history of asthma. Out of the patients at risk, 75.0% of the patients had at 
least one prescription of β-blocker oral preparations or eye drops. The prescribed β-blockers 
were carvedilol and metoprolol. 
Outcome 2b: Proportion of β-blocker users among patients with asthma and without 
CHD 
Twenty-four patients had a history of asthma and no history of CHD. Out of the patients at 
risk, 16.7% had received at least one prescription of β-blocker oral preparations or eye-drops. 
The prescribed β-blockers were atenolol, metoprolol and timolol eye drops. 
Outcome 3: Proportion of patients without check of renal function among patients aged 
≥ 75 years on ACEI or loop diuretics 
There was one patient aged ≥ 75 years with evidence of long-term (> 15 months) prescription 
of ACE inhibitors or loop diuretics. This patient had received a check of his renal function in 
the previous 15 months. 
Outcome 4: Proportion of oral contraceptive users among female patients with venous 
or arterial thromboembolism 
One female patient had venous or arterial thromboembolism. The patient was not on any oral 
contraceptive. 
Outcome 5a, 5b: Proportion of patients without full blood count or liver function test 
among methotrexate users 
There were no patients with evidence of at least three months of prescribing of methotrexate. 
Outcome 6: Proportion of patients without INR among warfarin users 
There were two patients with evidence of at least three months of prescribing of warfarin. 
None of the patients at risk had no INR recording in the previous three months. 
Outcome 7: Proportion of patients without a lithium level check among lithium users 
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There was one patient with evidence of at least three months of prescribing of lithium. This 
patient at risk had not had a lithium level check in the previous three months. 
Outcome 8: Proportion of patients without thyroid function test among amiodarone 
users 
None of the patients were using amiodarone. 
Outcome 9: Proportion of patients without instructions taken every week among 
methotrexate users 
None of the patients were using methotrexate. 
Outcome 10: Proportions of patients receiving a dose of more than 200 mg per day 
among amiodarone users   
None of the patients were using amiodarone. 
Outcome 11: Proportion of patients with at least one prescribing problem (i.e. Outcomes 
1, 2 and 4) among patients at risk of at least one prescribing problem 
There were 30 “at risk” patients with at least one prescribing problem. Of the patients at risk, 
23.3% had experienced at least one prescribing problem. 
Outcome 12: Proportion of patients with at least one monitoring problem (i.e. Outcomes 
3, 5 (a or b), 6, 7 and 8) among patients at risk of one monitoring problem 
There were four “at risk” patients with at least one monitoring problem. Of the patients at 
risk, 25.0% had at least one monitoring problem. 
Outcome 13: Proportion of patients prescribed an oral NSAID (excluding aspirin), 
without co-prescription of an ulcer-healing drug among patients aged ≥ 65 years 
Twenty-seven patients were aged ≥ 65 years without co-prescription of an ulcer-healing drug. 
Of the patients at risk, 22.2% had been given at least one prescription of an oral NSAID 
(except aspirin) without co-prescription of an ulcer-healing drug. The NSAIDs prescribed 
were diclofenac, celexoxib, meloxicam and naproxen.  
 
Outcome 14: Proportion of patients prescribed an anti-platelet drug without co-
prescription of an ulcer-healing drug among peptic ulcer patients 
Only one patient had a history of peptic ulcer without co-prescription of an ulcer-healing 
drug. The patient was not on any anti-platelet drug. 
123 
 
Outcome 15: Proportion of patients prescribed an oral NSAID (excluding aspirin)among 
warfarin or NOAC users  
Five patients had been prescribed warfarin or NOAC. None of the patients had at least one 
prescription of an oral NSAID.  
Outcome 16: Proportion of patients prescribed an anti-platelet drug without co-
prescription of an ulcer-healing drug among warfarin or NOAC users 
Four patients had been prescribed warfarin or NOAC without co-prescription of an ulcer-
healing drug. Out of the patients at risk, 75.0% had been given at least one prescription of an 
anti-platelet drug. The anti-platelet drugs prescribed were aspirin and clopidogrel. 
Outcome 17: Proportion of patients prescribed an anti-platelet drug without co-
prescription of an ulcer-healing drug among aspirin users  
Forty-six patients had been prescribed aspirin without co-prescription of an ulcer-healing 
drug. Out of the patients at risk, 8.7% had been given at least one prescription of an anti-
platelet drug. The anti-platelet drug prescribed was clopidogrel. 
Outcome 18: Proportion of patients prescribed a long-acting beta-2 agonist inhaler 
(excluding combination products with inhaled corticosteroid) who are not also 
prescribed an inhaled corticosteroid among asthma patients 
All patients with asthma had been prescribed a long-acting beta-2 agonist inhaler 
(combination products with inhaled corticosteroids).  
Outcome 19: Proportion of patients prescribed an oral NSAID (excluding aspirin) 
among patients with heart failure 
Five patients had heart failure. Out of the patients at risk, 40.0% had been given at least one 
prescription of an oral NSAID. The NSAID prescribed was meloxicam. 
Outcome 20: Proportion of patients prescribed an antipsychotic for > 6 weeks among 
patients aged ≥ 65 years with dementia but not psychosis 
Three patients aged ≥ 65 years had dementia (not psychosis). Out of the patients at risk, 
33.3% had been given at least one prescription of an antipsychotic for > 6 weeks. The 
antipsychotic prescribed was quetiapine. 
Outcome 21: Proportion of patients prescribed an oral NSAID (excluding aspirin) 
among patients with eGFR < 45 
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There were five patients with eGFR <45. Out of the patients at risk, none had been given at 
least one prescription of an oral NSAID.  
 
6.3.2 Overall period prevalence rate  
We found a total of 32 prescribing/monitoring errors during the study period, categorised as 
the following: 23 prescribing errors (contraindications), one monitoring error and 8 
Composite secondary outcome measures prescribing/monitoring errors. 
 
Overall period prevalence  
Numerator = the number of patients experiencing one or more medication error at any time 
during the 15 month period = 20 patients. 
Denominator = the total number of patients in the study population = 200 patients.  
The overall period prevalence of patients with at least one medication error over 15 months = 
20 (numerator) / 200 (denominator) = 10.0% (95% CI 5.8 to 14.2). 
 
Numerator = the number of medication errors at any time during the 15 month period = 32 
patients. 
Denominator = the total number of patients in the study population = 200 patients.  
The overall period prevalence of medication errors over 15 months= 16.0% (95% CI 8.2 to 
23.8). 
6.3.3 Risk factors  
Risk factors that significantly predicted the overall patients at risk of medication errors were 
patient’s age of ≥65 years and using OTC medications. 
On the basis of the estimated ORs, patients aged ≥ 65 years were estimated to be 35 times 
more likely to be at risk of experiencing medication error than those aged 18-64 years (OR 
35.1; 95% CI 8.1 to 151.9). Patients using OTC medications were estimated to be four times 
more likely to be at risk of experiencing medication error than those patients not using OTC 
(OR 3.8; 95% CI 1.1 to 12.5). There was no association between most of the risk factors and 




Age (≥ 65 / 
18-64 years) 











OR; 95% CI 
P 
value 
Taking five or more drugs 
(Polypharmacy) (yes/no) 









Overall patients at risk of experiencing medications errors 
 35.1; 8.1 to 
151.9 
0.00 0.5; 0.3 to 0.9 0.02 0.2; 0.1 to 0.5 0.00 0.2; 0.1 to 0.35 0.00 3.8; 1.1 to 
12.5 
0.03 
Number of individual patients at risk outcomes 
2a 1.6; 0.2 to 
16.3 
0.67 0.2; 0.0 to 1.8 0.14 NA - NA - NA - 
2b 1.3; 0.5 to 
3.9 
0.59 0.6; 0.3 to 1.5 0.29 0.4; 0.1 to 1.3 0.12 0.3; 0.1 to 0.9 0.04 1.2; 0.3 to 
5.9 
0.79 
6 5.0; 0.3 to 
81.9 
0.26 NA - NA - 1.5; 0.1 to 23.9 0.79 NA - 
11 1.6; 0.6 to 
4.1 
0.32 0.5; 0.2 to 1.1 0.09 0.3; 0.1 to 0.9 0.04 0.3; 0.1 to 0.8 0.02 0.9; 0.2 to 
4.4 
0.94 




Age (≥ 65 / 
18-64 years) 











OR; 95% CI 
P 
value 
Taking five or more drugs 
(Polypharmacy) (yes/no) 










13 NA - 0.8; 0.3 to 1.8 0.58 NA - 0.3; 0.1 to 0.8 0.02 2.8; 0.8 to 
9.8 
0.09 
15 1.2; 0.1 to 
11.3 
0.86 0.4; 0.05 to 
2.2 
0.28 0.7; 0.1 to 6.5 0.76 0.35; 0.0 to 3.2 0.36 NA - 
16 1.6; 0.2 to 
16.3 
0.67 0.6; 0.1 to 4.0 0.56 NA - 0.5; 0.0 to 4.7 0.53 NA - 
17 4.7; 2.15 to 
10.3 
0.00 0.6; 0.3 to 
1.15 
0.12 0.35; 0.1 to 0.9 0.03 0.15; 0.1 to 0.4 0.00 5.2; 1.7 to 
15.9 
0.00 
19 22.0; 2.4 to 
203.7 
0.01 0.1; 0.0 to 1.2 0.07 NA - NA - NA - 
20 NA - 0.3; 0.0 to 3.1 0.29 NA - 0.7; 0.1 to 8.2 0.80 NA - 




Age (≥ 65 / 
18-64 years) 











OR; 95% CI 
P 
value 
Taking five or more drugs 
(Polypharmacy) (yes/no) 











Table 6-3. Pilot study association between risk factors and patients at risk of medication error outcome. (Data obtained from logistic 
regression models). NA: No association. OR = 1. 
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6.4 Chapter summary 
In this pilot retrospective study, a random sample was selected from the Family Medicine and 
Polyclinics in KFSH&RC, Riyadh, SA. EHRs were screened and relevant data collected to 
investigate the period prevalence and risk factors of patient at risk of clinically important 
errors in the medicine management in adults. The outcome measures used included the 
prescription of aspirin, anti-platelet, antipsychotics, β-blockers, NSAIDs, NOACs and 
warfarin and the monitoring of ACE inhibitor or loop diuretics, amiodarone, methotrexate, 
lithium, and warfarin.  
The overall period prevalence of patients with at least one medication error over 15 months 
was (10.0%; 95% CI 5.8 to 14.2). The overall period prevalence of medication errors over 15 
months was (16.0%; 95% CI 8.2 to 23.8). The pilot study suggested that clinically important 
errors in medicine management in adults are common. The highest risk of prescribing error 
was in patients with asthma who had been prescribed a β-blocker and in patient prescribed 
warfarin or NOAC and an anti-platelet drug in combination without co-prescription of an 
ulcer-healing drug. A monitoring error was found in one patient receiving lithium for at least 
three months who had not received a recorded check of their lithium concentrations in the 
previous three months. Risk factors that significantly predicted the overall patients at risk of 
medication errors were patient’s age of ≥65 years and using OTC medications. However, the 
data suggested that other factors might be identified in the larger planned follow-on study (see 
Chapter 7).  
The findings from this phase of the research suggested that the continuation of the cohort 
study was important. This study’s approval and protocol were then used for the main cohort 
study. The continuation of Phase 4 was undertaken without excluding any of the outcome 
measures, because any outcomes not appearing in this phase may appear when screening a 
higher number of records. Clearly, more long-term data were needed to explore further the 
effects of physician-related risk factors on the patients at risk of experiencing medication 





Chapter Seven: Phase 4: Retrospective Cohort Study Investigating the Epidemiology 
of Medication Errors in Adults Using Electronic Health Records in Riyadh, Saudi 
Arabia 
7.1 Introduction 
The epidemiology of medication errors among patients in ambulatory care has never been 
studied in SA as shown in my systematic review (Chapter 4).(113) Therefore, in 2017, as part 
of this research, a feasibility and pilot study (Phases 2 and 3) were initiated to test the 
feasibility and reliability of using data extraction from the EHRs of KFSH&RC Family 
Medicine and Polyclinics, Riyadh, SA (see Chapters 5 and 6). The purpose of Phase 3 was to 
pilot plans to determine the period prevalence of clinically important errors in medicine 
management, as well as their risk factors, and to inform sample size calculations for a 
retrospective cohort study (Phase 4). No changes to the methodology of the pilot retrospective 
cohort study were made, except for adding physician-related risk factors (see Section 7.2.3). 
Phase 4 of my research focused only on the medication errors as in Phases 2 and 3. 
This chapter reports on an investigation into the epidemiology of clinically important errors in 
medicine management as defined by the PINCER trial.(85) The results from this study will 
assist in allocating resources and improving the quality of healthcare provided in ambulatory 
and primary care in SA. 
It should be noted that Phase 1 of this research focused on both medication errors and error-
related ADEs, but Phases 2, 3 and 4 focused solely on medication errors. 
7.2 Methods 
7.2.1 Study design  
A cohort study is “The analytic epidemiological study in which subsets of a defined 
population can be identified who are, have been, or in the future may be exposed or not 
exposed—or exposed in different degrees—to a factor or factors hypothesized to influence the 
occurrence of a given outcome”.(106)  
The choice of study design in research depends on many factors, including prior research, 
130 
 
availability of study participants, funding, and time constraints.(126) An observational study 
design, rather than an intervention design, was chosen for my research considering the limited 
research team and time available. There are three main types of observational studies: a) 
cross-sectional, b) case-control and c) cohort study. All three study designs have the 
advantage of the ability to control for multiple confounders, where a confounder is “a 
variable that can be used to decrease confounding bias (bias of the estimated effect of an 
exposure on an outcome due to the presence of common causes of the exposure and the 
outcome) when properly adjusted for”.(106) The case-control study was excluded because it 
cannot measure the prevalence of outcome and can only assess one outcome. In addition, the 
cross-sectional design was excluded because it only provides a snapshot of a particular sample 
at a given point in time, unlike longitudinal studies that look at a sample over an extended 
period.(126) 
A cohort design was chosen for this study because: a) of its ability to assess multiple 
exposures, b) it can assess multiple outcomes, and c) of its ability to either follow-up over a 
period of time to identify which participants develop the outcome(s) of interest (prospective), 
or look back at data that were created in the past, prior to the development of the outcome 
(retrospective).(126) 
A retrospective cohort study design was undertaken to measure the period prevalence of the 
primary, secondary, composite secondary and revised updated outcome measures and risk 
factors.(85, 107) 
 
7.2.2 Participants and sampling 
A random sample of patients visiting the Family Medicine and Polyclinics was selected.  
Subjects were selected from the Family Medicine and Polyclinics at KFSH&RC. Sampling 
took one month in 2017; follow-up was carried out retrospectively, over the 15 months prior 
to the data extraction from 1 August 2016 to 30 November 2017. Data collection took three 
months (01 October 2017 to 31 December 2017) complying with the time limit set by the 
Saudi Bureau for fieldwork inside SA.(127) The retrospective cohort study flowchart (Figure 
7-1) shows a description of the population and sample included.   
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Figure 7-1. Cohort study flowchart outlines population and sample enrolment. 
 
Method of sampling:  
A list of all patients who visited the family medicine department one month before data 
collection (01 October 2017) was generated. One month was specified because the maximum 
duration that could be specified by the ICIS for generating a patient list was two weeks, which 
yielded around 1,500 records. Therefore, the patient list was generated twice to achieve the 
required sample size. A serial number was assigned to each record, after which paediatric 
patients were excluded. Then, numbers were selected at random from a table of random 
Number of all patients at 
sampling n=4398 Excluding patients managed in unrelated clinic 
n=20 
Excluding < 18 years old patients n=171 
Total exclusion: n=191 
 
Number of ≥ 18 years old 
patients n=4207 
Random sample of 2524 
Number of patients’ 




Excluding registered for <15 months n= 
508 
Excluding patients not on medications 
n=16 
Total exclusion: n=524 
 
Number of ≥ 18 years old 
patients n=3659 
Excluding duplicated records n=548 
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numbers, until the desired sample size was attained.(106) Electronic records were randomly 
selected using a random number table generated using the ‘simple random sample without 
replacement’ function in STATA (version 14). Unfortunately, Saudi national data are not 
available to enable comparison between the baseline characteristics of the sample population 
and the whole population.  
 
7.2.3 Variables  
Baseline characteristics:  
Patients’ characteristic: 
Patients’ baseline characteristic variables recorded were age, gender, nationality 
(Saudi, non-Saudi), diagnosis or underlying conditions, OTC recorded at any point 
during the 15 months and polypharmacy (taking five or more medications at any point 
during the 15 months). 
Physicians’ characteristic: 
Family medicine/general practice physicians’ baseline characteristic variables 
recorded were age (18-50 years, ≥51 years), gender, nationality (Saudi, non-Saudi), 
number of physicians involved in each patient’s care (one, more than one), 
certification (American, British, Canadian, Jordanian, or none) and number of years of 
experience (1-9 years, ≥ 10 years). A list of all physicians in the Family Medicine and 
Polyclinics was obtained and each physician assigned a code (e.g. PHa, PHb, etc.). 
Exposures:  
1. Prescribed medications and/or OTC drugs.  
2. Patient and physician-related risk factors. 
 
Outcome variables:  
1. Period prevalence of the primary, secondary, composite secondary and revised 
updated outcome measures. 
For details of the primary, secondary, composite secondary and revised updated 
outcome measures see Chapter 5 (Box 5-1).(85, 107) 
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7.2.4 Data sources/measurement 
Identification of outcomes 
After selecting a random sample from the Family Medicine and Polyclinics, in-depth EHR 
screening involving assessment of diagnostic, medication list and laboratory data was 
undertaken in order to investigate the period prevalence of clinically important errors and 
patient and physician-related risk factors that were associated with patients at risk of clinically 
important errors in medicines management. The presence, or absence, of the primary, 
secondary, composite secondary and revised updated outcome measures (the numerator) and 
the denominator for each outcome measure was recorded. During this review of EHRs, I only 
focused on the outcomes detailed in Chapter 5 (Box 5-1).(85, 107) 
The secondary trained data extractor Sarah Al-hathlool (SH) did a manual and independent 
data extraction on 10% (200 records) of the cohort study sample size (2000 records).(114, 
128) Any discrepancies or disagreements were discussed and resolved by double-checking the 
records or via arbitration by the third reviewer (AK) if a decision could not be reached. In 
case of high discrepancies (poor-to-fair agreement), more records would be checked. 
Data collection tool: 
Data were extracted manually from the EHR using a paper-based data collection form. The 
reason for using the manual data extraction was explained in Section 5.5.5. An extensive 
summary description of all relative information available in the EHRs for the patient’s 
demographics and outcome measures was collected (see Appendix 12). The paper data 
collection forms were stored in secure locations; locked office in the outpatient department in 
Riyadh, SA and the PhD office in Edinburgh, UK. 
The information in the paper-based data collection tool was transferred to an electronic data 
sheet using an Excel spreadsheet to facilitate analysis. The electronic data sheet was stored in 
a password-protected computer and no patient identifying information was recorded. 
 
7.2.5 Bias  
See Chapter 6 Section 6.2.5 for a discussion on potential sources of bias and how I attempted 
to minimise the effects of these sources. 
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7.2.6 Study size 
Every record needed a maximum of 15 minutes to scan and extract data. The largest sample 
size that was feasible was chosen, taking into account the time available, resources and 
research team; resulting in a total of 2000 records. See Chapter 6 section 6.2.6 for more 
details relating to this issue.  
 
7.2.7 Data access and cleaning methods  
See Chapter 6 Section 6.2.7 for a discussion on data access and cleaning methods. An 
inventory of medical record numbers, patients’ code numbers and patients’ attendance dates 
was used to ensure patients were not included in the dataset more than once. 
 
7.2.8 Statistical methods  
Microsoft Excel was used to process data and STATA (version 14) was used to analyse the 
data. See Chapter 6. Section 6.2.8 for further information relating to this matter. 
Descriptive analysis: 
To illustrate patients’ demographic characteristics and diagnosis, descriptive statistics in terms 
of frequency counts and proportions were used.  
Risk factors: 
To evaluate the association of risk factors and outcome, I used a logistic regression model. 
The results of the regression analysis were presented in terms of (OR; 95% CI). Each logistic 
regression involved the entry of a single dependent variable and a single independent variable.   
The patient and physician-related independent variables were detailed in Section 7.2.3. The 
dependent variable was defined as the presence/absence of the outcome i.e. the 
presence/absence of patients at risk of medication error. Significance measures P <0.05 and 




Agreement between two data extractors:  
Cohen’s Kappa coefficient was also calculated see Chapter 6, Section 6.2.8 for details on 
Kappa score agreements. If poor-to-fair agreement was achieved, more samples would be 
checked for their reliability. 
The number of observations with positive (error or risk) in the cohort study dataset is 48 in 
200 Patients. The data were entered as a two-way table. For details on the Kappa coefficient 
method for calculation see Appendix 8. 
Comparison: 
It should be emphasised that the results of the UK-based PINCER trial cannot be directly 
compared to the cohort study, because the PINCER trial is an interventional study. However, 
it was possible to compare the study’s results with the QRESEARCH analysis of secular 
trends i.e. the large national QRESEARCH general practice database, one of the largest 
aggregate general practice electronic databases worldwide, consisting of 1,500 general 
practices.(129, 130)  
 
7.2.9 Ethics and regulatory approvals 
Since no major changes were applied after the pilot phase, the ethical approval for the pilot 
retrospective cohort study remained valid.  I had received ethical approval for Phases 2 and 3 
from the Clinical Research Committee and the REC of the institution’s Office of Research 
Affairs, KFSH&RC, Riyadh, SA (see Section 5.2.6) (see Appendix 9). In addition, the 
proposal for data collection and extraction from 2000 electronic records, together with the 
addition of physician-related risk factors into the cohort study, was reviewed by the REC and 
approved (Appendix 13). 
 
7.2.10 Reporting  
The methodology for Phase 4, retrospective cohort study, follows the STROBE checklist 
(124) and RECORD statement (see Appendix 14).(125) 
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7.3 Results  
At sampling, the number of all patients who visited the Family Medicine department one 
month before data collection was 4,398. I collected the required information of 2000 
electronic records after excluding patients aged <18 years, patients registered for <15 months, 
those who were not on medications, and those who had died, left the clinic or had not 
attended. (See Figure 7-1Figure 7-1). 
The percentages of adults in the age range 18-64 and ≥65 years were 83.85% and 16.15%, 
respectively. The majority of the study’s population was of Saudi nationality (67.2%); Table 
7-1 summarises the data on adults’ characteristics. 
The agreement between the two independent data extractors for 200 records was substantial 
(Kappa 0.8). All discrepancies were resolved by discussion and by double-checking the 
records. For details on the Kappa coefficient result see Appendix 8. 
Variable Mean (years; 95% CI) 
 
Age (49.9; 95% CI 48.2 to 49.6) 
Variable  Count (%) 
Age 18-64 years 1,677 (83.85%) 
≥ 65 years 323 (16.15%) 
Gender Male 698 (34.9%) 
Female 1,302 (65.1%) 
Nationality  Saudi 1,344 (67.2%) 
Non-Saudi  656 (32.8%) 
Polypharmacy Yes: ≥ 5 medications  1,115 (55.75%) 
No: 1-4 medications 885 (44.25%) 
OTC medicines Yes:  using OTC 1,899 (94.95%) 
No: not using OTC 101(5.05%) 
Diagnosis  Cardiac and vascular disorder  Gastrointestinal disorder 




Table 7-1. Cohort study demographic characteristics. 
7.3.1 Proportions of errors in patients at risk of each outcome measure 
The results were compared with the QRESEARCH analysis of secular trends. The overall 
period prevalence of the first 12 clinically important errors in medicine management estimates 
was (3.4%; 95% CI 2.2 to 4.6) in this research compared with 0.9% for the QRESEARCH 
analysis of secular trends.(129) The distribution of each estimate for the outcome measures 
are set out below: in my study, higher period prevalence estimate were found in Outcomes 2a 
and 2b (asthma and β-blocker), Outcome 6 (warfarin and INR), Outcome 7 (lithium and 
lithium level), Outcome 11 (at least one prescription error) and Outcome 12 (at least one 





Essential hypertension 816 
(40.8%) 
History of H. pylori  22 
(1.1%) 
Heart failure 14 (0.7%) Renal disorder  
Ischemic heart disease 69 
(3.45%) 
Chronic kidney disease  60 
(3.0%) 









Endocrine disorder  
Psychiatric disorder  Hypo/hyperthyroidism  353 
(17.65%) 
Depression  164 
(8.2%) 
Diabetes mellitus  595 
(29.75%) 




I could not estimate rates for the following outcomes, because there were no events: Outcome 
1 (peptic ulcer and NSAID without an ulcer-healing drug), Outcome 3 (ACE inhibitor / 
diuretics and lab test), Outcome 4 (venous or arterial thromboembolism and arterial 
thrombosis and combined oral contraceptives), Outcome 5a (methotrexate and full blood 
count, and 5b: methotrexate and liver function test). For Outcome 8 (amiodarone and thyroid 
function test) and Outcome 10 (amiodarone dose) there was no patient on amiodarone. 
There follows a comparison of this study with the QRESEARCH analysis of secular trends 




 Cohort study  QRESEARCH analysis of secular trends (129) 
Outcome measures  Numerator Denominator Proportion of 
errors in patients 











patients at risk 
interquartile 
range (IQR)  
Primary outcomes 
1.Patients with a history of 
peptic ulcer who have been 
prescribed a non-selective 
NSAID without co-
prescription of a PPI 
0 4 0 1182 30204 4 3.45 (1.5 to 5.7) 
(2a) Patients with asthma 
who have been prescribed 
a β-blocker 
7 13 53.8; 95% CI 22.5 
to 85.2 
8130 324778 3 2.4 (1.75 to 3.1) 
3.Patients aged 75 years 
and older who have been 
0 11 0 8461 79496 11 
 
9.2 (5.2 to 14.3) 
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 Cohort study  QRESEARCH analysis of secular trends (129) 
prescribed an ACE 
inhibitor or a loop diuretic 
long-term who have not 
had a computer-recorded 
check of their renal 
function and electrolytes in 
the previous 15 months 
Secondary outcomes  
(2b) Patients with asthma 
[and no history of CHD] 
who had been prescribed a 
β blocker 
21 241 8.7; 95% CI 5.1 
to12.3 
 
   1.55 (1.1 to 2.2) 
4.Proportions of women 
with a past medical history 
of venous or arterial 
thrombosis who had been 
prescribed the combined 
oral contraceptive pill 
0 4 0 
 
223 27225 0.8 0 (0 to 0) 
5.Patients receiving (5a) 0 (5a) 14 (5a) 0 (5a) (5a) 6424 (5a) 22 (5a) 16.7 (3.45 to 
141 
 
 Cohort study  QRESEARCH analysis of secular trends (129) 
methotrexate for at least 3 
months who had not had a 
full blood count recorded 
(5a), or liver function test 






























(5b) 20.0 (4.55 
to 46.7) 
6.Patients receiving 
warfarin for at least 3 
months who had not had a 
recorded check of their 
INR in the previous 12 
weeks 
4 16 25.0; 95% CI 1.2 
to 48.8 
As median  4.0 (1.2 to 12.5) 
7.Patients receiving lithium 
for at least 3 months who 
had not had a recorded 
check of their lithium 
concentrations in the 
previous 3 months 
2 2 100.0; 95% CI 
100.0 to 100.0 
985 3245 30 28.6 (12.5 to 
46.6) 
8.Patients receiving 0 0 Not calculable 2114 4613 33 50.0 (30.0 to 
142 
 
 Cohort study  QRESEARCH analysis of secular trends (129) 
amiodarone for at least 6 
months who had not had a 
thyroid function test in the 





instructions that the drug 
should be taken every 
week 
0 14 0     
10.Patients receiving 
prescriptions of 
amiodarone for at least 1 
month who are receiving a 
dose of more than 200 mg 
per day 
0 0 Not calculable     
Composite secondary outcome measures 
11.Patients with at least 
one prescription problem 
28 259 10.8; 95% CI 7.0 
to 14.6 
   2.45 (1.8 to 3.1) 
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 Cohort study  QRESEARCH analysis of secular trends (129) 
(a combination of outcome 
measures 1, 2, or 4) 
 
12.Patients with at least 
one monitoring problem (a 
combination of outcome 
measures 3, 5, 6, 7, and 8) 
6 43 13.95; 95% CI 3.2 
to 24.7 
   12.4 (7.8 to 19.0) 




















Total of 33 
patients with 




1.65; 95% CI 1.1 
to 2.2 
    
Additional revised updated outcomes measures   
13.Prescription of an oral 
NSAID, without co-




 Cohort study  QRESEARCH analysis of secular trends (129) 
prescription of an ulcer-
healing drug, to a patient 
aged ≥65 years 
14.Prescription of an anti-
platelet drug without co-
prescription of an ulcer-
healing drug, to a patient 
with a history of peptic 
ulceration 
1 4 25.0; 95% CI  -
54.6 to104.6 
15.Prescription of warfarin 
or NOAC in combination 
with an oral NSAID 
2 32 6.25; 95% CI -2.6 
to 15.1 
16.Prescription of warfarin 
or NOAC and an anti-
platelet drug in 
combination without co-
prescription of an ulcer-
healing drug 
11 22 50.0; 95% CI 27.3 
to 72.7 
17.Prescription of aspirin 23 344 6.7; 95% CI 4.0 to 
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 Cohort study  QRESEARCH analysis of secular trends (129) 
in combination with 
another anti-platelet drug 
without co-prescription of 
an ulcer-healing drug 
9.3 
18.Prescription of a long-
acting beta-2 agonist 
inhaler (excluding 
combination products with 
inhaled corticosteroid) to a 
patient with asthma who is 
not also prescribed an 
inhaled corticosteroid 
0 0 Not calculable 
19.Prescription of an oral 
NSAID to a patient with 
heart failure 
3 14 21.4; 95% CI -3.15 
to 46.0 
20.Prescription of 
antipsychotics for >6weeks 
in a patient aged ≥ 65 years 
with dementia but not 




 Cohort study  QRESEARCH analysis of secular trends (129) 
psychosis 
21.Prescription of an oral 
NSAID to a patient with 
eGFR < 45 
0 38 0 






8.1; 95% CI 6.5 to 
9.7 
 
Period prevalence Total of 117 
patients with 




5.85; 95% CI 4.8 
to 6.9 
Table 7-2. Cohort study proportion of errors in patients at risk of each primary, secondary, composite and revised updated outcome 




Outcome 1: Proportion of patients prescribed a NSAID (excluding aspirin), without a 
PPI among patients with a history of peptic ulcer  
Four patients had a history of peptic ulcer without PPI. None of the patients had been 
prescribed NSAID. 
Outcome 2a: Proportion of β-blocker users among patients with asthma 
Thirteen patients had a history of asthma. Out of the patients at risk, 53.8% had at least one 
prescription of β-blocker oral preparations or eye drops. The prescribed β-blockers were 
atenolol, carvedilol and metoprolol. 
Outcome 2b: Proportion of β-blocker users among patients with asthma and without 
CHD 
Two hundred and forty-one patients had a history of asthma and no history of CHD. Out of 
the patients at risk, 8.7% had received at least one prescription of β-blocker oral preparations 
or eye-drops. The prescribed β-blockers were atenolol, carvedilol, metoprolol propranolol and 
timolol eye drops. 
Outcome 3: Proportion of patients without check of renal function among patients aged 
≥ 75 years on ACEI or loop diuretics 
There were 11 patients aged ≥ 75 years with evidence of long-term (> 15 months) prescription 
of ACE inhibitors or loop diuretics. All patients had received a check of their renal function in 
the last 15 months. 
Outcome 4: Proportion of oral contraceptive users among female patients with venous 
or arterial thromboembolism 
Four female patients had venous or arterial thromboembolism. No patients were on any oral 
contraceptive. 
Outcome 5a, 5b: Proportion of patients without full blood count or liver function test 
among methotrexate users 
There were 14 patients with evidence of at least three months of prescribing of methotrexate. 
All patients had been given a full blood count or liver function test. 
Outcome 6: Proportion of patients without INR among warfarin users 
There were 16 patients with evidence of at least three months of prescribing of warfarin. Of 
the patients at risk, 25.0% had no INR recording in the previous three months. 
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Outcome 7: Proportion of patients without a lithium level check among lithium users 
There were two patients with evidence of at least three months of prescribing of lithium. They 
had not had a lithium level check in the last three months. 
Outcome 8: Proportion of patients without thyroid function test among amiodarone 
users 
None of the patients was using amiodarone. 
Outcome 9: Proportion of patients without instructions taken every week among 
methotrexate users 
Fourteen patients were using methotrexate. All patients had been given instructions to take it 
every week. 
Outcome 10: Proportions of patients receiving a dose of more than 200 mg per day 
among amiodarone users   
None of the patients was using amiodarone. 
Outcome 11: Proportion of patients with at least one prescribing problem (i.e. Outcomes 
1, 2 and 4) among patients at risk of at least one prescribing problem 
There were 259 “at risk” patients with at least one prescribing problem. Of the patients at risk, 
10.8% had experienced at least one prescribing problem. 
Outcome 12: Proportion of patients with at least one monitoring problem (i.e. Outcomes 
3, 5 (a or b), 6, 7 and 8) among patients at risk of one monitoring problem 
There were 43 “at risk” patients with at least one monitoring problem. Of the patients at risk, 
13.95% had at least one monitoring problem. 
Outcome 13: Proportion of patients prescribed an oral NSAID (excluding aspirin), 
without co-prescription of an ulcer-healing drug among patients aged ≥ 65 years 
Two hundred and sixty-nine patients were aged ≥65 years without co-prescription of an ulcer-
healing drug. Of the patients at risk, 19.3% had been given at least one prescription of an oral 
NSAID (except aspirin) without co-prescription of an ulcer-healing drug. The NSAIDs 
prescribed were diclofenac, ibuprofen and meloxicam.  
Outcome 14: Proportion of patients prescribed an anti-platelet drug without co-
prescription of an ulcer-healing drug among peptic ulcer patients 
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Four patients had a history of peptic ulcer without co-prescription of an ulcer-healing drug. 
Out of the patients at risk, 25.0% had been prescribed an anti-platelet drug. The anti-platelet 
prescribed was aspirin. 
Outcome 15: Proportion of patients prescribed an oral NSAID (excluding aspirin) 
among warfarin or NOAC users  
Thirty-two patients had been prescribed warfarin or NOAC. Out of the patients at risk, 6.25% 
had at least one prescription of an oral NSAID. The NSAID prescribed was meloxicam. 
Outcome 16: Proportion of patients prescribed an anti-platelet drug without co-
prescription of an ulcer-healing drug among warfarin or NOAC users 
Twenty-two patients had been prescribed warfarin or NOAC without co-prescription of an 
ulcer-healing drug. Out of the patients at risk, 50.0% had been given at least one prescription 
of an anti-platelet drug. The anti-platelet drugs prescribed were aspirin and clopidogrel. 
Outcome 17: Proportion of patients prescribed an anti-platelet drug without co-
prescription of an ulcer-healing drug among aspirin users  
Three hundred and forty-four patients had been prescribed aspirin without co-prescription of 
an ulcer-healing drug. Out of the patients at risk, 6.7% had been given at least one 
prescription of an anti-platelet drug. The anti-platelet drug prescribed was clopidogrel. 
Outcome 18: Proportion of patients prescribed a long-acting beta-2 agonist inhaler 
(excluding combination products with inhaled corticosteroid) who were not also 
prescribed an inhaled corticosteroid among asthma patients 
All patients with asthma had been prescribed a long-acting beta-2 agonist inhaler 
(combination products with inhaled corticosteroids).  
 
Outcome 19: Proportion of patients prescribed an oral NSAID (excluding aspirin) 
among patients with heart failure 
Fourteen patients had heart failure. Out of the patients at risk, 21.4% had been given at least 
one prescription of an oral NSAID. The NSAID prescribed was meloxicam.  
Outcome 20: Proportion of patients prescribed an antipsychotic for > 6 weeks among 
patients aged ≥65 years with dementia but not psychosis 
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Seventeen patients aged ≥65 years had dementia (not psychosis). Out of the patients at risk, 
11.8% had been given at least one prescription of an antipsychotic for > 6 weeks. The 
antipsychotics prescribed were risperidone and quetiapine. 
Outcome 21: Proportion of patients prescribed an oral NSAID (excluding aspirin) 
among patients with eGFR < 45 
There were 38 patients with eGFR < 45. Out of the patients at risk, none had at least one 
prescription of an oral NSAID.  
The highest risk of prescribing error was in patients with asthma who had been prescribed a β-
blocker. The highest monitoring error was in patients receiving lithium for at least three 
months who had not received a recorded check of their lithium concentrations in the previous 
three months. 
 
7.3.2 Overall period prevalence rate  
We found a total of 162 prescribing/monitoring errors during the study period, categorised as 
the following: 122 prescribing errors (contraindications), six monitoring error and 34 
Composite secondary outcome measures prescribing/monitoring errors. 
Overall period prevalence rate 
Numerator = the number of patients experiencing one or more medication error at any time 
during the 15 month period = 117 patients. 
Denominator = the total number of patients in the study population = 2000 patients.  
The overall period prevalence of patients with at least one medication errors over 15 months= 
117 (numerator)/2000 (denominator) = 5.85% (95% CI 4.8 to 6.9). 
 
Numerator = the number of medication errors at any time during the 15 month period = 162 
patients. 
Denominator = the total number of patients in the study population = 2000 patients.  
The overall period prevalence of medication errors over 15 months= 162 (numerator)/2000 





7.3.3 Risk factors  
a. Medication and patient-related risk factors 
Risk factors that significantly predicted the overall patients at risk of experiencing 
medications errors were: 
1. Patients aged ≥ 65 years. Such patients were estimated to be 27 times more likely to be at 
risk of experiencing medication error than those aged 18-64 years (OR 27.2; 95% CI 18.6 to 
39.85) 
2. Male patients were estimated to be two times more likely to be at risk of experiencing 
medication error than female patients (OR 1.9; 95% CI 1.5 to 2.25) 
3. Saudi nationality patients were estimated to be three times more likely to be at risk of 
experiencing medication error than non-Saudi patients (OR 2.7; 95% CI 2.2 to 3.3) 
4. Patients taking five or more drugs (polypharmacy) were estimated to be five times more 
likely to be at risk of experiencing medication error than those taking fewer than five drugs 











Age (≥ 65 / 18-
64 years) 





OR; 95% CI 
P 
value 
Nationality (Saudi / 
non-Saudi) 
OR; 95% CI 
P 
value 













Overall patients at risk of experiencing medications errors 
 27.2; 18.6 to 
39.85 
0.00 1.9; 1.5 to 2.25 0.00 2.7; 2.2 to 3.3 0.00 4.7; 3.8 to 5.8 0.00 0.8; 0.55 to 
1.25 
0.38 
Number of individual patients at risk outcome 
1 15.7; 1.6 to 
151.5 
0.02 5.6; 0.6 to 54.1 0.14 1.5; 0.15 to 14.1 0.74 NA - NA - 
2a 4.5; 1.5 to 13.5 0.01 2.2; 0.7 to 6.5 0.16 2.7; 0.6 to 12.2 0.19 NA - NA - 
2b 1.5; 1.0 to 2.05 0.03 0.9; 0.7 to 1.2 0.46 1.3; 0.9 to 1.8 0.06 2.7; 2.0 to 3.7 0.00 1.4; 0.7 to 
2.9 
0.32 
3 NA - 1.1; 0.3 to 3.65 0.91 NA - 3.6; 0.8 to 16.7 0.10 NA - 




Age (≥ 65 / 18-
64 years) 





OR; 95% CI 
P 
value 
Nationality (Saudi / 
non-Saudi) 
OR; 95% CI 
P 
value 













5a NA - 0.5; 0.1 to 1.8 0.29 1.8; 0.5 to 6.5 0.37 2.9; 0.8 to 10.5 0.10 NA - 
5b NA - 0.5; 0.1 to 1.8 0.29 1.8; 0.5 to 6.5 0.37 2.9; 0.8 to 10.5 0.10 NA - 
6 5.3; 1.9 to 14.2 0.00 1.45; 0.5 to 3.9 0.46 3.4; 0.8 to 15.2 0.10 5.6; 1.3 to 24.8 0.02 NA - 
7 NA - NA - NA - 0.8; 0.1 to 12.7 0.87 0.05; 0.0 to 
0.85 
0.04 
9 NA - 0.5; 0.1 to 1.8 0.29 1.8; 0.5 to 6.5 0.37 1.9; 0.6 to 6.4 0.25 NA - 
11 1.6; 1.2 to 2.2 0.00 0.95; 0.7 to 
1.25 
0.74 1.4; 1.1 to 1.9 0.02 2.8; 2.1 to 3.8 0.00 1.55; 0.8 to 
3.1 
0.22 
12 3.9; 2.1 to 7.2 0.00 0.9; 0.5 to 1.7 0.75 2.2; 0.9 to 4.7 0.05 3.55; 1.6 to 7.7 0.00 2.3; 0.3 to 
16.6 
0.42 






Age (≥ 65 / 18-
64 years) 





OR; 95% CI 
P 
value 
Nationality (Saudi / 
non-Saudi) 
OR; 95% CI 
P 
value 













14 15.7; 1.6 to 
151.5 
0.02 5.6; 0.6 to 54.1 0.14 1.5; 0.15 to 14.1 0.74 NA - NA - 
15 6.2; 3.0 to 
12.45 
0.00 1.5; 0.7 to 2.95 0.29 2.7; 1.0 to 6.9 0.05 4.4; 1.7 to 11.4 0.00 1.65; 0.2 to 
12.3 
0.62 
16 4.4; 1.9 to 10.3 0.00 1.3; 0.55 to 3.0 0.55 3.1; 0.9 to 10.6 0.07 2.7; 1.0 to 7.4 0.05 1.1; 0.1 to 
8.4 
0.91 
17 4.7; 3.6 to 6.1 0.00 2.3; 1.8 to 2.9 0.00 2.4; 1.8 to 3.25 0.00 5.2; 3.8 to 6.9 0.00 0.6; 0.4 to 
0.9 
0.02 
19 5.3; 1.8 to 15.2 0.00 0.5; 0.1 to 1.8 0.29 6.4; 0.8 to 49.0 0.07 NA - NA - 
20 NA - 2.1; 0.8 to 5.5 0.13 NA - 3.7; 1.1 to 13.0 0.04 0.4; 0.1 to 
1.7 
0.22 




Age (≥ 65 / 18-
64 years) 





OR; 95% CI 
P 
value 
Nationality (Saudi / 
non-Saudi) 
OR; 95% CI 
P 
value 














Table 7-3. Cohort study association between patient and medication-related risk factors and patients at risk of error outcomes. (Data 




b. Physician-related risk factors 
Risk factors that significantly predicted the overall patients who were at risk of experiencing 
medication errors were a) physician’s male gender was estimated to be two times more likely 
to be at risk of experiencing medication error than physician’s female physicians (OR 1.6; 
95% CI 1.3 to 2.1) and b) Saudi nationality physicians were estimated to be two times more 
likely to be at risk of experiencing medication error than non-Saudi physicians (OR 1.9; 95% 


















































certified, or none) 





10 /1-9 years) 










Overall patients at risk of experiencing medications errors 
 1.0; 0.8 
to 1.3 
0.84 1.6; 1.3 to 
2.1 
0.00 1.9; 1.5 to 2.5 0.00 1.0; 0.9 to 1.2 0.49 1.1; 0.9 to 1.4 0.39 0.5; 0.4 to 
0.6 
0.00 
Number of individual patients at risk outcome 
2a 0.6; 0.15 
to 2.2 
0.42 1.7; 0.45 
to 6.55 
0.42 2.85; 0.9 to 
9.4 
0.09 1.3; 0.7 to 2.3 0.41 1.2; 0.35 to 4.2 0.74 0.3; 0.1 to 
1.1 
0.08 
2b 1.4; 0.9 
to 1.9 
0.06 1.1; 0.8 to 
1.5 
0.65 0.9; 0.6 to 1.3 0.59 1.05; 0.9 to 1.2 0.49 1.0; 0.75 to 1.4 0.84 1.05; 0.7 
to 1.6 
0.79 




























certified, or none) 





10 /1-9 years) 










to 6.2 to 4.5 1.55 
4 0.8; 0.1 
to 8.5 
0.83 0.3; 0.0 to 
3.55 
0.36 NA - 0.3; 0.05 to 2.0 0.23 0.35; 0.0 to 3.9 0.39 NA - 
5a 1.9; 0.6 
to 6.1 
0.31 0.4; 0.1 to 
1.25 
0.11 1.3; 0.3 to 4.8 0.72 0.7; 0.4 to 1.4 0.33 3.2; 0.7 to 14.8 0.14 0.6; 0.15 
to 2.0 
0.38 
5b 1.9; 0.6 
to 6.1 
0.31 0.4; 0.1 to 
1.25 
0.11 1.3; 0.3 to 4.8 0.72 0.7; 0.4 to 1.4 0.33 3.2; 0.7 to 14.8 0.14 0.6; 0.15 
to 2.0 
0.38 
6 0.6; 0.15 
to 2.2 
0.42 1.1; 0.3 to 
3.9 
0.85 1.3; 0.3 to 4.8 0.72 0.8; 0.4 to 1.5 0.49 1.2; 0.35 to 4.2 0.74 1.1; 0.2 to 
4.8 
0.92 






























certified, or none) 





10 /1-9 years) 










9 1.9; 0.6 
to 6.1 
0.31 0.5; 0.2 to 
1.8 
0.30 1.3; 0.3 to 4.8 0.72 0.7; 0.4 to 1.4 0.33 1.9; 0.5 to 7.1 0.35 0.6; 0.15 
to 2.0 
0.38 
11 1.3; 0.9 
to 1.7 
0.13 1.1; 0.8 to 
1.5 
0.56 0.9; 0.7 to 1.4 0.83 1.0; 0.9 to 1.2 0.54 1.0; 0.7 to 1.4 0.95 0.9; 0.7 to 
1.4 
0.95 
12 1.1; 0.5 
to 2.3 
0.76 0.7; 0.3 to 
1.4 
0.29 1.2; 0.5 to 2.7 0.69 0.7; 0.5 to 1.1 0.13 1.7; 0.8 to 3.8 0.17 0.6; 0.3 to 
1.2 
0.15 
13 0.9; 0.7 
to 1.25 
0.61 2.6; 1.8 to 
3.7 
0.00 2.7; 1.9 to 3.7 0.00 1.1; 0.9 to 1.3 0.23 1.4; 1.0 to 1.9 0.04 0.3; 0.2 to 
0.4 
0.00 
15 0.7; 0.3 
to 1.6 
0.38 1.8; 0.7 to 
4.7 
0.19 1.5; 0.6 to 3.7 0.38 0.8; 0.55 to 1.3 0.45 1.1; 0.5 to 2.55 0.83 0.45; 0.2 
to 1.0 
0.06 




























certified, or none) 





10 /1-9 years) 










to 1.9 5.2 to 1.0 
17 0.9; 0.7 
to 1.2 
0.63 1.7; 1.3 to 
2.3 
0.00 1.9; 1.45 to 
2.7 
0.00 0.9; 0.85 to 1.1 0.78 0.9; 0.7 to 1.3 0.91 0.7; 0.5 to 
0.9 
0.01 
19 0.7; 0.2 
to 2.6 
0.55 5.9; 0.7 to 
46.4 
0.09 5.2; 1.4 to 
18.4 
0.01 1.1; 0.6 to 2.0 0.79 1.6; 0.4 to 6.4 0.47 0.6; 0.15 
to 2.0 
0.38 
20 0.8; 0.2 
to 2.6 
0.67 7.2; 0.9 to 
55.8 
0.06 1.1; 0.3 to 4.2 0.85 1.05; 0.6 to 1.8 0.86 0.3; 0.1 to 1.2 0.09 0.3; 0.1 to 
0.8 
0.01 
21 0.8; 0.4 
to 1.8 
0.62 3.6; 1.2 to 
10.6 
0.02 2.9; 1.4 to 6.5 0.01 1.3; 0.9 to 1.9 0.16 1.9; 0.8 to 4.6 0.14 0.4; 0.2 to 
0.75 
0.01 
Table 7-4. Cohort study association between physician-related risk factors and patients at risk of error outcomes. (Data obtained from 
logistic regression model). NA: No association. OR = 1.
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7.4 Chapter summary 
In this retrospective cohort study of adult patients from Family Medicine and Polyclinics in 
KFSH&RC, Riyadh, SA, clinically important errors in medicine management were found to 
be common in a randomly selected sample of 2000 patients’ records. The overall period 
prevalence of patients with at least one medication error over 15 months was (5.85%; 95% CI 
4.8 to 6.9). The overall period prevalence of medication errors over 15 months was (8.1%; 
95% CI 6.5 to 9.7). The highest risk of prescribing error was in patients with asthma who had 
been prescribed a β-blocker. The highest risk of monitoring error was in patients receiving 
lithium for at least three months who had not received a recorded check of their lithium 
concentrations in the previous three months. The overall period prevalence estimate of the 
first 12 clinically important errors in medicine management in the cohort study was more 
compared to the QRESEARCH analysis of secular trends estimates. This prevalence variation 
may reflect the different healthcare services provided and the different method of data 
extraction employed in the two countries (SA and UK). 
Medication and patient-related risk factors that significantly predicted the overall patients at 
risk of medication errors were patient’s age of ≥ 65 years, male gender, Saudi nationality and 
taking five or more drugs (polypharmacy). Physician-related risk factors that significantly 
predicted the overall patients at risk of experiencing medication errors were physician’s male 
gender and physician’s Saudi nationality. 
This cohort study is the first in a Saudi Arabian ambulatory care setting that has been 
designed to compare the period prevalence of clinically important errors in medicine 
management with that in another country i.e.UK. 
 
Next chapter provides a discussion and conclusions for this study. 
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Chapter Eight: Discussion and Conclusions 
8.1 Introduction 
Patient safety is a public concern in healthcare systems across the world.(8) Medication errors 
and ADEs are common and are responsible for considerable patient harm.(8) Patient safety in 
hospital settings has been extensively studied.(2, 12, 13) In an effort to complement this, my 
research focused on measuring the epidemiology of medication errors and ADEs in 
community settings, since the latter location is where most of medication use takes place. 
Most of the previous studies have been conducted on elderly populations in economically-
developed countries. There is therefore clearly a need to extend this work to low- and middle-
income countries, particularly given the WHO’s recent launch of a Global Patient Safety 
Challenge.(90, 91) Thus, the primary question for my research was “What is the 
epidemiology of medication errors, associated ADEs and risk factors for these outcomes in 
the community settings?”. In order to address this research question, the following objectives 
were developed:  
1. To review the literature on medication errors in community settings.  
2. To estimate the incidence/period prevalence of medication errors and error-related 
ADEs in community settings. 
3. To estimate the period prevalence of medication errors in community settings in 
Riyadh, SA.  
4. To identify risk factors associated with medication errors and error-related ADEs.   
5. To compare the QRESEARCH analysis of secular trends in the UK with the findings 
from my cohort in SA. 
A phased programme of work was developed to achieve these objectives: Phase 1, a 
systematic literature review; Phase 2, a feasibility study; Phase 3, a pilot retrospective cohort 
study and Phase 4, a larger-scale retrospective cohort study.  
 
For Phases 2-4, I used a list of 21 clinically important errors in medicine management (21 
medication errors).(85, 107) It was considered by a panel of healthcare professionals that 13 
of these errors are associated with high risk and three (Outcome 1: peptic ulcer and NSAID 
without ulcer-healing drug, Outcome 6: warfarin and INR and Outcome 21: eGFR < 45 and 
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NSAID) with extreme risk to patients.(99) Phases 2-4 focused only on the errors; not the 
adverse events themselves. Details of the risk and associated ADEs are described in Appendix 
7. 
 
8.2 Key research findings 
There were 60 observational studies identified in Phase 1, the systematic review of the 
epidemiology of medication errors and error-related adverse events and their risk factors. 
These studies were conducted in different countries and with different populations, methods 
for errors detection, medication error definitions and outcome measures. The prevalence of 
prescribing errors was reported in 46 studies; point or period prevalence estimates ranged 
widely from 2.0-94.0%. Inappropriate prescribing was the most common type of error 
reported. Only one study reported the prevalence of monitoring errors, finding that incomplete 
therapeutic/safety laboratory-test monitoring occurred in 73.0% of patients. The incidence of 
preventable ADEs was estimated as 15/1000 person-years, the prevalence of DDI-related 
ADR as 7.0% and the prevalence of preventable ADE as 0.4%. A number of patient, 
healthcare professional and medication-related risk factors were identified, including the 
number of medications used by the patient, increased patient age (≥75 years), the number of 
multi-morbidities, use of anticoagulants, cases where more than one physician was involved 
in patients’ care and care being provided by family the physicians/GP.  
 
My systematic review identified important limitations and discrepancies in the methodologies 
used, as well as gaps in the literature on the epidemiology and outcomes of medication errors 
in community settings. In addition, my systematic review did not identify a validated method 
for detecting all classes of medication errors and was unable to find a study that investigated 
the incidence of medication errors. Bearing the above points in mind, and the fact that most of 
the preventable ADEs were as a result of prescribing errors and medication monitoring errors 
and following discussion with other researchers and supervisors, I identified a validated tool 
for measuring medication errors developed by Avery et al. (2012) in the PINCER trial 
consisting of a list of clinically important errors in prescribing and monitoring in primary 
care. The PINCER trial is one of the world’s first randomised studies aiming to reduce the 




The decision in Phase 2, the feasibility study, was to: a) identify the ambulatory setting and 
electronic database; b) test the feasibility of data extraction as well as the reliability of key 
outcome measures; and c) facilitate the conduct of my epidemiological research on a pre-
specified list of clinically important errors in medicine management. The main findings from 
this phase were that I selected the EHRs of KFSH&RC Family Medicine and Polyclinics, 
Riyadh, SA and that the pilot phase was feasible, likely to provide random sample and all 
information needed for data collection was available in one electronic system and were 
useable in the following two phases.  
 
Phase 3 was the pilot retrospective cohort study to pilot the research procedure and to inform 
sample size calculations for undertaking a larger cohort study. In this study, a random sample 
of 200 records was selected. Thirty-two clinically important errors in medicine management 
were identified. The overall period prevalence of patients with at least one medication error 
over 15 months was (10.0%; 95% CI 5.8 to 14.2). The overall period prevalence of 
medication errors over 15 months was (16.0%; 95% CI 8.2 to 23.8). Risk factors that 
significantly predicted the overall patients at risk of medication errors were patient’s age of 
≥65 years and using OTC medications. 
 
The findings from this phase suggested that more long-term data were needed to explore 
further the effects of physician-related risk factors on medication errors outcomes, a goal that 
was accomplished with a larger-scale, retrospective cohort study. 
 
In Phase 4, the retrospective cohort study, a random sample of 2000 records was selected, 
resulting in 162 clinically important errors in medicine management being identified. 
Therefore, the overall period prevalence of patients with at least one medication error over 15 
months was (5.85%; 95% CI 4.8 to 6.9). The overall period prevalence of medication errors 
over 15 months was (8.1%; 95% CI 6.5 to 9.7). I obtained lower precision of estimates from 
my cohort study compared to the pilot study (Phase 3). Medication and patient-related risk 
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factors that significantly predicted the overall patients at risk of errors were patient’s age of ≥ 
65 years, male gender, Saudi nationality and taking five or more drugs (polypharmacy). 
 
In both Phases 3 and 4, the highest risk of prescribing error was found to be in Outcome 2a 
(patients with asthma who had been prescribed a β-blocker) affecting 10 patients; three 
patients in Phase 3 and seven patients in Phase 4, while, for monitoring error, the highest risk 
was in Outcome 7 (patients receiving lithium for at least three months who had not had a 
recorded check of their lithium concentrations in the previous three months), affecting only 
three patients; one patient in Phase 3 and two patients in Phase 4. The overall period 
prevalence estimate of the first 12 clinically important errors in medicine management in the 
cohort study was more compared to the QRESEARCH analysis of secular trends estimate. 
This may reflect different healthcare services provided and the different method of data 
extraction between both countries. 
The main cohort study phase results were consistent with my systematic review (Phase 1) 
results. Medication errors in community settings are common, particularly prescribing errors; 
as well as in relation to the most common risk factors seen in both phases i.e. the number of 
medications used by the patient and increased patient age. 
 
8.3 Strengths and limitations  
Strengths  
A logical and systematic course of action has been employed in this study, which started with a 
systematic review and progressed from feasibility to pilot work then, my definitive larger 
retrospective cohort study. 
 
Phase 1. The main strengths of this systematic review are that a rigorous and transparent 
process was employed, which included no language restrictions, an independent screening of 
titles and abstracts, independent data extraction and critical appraisal of included studies by 
two reviewers. The use of the International Classifications for Patient Safety (ICPS) 
conceptual framework,(131) which provides a comprehensive definition of each concept and 
type of error in the medicines’ management process, is a further strength. In addition, the 
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systematic review is the first medication errors and error-related adverse events review 
located within community settings.  
 
For Phases 2 and 3: all the required information was available in the one system and no 
missing data were found. 
 
For Phase 3: firstly, this is the first epidemiological pilot study working on a pre-specified list 
of clinically important errors in ambulatory care in SA. Secondly, a simple random sample 
was applied to avoid selection bias in sampling. Lastly, independent data collection by two 
researchers allowed a more accurate rate of medication errors to be measured with less bias.  
 
Phase 4. Firstly, the list of clinically important errors in prescribing and monitoring stages that 
were used in my study was validated and developed according to a systematic review, other 
research and expertise, and consensus on overall burden and severity of iatrogenic harm in 
primary care in the PINCER trial.(92, 101, 102) Secondly, data collection of 10% of the 
sample size was independently undertaken by two reviewers, resulting in substantial 
agreement. Thirdly, both medication and physician-related factors that contribute to the 
occurrence of the risk of experiencing medication errors in the cohort study were considered. 
Fourthly, the large, representative cohort of adults was followed up over a 15 month period. 
Fifthly, Outcome 5, for methotrexate, was seen more in the cohort study compared to the pilot 
study. This could be due to the greater sample size and the higher rate of patients having 
rheumatoid arthritis, psoriasis or psoriatic arthritis. Lastly, it should be noted that this is the 
first epidemiological cohort study working on a pre-specified list of clinically important errors 
in ambulatory care in SA. 
 
Limitations 
The Saudi healthcare system has a variety of limitations that result in challenges to its system 
when located in the community. Medication use and monitoring in the community care 
context, where the actual medication use takes place, is not controlled or restricted and a 
number of prescription medications are available as OTC drugs; the exception being 
narcotics, psychotropic substances and antibiotics, antibiotics were recently added by the 
MOH.(67) As a result, current patient medication lists may be missing. In addition, there is a 
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lack of a unified electronic national health information system and limited use of 
computerised provider order entry. Furthermore, the concept of medication safety is still 
new.(78) 
 
Phase 1. Firstly, despite the thorough process, no data were found regarding the dispensing 
error stage. This might be due to the lack of a ‘dispensing error’ key-term in our search 
strategy, although ‘medication therapy management’ as a key-term was included. However, 
10 studies on dispensing errors were excluded because they failed to satisfy the inclusion 
criteria on one or more counts. Secondly, no data were found regarding the administration 
error stage. However, 14 studies on administration errors were also excluded for the same 
previous reason; the studies failed to meet the inclusion criteria. Thirdly, this systematic 
review had different outcomes reported in a variety of ways using different tools and 
methodologies that made combining results into meta-analysis difficult. Lastly, the studies 
addressed risk factors adjusted for different confounders, which made it difficult to generate 
comparable estimates and/or make causal inferences about whether the harm resulted from the 
medication error.  
 
Phase 2. Firstly, all the outcomes were seen at least once in a total of 500 patients except for 
Outcomes number 7, 8 and 10 involving amiodarone and lithium. Although amiodarone and 
lithium were not restricted to a specific specialist, none of the patients were on lithium, which 
could be because more cases are seen in psychiatric clinics and/or the rate of bipolar disorder 
in our studied population was low. In addition, none of the patients were on amiodarone, and 
that could be because the majority of atrial fibrillation patients are seen in the cardiology 
clinic and amiodarone is rarely prescribed. It was concluded there was a low prescribing rate 
of amiodarone to cardiac arrhythmia patients. 
 
Phase 3. Firstly, this was an observational study conducted using a retrospective study design 
with a small sample size, the OR estimates had wide 95% CI, and, as a result, the estimates 
obtained should be interpreted with caution. Secondly, due to the different rate of disease in 
the studied populations, Outcome 5 and 9 (methotrexate) was not seen, this could be due to 
the low rate of patients having rheumatoid arthritis and the low number of patients on 
methotrexate who were visiting the Family Medicine and Polyclinics. Lastly, maximum 
likelihood estimation of the logistic regression model in the pilot study suffers from small 
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sample bias; because of the rare events, i.e. the number of events in some of the patients at 
risk outcomes (denominator) is small.(132)  
 
For Phases 3 and 4: firstly, manual data collection was carried out because of the lack of 
technical capacity to ensure accuracy and quality of data. Manual data collection was also 
employed in order to avoid the delay that would be necessary for generating the required 
anonymised data electronically from the electronic medical records department in 
KFSH&RC. Secondly, documentation bias may occur within the retrospective review because 
the investigator must rely on information provided only in the electronic records to identify or 
assess the outcome. Selection bias is a particular problem with retrospective cohort studies, 
such as the one in this research, where exposure and outcomes have already occurred at the 
time of subject enrolment. Thirdly, I focused only on medication errors, excluding the 
associated adverse events, because of the limited research team and time period available to 
accomplish this PhD research. Fourthly, the most common non-prescribed medications were 
acetaminophen, ascorbic acid, cetirizine HCl, calcium carbonate, ferrous gluconate, folic acid, 
ibuprofen, loratadine, omeprazole, pseudoephedrine and ranitidine, their actual rate used by 
the patients might not be known because high number of OTC medications can be brought in 
from outside the hospital and may not be recorded by the physicians. Fifthly, due to the 
different rates of disease in the studied populations, Outcomes 8 and 10 (amiodarone), were 
not seen. That lack of cases could be because of the low prescribing rate of amiodarone to 
cardiac arrhythmia patients. Lastly, patients visiting the Family Medicine and Polyclinics may 
not be representative of the ambulatory population of SA. It was not possible formally to 
assess this point because Saudi national data are not available to enable comparisons between 
the baseline characteristics of the sample population and the whole population and the results 
may not be generalisable because this study was performed in a single ambulatory care 
context in SA. 
 
For Phase 4: there is inconsistent type of precisions between my cohort period prevalence 
proportion (i.e. 95% CI) and QRESEARCH analysis of secular trends period prevalence 




8.4 Interpretation of findings in light of the existing literature 
In Phase 1, the systematic literature review, the definitional variation issue was supported by 
another two reviews.(133, 134) Other systematic reviews focusing on the safety of primary 
care contexts identified studies with vastly different prevalence estimates of the rates of 
medication errors. This reflected differences in definitions, sampling strategy and the types of 
populations studied; the previous reviews had not investigated the risk factors for medication 
errors.(135, 136) 
 
In Phase 3, the pilot retrospective cohort study, Akbarov et al. (2015) in a cross-sectional 
study using linked records in the UK general practices, used 22 medication safety indicators 
(18 prescribing indicators with an overall prevalence as 5.45% and 4 monitoring indicators 
with an overall prevalence as 7.65%).(137) In order to compare my study results with the 
findings from the research by Akbarov et al. (2015) study, it is important to have a consistent 
definition of numerator and denominator. Only 13 consistent indicators can be compared with 
my outcome measures. The other nine indicators were not used in my study, so a comparison 
between my overall outcome measures’ estimate and the Akbarov et al. (2015) study overall 
outcome measures’ estimates cannot be made. This research found higher period prevalence 
estimates for the following:  
Outcomes 2b (asthma and β-blocker) 
Outcome 13 (aged≥ 65 years using NSAID without an ulcer-healing drug) 
Outcome 19 (heart failure and NSAID). 
 
In this pilot study, I could not estimate rates for the following outcomes, because there were 
no events:  
Outcome 1 (peptic ulcer and NSAID without an ulcer-healing drug)  
Outcome 3 (ACE inhibitor / diuretics and lab test) 
Outcome 4 (venous or arterial thromboembolism and arterial thrombosis and 
combined oral contraceptives) 
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Outcome 6 (warfarin and INR) 
Outcome 15 (warfarin/ NOAC and NSAID) 
Outcome 21 (eGFR < 45 and NSAID). 
 
For Outcome 8 (amiodarone and thyroid function test), no patient in this study was on 
amiodarone. For Outcome 18 (long-acting beta-2 agonist inhaler [excluding combination 
products with inhaled corticosteroid] to a patient with asthma who is not also prescribed an 
inhaled corticosteroid), all the study’s patients were on combination products with inhaled 
corticosteroid.  
 
In Phase 4, the retrospective cohort study, the results of the PINCER trial cannot be directly 
compared to the cohort study, because the PINCER trial is an interventional study. However, 
it is possible to compare my research results with the QRESEARCH analysis of secular trends 
i.e. the large national QRESEARCH general practice database.(129) 
The overall period prevalence of the first 12 clinically important errors in medicine 
management estimate was (3.4%; 95% CI 2.2 to 4.6) in this research compared with 0.9% for 
the QRESEARCH analysis of secular trends.(129) The distribution of each estimate for the 
outcome measures was as follow: 
In my study, higher period prevalence estimates were found for:  
Outcomes 2a and 2b (asthma and β-blocker) 
Outcome 6 (warfarin and INR) 
Outcome 7 (lithium and lithium level) 
Outcome 11 (at least one prescription error) 
Outcome 12 (at least one monitoring error)  




Outcome 1 (peptic ulcer and NSAID without an ulcer-healing drug)  
Outcome 3 (ACE inhibitor / diuretics and lab test) 
Outcome 4 (venous or arterial thromboembolism and arterial thrombosis and 
combined oral contraceptives) 
Outcomes 5a and 5b (methotrexate and full blood count and methotrexate and liver 
function test). 
For (Outcome 8: amiodarone and thyroid function test) and (Outcome 10: amiodarone dose) 
there was no patient on amiodarone. This may reflect both the differences in healthcare 
services provided in both countries and the varied methods of extracting data and outcomes 
employed in the two studies. In the QRESEARCH data were collected prospectively through 
a computer-recorded method and the level of accuracy and completeness was shown to be 
high.(129, 138) While in my study, the data were collected retrospectively through manual 
data extraction methods.  
 
8.5 Implications for policy, practice and research 
As mentioned in Chapter 2, there are several challenges and limitations in the Saudi 
healthcare system generally and in the community care specifically. The uncontrolled and 
non-restricted use of medications resulted in an increase in the number of concurrent 
medications used by the patients, which may have increased the risk of medication errors 
identified in my cohort study. Improving healthcare services and quality standards could 
potentially be achieved through healthcare organisation leaders and policymakers in SA 
building a unified national electronic health information system. Such an initiative will help 
facilitate medication restriction and fill the communication gaps between the healthcare 
settings in SA. 
For healthcare professionals there is a need for a) training, education and monitoring with the 
involvement of specialised medication safety pharmacists in the community; b) increase the 
implementation of computerised prescribing with an integration of software to detect such 
clinically important errors in medicine management during prescription entry;(139, 140) c) 
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providing a record of current medication lists for each patient in the community; d) 
empowering and educating the patients and the public, particularly those with chronic 
diseases and those taking five or more drugs (polypharmacy), in order to increase their 
knowledge of medication safety; and e) encourage the reporting of medication errors, 
administration errors and dispensing errors, particularly in the community settings where 
there is a lack of reporting such outcomes.(90)  
 
For patients in community settings (hence, compared to inpatient settings, patients in the 
community settings play a more active role in administering and managing their medications), 
there is a need to use tools and technology, particularly for monitoring and follow-up where 
most medication errors happen in this stage because of irregular outpatient visits and to show 
the current medication list for each pharmacy visit. 
 
These three initiatives would improve the medical and pharmaceutical services provided for 
adults resulting in a safer environment in which the community can safely self-care. 
 
As explained in the systematic review, this research has identified important limitations and 
discrepancies in the methodology used to study medication errors and error-related adverse 
drug events in community settings. There is a need for improvement in the quality of research 
in this area. Researchers should use a more consistent set of definitions or internationally 
accepted terminology and definitions of key concepts and should use a standardised set of 
outcome measures of medication errors in order to facilitate collation and synthesis of data. 
An example of definitions that could be used for medication error outcomes is the ICPS.(131) 
More research is needed in the areas of incidence of medication errors, administration and 
dispensing errors and reporting.  
The findings in this cohort study have identified a high prevalence of medication errors 
among adults in the community settings in Riyadh. This evidence can provide baseline data 
for the patient safety authorities in SA. In order to increase the generalisability of my study’s 
findings, it is important that this work is now extended by building a programme of research 
and continuing with multicentre cohort studies in different ambulatory care contexts in 
Riyadh, such as King Khalid University Hospital as well as in other Saudi regions.  
173 
 
Thus, a number of follow-on cohort studies are required in SA. If the high prevalence of 
medication errors is confirmed, relevant patient safety authorities should undertake action by 
planning to create and implement preventive strategies which should then be evaluated to see 
if they can help to reduce the risk of these medication errors. 
By creating such an initiative, more information will be collected and a complete picture of 
medication error prevalence in the country can be formed. 
These findings need to be considered in the context of designing future research related to 
medication safety; thereby strengthening the quality of research and improve the development 
of strategies to detect and prevent these errors. 
8.6 Conclusions  
In the area of medication errors, previous research studies have examined the prevalence of 
medication errors, incidence/prevalence of ADEs and associated risk factors with inconsistent 
outcomes and results. In SA, this topic has not received the attention it warrants. To my 
knowledge, the prevalence of medication errors in community settings has not been examined 
before. Given the dearth of studies looking at medication errors in the community globally 
and the global and particular shift in SA from secondary and tertiary care to community-based 
care, the focus of this PhD research is important and timely. The epidemiology of clinically 
important errors in medicines management in SA has been investigated. It is the first 
comprehensive in-depth studies researching medication errors in community settings in 
Riyadh, SA. This study shows that clinically important medication errors are common with a 
period prevalence estimate of 8.1% and could have the potential to harm patients. Patient-
related risk factors that significantly predicted overall patients who were at risk of 
experiencing medication errors were age of ≥ 65 years, male gender, Saudi nationality, and 
taking five or more drugs (polypharmacy). Physician-related risk factors that significantly 
predicted the overall patients at risk of errors were physician’s male gender and physician’s 
Saudi nationality. 
 
Healthcare professional education, recruiting physicians and clinical pharmacists who are 
specialised in the detection and prevention of medication errors, finding safer medications or 
integration of software to detect such clinically important errors in medicine management 
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during prescription entry, could improve the medical services provided for adult patients in 
SA and beyond. 
 
Future research needs to replicate these findings in different ambulatory care contexts in SA, 
to explore further the error-related adverse events and to develop and evaluate interventions 
aimed at reducing the risk of clinically important errors in medicine management in 







1. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The 
nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice 
Study II. The New England Journal of Medicine. 1991;324(6):377-84. 
2. Kohn LT, Corrigan JM, Donaldson M. To Err is Human: Building a Safer Health 
System. Washington (DC): National Academies Press; 2000. 
3. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. 
WHO Policy Perspectives on Medicines. 2004;9. 
4. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide 
to terminology, documentation, and reporting. Annals of Internal Medicine. 
2004;140(10):795-801. 
5. Bates D. Frequency, consequences and prevention of adverse drug events. Journal of 
Quality in Clinical Practice. 1999;19(1):13-7. 
6. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of 
adverse drug events and potential adverse drug events. Implications for prevention. Journal of 
the American Medical Association. 1995;274(1):29-34. 
7. Morimoto T, Gandhi T, Seger A, Hsieh T, Bates D. Adverse drug events and 
medication errors: detection and classification methods. Quality and Safety in Health Care. 
2004;13(4):306-14. 
8. Mark SM, Little JD, Geller S, RJ. W. Principles and Practices of Medication Safety. 
In: DiPiro JT TR, Yee GC, Matzke GR, Wells BG, Posey L., editor. Pharmacotherapy: A 
Pathophysiologic Approach. New York: McGraw-Hill; 2011. 
9. Institute of Medicine. Report brief: preventing medication errors.2007. 
10. Sorensen L, Stokes JA, Purdie DM, Woodward M, Roberts MS. Medication 
management at home: medication risk factor prevalence and inter-relationships. Journal of 
Clinical Pharmacy and Therapeutics. 2006;31(5):485-91. 
11. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-
of-illness model. Journal of the American Pharmaceutical Association. 2001;41(2):192-9. 
12. Sheikh A, Panesar SS, Larizgoitia I, Bates DW, Donaldson LJ. Safer primary 
care for all: a global imperative. The Lancet Global Health. 2013;1(4):e182-e3. 
13. Cresswell KM, Panesar SS, Salvilla SA, Carson-Stevens A, Larizgoitia I, 
Donaldson LJ, et al. Global research priorities to better understand the burden of iatrogenic 
176 
 
harm in primary care: an international Delphi exercise. PLoS Medicine. 
2013;10(11):e1001554. 
14. Monitor. Moving healthcare closer to home: literature review of clinical 
impacts. 2015. [Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/459268/Movin
g_healthcare_closer_to_home_clinical_review.pdf. 
15. Slee VN, Slee DA, Schmidt HJ. Health care terms. Third ed. St. Paul, Mn.: 
Tringa Press; 1996. 
16. Patient safety network. Contemporary View of Medication-Related Harm. A 
New Paradigm  [Available from: 
https://psnet.ahrq.gov/resources/resource/28896/contemporary-view-of-medication-related-
harm-a-new-paradigm  
17. What is a Medication Error? National Coordinating Council for Medication 
Error Reporting and Prevention.  [Available from: http://www.nccmerp.org/about-medication-
errors. 
18. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L. Relationship 
between medication errors and adverse drug events. Journal of General Internal Medicine. 
1995;10(4):199-205. 
19. Zaal RJ, van Doormaal JE, Lenderink AW, Mol PG, Kosterink JG, Egberts 
TC, et al. Comparison of potential risk factors for medication errors with and without patient 
harm. Pharmacoepidemiology and Drug Safety. 2010;19(8):825-33. 
20. Avery AJ, Sheikh A, Hurwitz B, Smeaton L, Chen Y-F, Howard R, et al. Safer 
medicines management in primary care. The British Journal of General Practice. 
2002;52(Suppl):S17-S22. 
21. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et 
al. Medication errors and adverse drug events in pediatric inpatients. The Journal of the 
American Medical Association. 2001;285(16):2114-20. 
22. Gandhi TK, Burstin HR, Cook EF, Puopolo AL, Haas JS, Brennan TA, et al. 
Drug complications in outpatients. Journal of General Internal Medicine. 2000;15(3):149-54. 
23. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. 




24. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events 
among nursing home residents. Archives of Internal Medicine. 2001;161(13):1629-34. 
25. Martin CM. Avoiding errors during transitions of care: medication 
reconciliation. Journal of the American Society of Consultant Pharmacists. 2012;27(11):764-
9. 
26. Kripalani S, Roumie CL, Dalal AK, Cawthon C, Businger A, Eden SK. 
Medication errors after hospital discharge. Annals of Internal Medicine. 2012;157(1):I-32. 
27. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug 
events occurring following hospital discharge. Journal of General Internal Medicine. 
2005;20(4):317-23. 
28. Walsh KE, Stille CJ, Mazor KM, Gurwitz JH. Using home visits to understand 
medication errors in children. Advances in Patient Safety: New Directions and Alternative 
Approaches. 2008;4. 
29. Reason J. Human error: models and management. BMJ. 2000;320(7237):768-
70. 
30. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, et al. 
Systems analysis of adverse drug events. ADE Prevention Study Group. Journal of the 
American Medical Association. 1995;274(1):35-43. 
31. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? 
A systematic review of definitions. BMC Geriatrics. 2017;17(1):230. 
32.  Institute for Safe Medication Practices high alert medications. 2015 [Available 
from: https://www.ismp.org/Tools/highAlertMedicationLists.asp. 
33. Blix HS, Viktil KK, Moger TA, Reikvam A. Drugs with narrow therapeutic 
index as indicators in the risk management of hospitalised patients. Pharmacy Practice 
Granada. 2010;8:50-5. 
34. Sorensen L, Stokes JA, Purdie DM, Woodward M, Roberts MS. Medication 
management at home: medication-related risk factors associated with poor health outcomes. 
Age Ageing. 2005;34(6):626-32. 
35. Zakharov S, Tomas N, Pelclova D. Medication errors--an enduring problem 
for children and elderly patients. Upsala Journal of Medical Sciences. 2012;117(3):309-17. 
36. Machado JE, Moncada JC, Mesa G. [Prescription patterns for antilipidemic 




37. Kozer E. Medication errors in children. Pediatric Drugs. 2009;11(1):52-4. 
38. Al-Ahmadi H, Roland M. Quality of primary health care in Saudi Arabia: a 
comprehensive review. International Journal for Quality in Health Care. 2005;17(4):331-46. 
39. Aljadhey H, Mahmoud MA, Hassali MA, Alrasheedy A, Alahmad A, Saleem 
F, et al. Challenges to and the future of medication safety in Saudi Arabia: A qualitative 
study. Saudi Pharmaceutical Journal. 2014;22(4):326-32. 
40. Aljadhey H, Assiri GA, Mahmoud MA, Al-Aqeel S, Murray M. Self-
medication in central Saudi Arabia. Community pharmacy consumers' perspectives. Saudi 
Medical Journal. 2015;36(3):328-34. 
41. Almalki M, Fitzgerald G, Clark M. Health care system in Saudi Arabia: an 
overview. Eastern Mediterranean Health Journal. 2011;17(10):784-93. 
42. Central Intelligence Agency. The world factbook. Saudi Arabia 2018 
[Available from: https://www.cia.gov/library/publications/the-world-factbook/geos/sa.html. 
43. Al-Rasheed M. A history of Saudi Arabia. United Kingdom: Cambridge 
University Press; 2002. 
44. General authority for statistics kingdom of Saudi Arabia. Population estimates  
[Available from: https://www.stats.gov.sa/en/43. 
45. "Saudi Arabai". Organization of the Petroleum Exporting Countries Saudi 
Arabia [Available from: http://www.opec.org/opec_web/en/about_us/169.htm. 
46. Country Cooperation Strategy for WHO and Saudi Arabia 2012-2016 World 
Health Organization Regional Office for the Eastern Mediterranean. WHO-EM/PME/003/E; 
2013. 
47. Albejaidi FM. Healthcare system in Saudi Arabia: An analysi s of structure, 
total quality management and future challenges. Journal of Alternative Perspectives in the 
Social Sciences. 2010;2(2):794-818. 
48. Countries: Saudi Arabia. World health organization  [Available from: 
http://www.who.int/countries/sau/en/. 
49. Walston S, Al-Harbi Y, Al-Omar B. The changing face of healthcare in Saudi 
Arabia. Annals of Saudi medicine. 2008;28(4):243-50. 
50. General authority for statistics kingdom of Saudi Arabia. Labor force  
[Available from: https://www.stats.gov.sa/en/814. 




52. Global, regional, and national incidence, prevalence, and years lived with 
disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for 
the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1211-59. 
53. Health statistics annual book Kingdom of Saudi Arabia. General directorate of 
statistics and information: Ministry of Health Kingdom of Saudi Arabia; 2013. 
54. Kingdom of Saudi Arabia statistical year book 2016. General directorate of 
statistics and information: Ministry of Health Kingdom of Saudi Arabia; 2016. 
55. Khaliq AA. " The Saudi healthcare system: a view from the minaret": more 
similarities than differences. World Health and Population. 2012;13(3):65. 
56. Sahih Muslim.The Book of Greetings.Hadith  [Available from: 
http://sunnah.com/muslim/39/95. 
57. Rassool GH. The crescent and Islam: healing, nursing and the spiritual 
dimension. Some considerations towards an understanding of the Islamic perspectives on 
caring. Journal of Advanced Nursing. 2000;32(6):1476-84. 
58. Riyad as-Salihin.The Book of Miscellany.Hadith  [Available from: 
http://sunnah.com/riyadussaliheen/1/516. 
59. Memish ZA, El Bcheraoui C, Tuffaha M, Robinson M, Daoud F, Jaber S. 
Obesity and associated factors - Kingdom of Saudi Arabia, 2013. Preventing Chronic Disease. 
2014;11:E174. 
60. Musaiger AO. Overweight and obesity in Eastern Mediterranean region: 
prevalence and possible causes. Journal of Obesity. 2011:17. 
61. Rassool GH. Cultural competence in nursing Muslim patients. Nursing Times. 
2015;111(14):12-5. 
62. The world health report 2000. Health systems: improving performance. 
Geneva: World Health Organization; 2000. 
63. Al-Yousuf M, Akerele TM, Al-Mazrou YY. Organization of the Saudi health 
system. Eastern Mediterranean Health Journal. 2002:645-53. 
64. Bawazir S. Saudi Arabia Pharmaceutical Country Profile. 2011. 
65. Ministry of Health Formulary (MOHF) Drug List: First Revised Edition. Saudi 
Arabia.2012. 




67. MOH warns against selling antibiotics without prescription: Ministry of Health 
Kingdom of Saudi Arabia; 2018 [Available from: 
https://www.moh.gov.sa/en/Ministry/MediaCenter/News/Pages/news-2018-04-17-004.aspx. 
68. Understanding Over-the-Counter Medicines. U.S. Food and Drug 
Administration  [Available from: 
https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understan
dingover-the-countermedicines/default.htm. 
69. Abduelkarem AR. Extending the role of pharmacists in patient care: are 
pharmacists in developing nations ready to change? Pharmacology and Pharmacy. 2014;2014. 
70. Qutub AF, AlJewair TS, Leake JL. A comparative study of the health care 
systems of Canada and Saudi Arabia: lessons and insights. International Dental Journal. 
2009;59(5):277-83. 
71. General authority for statistics kingdom of Saudi Arabia. Health personnel by 
profession, sector, nationality, and gender  [Available from: https://www.stats.gov.sa/en/932-
0. 
72. Al-Mazrou YY. Primary health care in Saudi Arabia: its development and 
future prospectives. Journal of Family and Community Medicine. 2002;9(2):15. 
73. El Bcheraoui C, Tuffaha M, Daoud  F, AlMazroa MA, Al Saeedi M, Memish 
Z, et al. Low uptake of periodic health examinations in the Kingdom of Saudi Arabia. Journal 
of Family Medicine and Primary Care. 2015;4(3):342-6  
74. Mohamed BA. How physician gender shapes the communication of medical 
care in Saudi Arabia: The case of female patients. Sudanese Journal of Public Health. 
2011;6(1). 
75. Mufti MH. Healthcare development strategies in the Kingdom of Saudi 
Arabia: Springer Science and Business Media; 2000. 
76. Tawfik A.M. Khoja, Ali M. Al Shehri, Abdul-Aziz F. Abdul-Aziz, Aziz KMS. 
Patterns of referral from health centres to hospitals in Riyadh region. Eastern Mediterranean 
Health Journal. 1997;3(2):236-43. 
77. Altuwaijri MM. Electronic-health in Saudi Arabia. Just around the corner? 
Saudi Medical Journal. 2008;29(2):171-8. 
78. Alshammari TM, Alshakka M, Aljadhey H. Pharmacovigilance system in 
Saudi Arabia. Saudi Pharmaceutical Journal. 2017;25(3):299-305. 
181 
 
79. Alshaikh M, Mayet A, Aljadhey H. Medication error reporting in a university 
teaching hospital in Saudi Arabia. Journal of Patient Safety. 2013;9(3):145-9. 
80. Aljadhey H, Mahmoud MA, Mayet A, Alshaikh M, Ahmed Y, Murray MD, et 
al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. 
International Journal for Quality in Health Care. 2013;25(6):648-55. 
81. Aljadhey H, Alhusan A, Alburikan K, Adam M, Murray MD, Bates DW. 
Medication safety practices in hospitals: a national survey in Saudi Arabia. Saudi 
Pharmaceutical Journal. 2013;21(2):159-64. 
82. Al-Dhawailie AA. Inpatient prescribing errors and pharmacist intervention at a 
teaching hospital in Saudi Arabia. Saudi Pharmaceutical Journal. 2011;19(3):193-6. 
83. Al-Jeraisy MI, Alanazi MQ, Abolfotouh MA. Medication prescribing errors in 
a pediatric inpatient tertiary care setting in Saudi Arabia. BMC research notes. 2011;4:294. 
84. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Elliott R, Howard R, et al. 
Protocol for the PINCER trial: a cluster randomised trial comparing the effectiveness of a 
pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically 
important errors in medicines management in general practices. Trials. 2009;10(1):28. 
85. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A 
pharmacist-led information technology intervention for medication errors (PINCER): a 
multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. The Lancet. 
2012;379(9823):1310-9. 
86. Assiri G GL, Aljadhey H,  Sheikh A. Investigating the epidemiology of 
medication errors and error-related adverse drug events (ADEs) in primary care, ambulatory 
care and home settings: a systematic review protocol. PROSPERO 2016:CRD42016048126 
2016 [Available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016048126  
87. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. 
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 
2015: elaboration and explanation. BMJ : British Medical Journal. 2015;349. 
88. Assiri GA, Grant L, Aljadhey H, Sheikh A. Investigating the epidemiology of 
medication errors and error-related adverse drug events (ADEs) in primary care, ambulatory 
care and home settings: a systematic review protocol. BMJ Open. 2016;6(8). 
182 
 
89. Gandhi TK, Seger AC, Overhage JM, Murray MD, Hope C, Fiskio J, et al. 
Outpatient adverse drug events identified by screening electronic health records. Journal of 
Patient Safety. 2010;6(2):91-6. 
90. Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. 
Medication without harm: WHO's third global patient safety challenge. Lancet. 
2017;389(10080):1680-1. 
91. Sheikh A, Dhingra-Kumar N, Kelley E, Kieny MP, Donaldson LJ. The third 
global patient safety challenge: tackling medication-related harm. Bulletin of the World 
Health Organization. 2017;95(8):546-A. 
92. Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the 
reasons for preventable drug related admissions to a medical admissions unit: observational 
study. Quality and Safety in Health Care. 2003;12(4):280-5. 
93. Field TS, Mazor KM, Briesacher B, Debellis KR, Gurwitz JH. Adverse drug 
events resulting from patient errors in older adults. Journal of the American Geriatrics 
Society. 2007;55(2):271-6. 
94. Tulner LR, Kuper IM, Frankfort SV, van Campen JP, Koks CH, Brandjes DP, 
et al. Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events 
and drug-drug interactions. American Journal of Geriatric Pharmacotherapy. 2009;7(2):93-
104. 
95. Cornu P, Steurbaut S, Leysen T, De Baere E, Ligneel C, Mets T, et al. 
Discrepancies in medication information for the primary care physician and the geriatric 
patient at discharge. Annals of Pharmacotherapy. 2012;46(7-8):983-90. 
96. Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, Guidoni CM, de Lyra Junior 
DP, Pilger D, et al. Adverse drug reactions caused by drug-drug interactions in elderly 
outpatients: a prospective cohort study. European Journal of Clinical Pharmacology. 
2012;68(12):1667-76. 
97. Baldoni AD, Ayres LR, Martinez EZ, Dewulf NDS, dos Santos V, Pereira 
LRL. Factors associated with potentially inappropriate medications use by the elderly 
according to Beers criteria 2003 and 2012. International Journal of Clinical Pharmacy. 
2014;36(2):316-24. 
98. Thomas SK, McDowell SE, Hodson J, Nwulu U, Howard RL, Avery AJ, et al. 
Developing consensus on hospital prescribing indicators of potential harms amenable to 
decision support. British Journal of Clinical Pharmacology. 2013;76(5):797-809. 
183 
 
99. Spencer R, Bell B, Avery AJ, Gookey G, Campbell SM. Identification of an 
updated set of prescribing-safety indicators for GPs. The British Journal of General Practice. 
2014;64(621):e181-90. 
100. Seidling HM, Bates DW. The Pharmacoepidemiology of Medication Errors. 
In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. Fifth ed: John Wiley 
& Sons, Ltd; 2012. 
101. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. 
Which drugs cause preventable admissions to hospital? A systematic review. British Journal 
of Clinical Pharmacology. 2007;63(2):136-47. 
102. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence 
and possible causes of prescribing potentially hazardous/contraindicated drug combinations in 
general practice. Drug Safety. 2005;28(1):67-80. 
103. Orsmond GI, Cohn ES. The distinctive features of a feasibility study: 
objectives and guiding questions. Occupation, Participation and Health. 2015;35(3):169-77. 
104. KFSH&RC HIMSS EMRAM Ambulatory Stage 7 2015 [cited 2018 
28/08/2018]. Available from: https://www.kfshrc.edu.sa/en/home/news/47. 
105. King Faisal Specialist Hospital and Research Centre. FAMILY MED / 
POLYCLINICS Department - Riyadh 2016 [Available from: 
https://www.kfshrc.edu.sa/en/home/hospitals/riyadh/familymedicinepolyclinics. 
106. A Dictionary of Epidemiology. Sixth ed. New York Oxford University Press; 
2014. 
107. Evidence-Based Summaries for Health Foundation. PINCER 2015.  [Available 
from: https://www.nottingham.ac.uk/primis/tools-audits/tools-audits/pincer/pincer.aspx. 
108. Terry AL, Chevendra V, Thind A, Stewart M, Marshall JN, Cejic S. Using 
your electronic medical record for research: a primer for avoiding pitfalls. Family Practice. 
2010;27(1):121-6. 
109. The research ethics committee: guidelines & policy manual. 2016 [Available 
from: http://www.kfshrc.edu.sa/en/home/research/researchcentrepolicies. 
110. World Health Organization, ICD-10 version 2016 website.  [Available from: 
http://apps.who.int/classifications/icd10/browse/2016/en. 




112. Saudi Food and Drug Authority. Registered Drugs and Herbal Products List. 
2017 [Available from: http://www.sfda.gov.sa/en/drug/search/Pages/default.aspx. 
113. Assiri GA, Shebl NA, Mahmoud MA, Aloudah N, Grant E, Aljadhey H, et al. 
What is the epidemiology of medication errors, error-related adverse events and risk factors 
for errors in adults managed in community care contexts? A systematic review of the 
international literature. BMJ Open. 2018;8(5). 
114. Kimberlin CL, Winterstein AG. Validity and reliability of measurement 
instruments used in research. American Society of Health-System Pharmacists. 
2008;65(23):2276-84. 
115. Gearing RE, Mian IA, Barber J, Ickowicz A. A methodology for conducting 
retrospective chart review research in child and adolescent psychiatry. Journal of the 
Canadian Academy of Child and Adolescent Psychiatry. 2006;15(3):126-34. 
116. Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plastic 
and Reconstructive Surgery. 2010;126(2):619-25. 
117. Lackey NR, Wingate AL. The pilot study: one key to research success. In: 
Brink PJ, Wood MJ, editors. Advanced Design in Nursing Research. Thousand Oaks, CA: 
Sage.1998. 
118. Tache SV, Sonnichsen A, Ashcroft DM. Prevalence of adverse drug events in 
ambulatory care: a systematic review. The Annals of Pharmacotherapy. 2011;45(7-8):977-89. 
119. Stoltzfus JC. Logistic regression: a brief primer. Academic Emergency 
Medicine 2011;18(10):1099-104. 
120. Choosing the correct statistical test in sas, stata, spss and r 2018 [cited 2019 
01/01/2019]. Available from: https://stats.idre.ucla.edu/other/mult-pkg/whatstat/  
121. Cook AN, G. Sheikh, A. . Basic Skills in Statistics:A Guide For Healthcare 
Professionals. London: Class Publishing, Barb House; 2004. 
122. Landis JR, Koh GG. The measurement of observer agreement for categorical 
data. Biometrics. 1977;33:159-74. 
123. World Health Organization. Ethical issues in patient safety research: 
interpreting existing guidance. Geneva: World Health Organization; 2013. 
124. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, 
Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE): Explanation and Elaboration. PLoS Medicine. 2007;4(10):e297. 
185 
 
125. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. 
The REporting of studies Conducted using Observational Routinely-collected health Data 
(RECORD) statement. PLoS Medicine. 2015;12(10):e1001885. 
126. Thiese MS. Observational and interventional study design types; an overview. 
Biochemia Medica. 2014;24(2):199-210. 







128. McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica. 
2012;22(3):276-82. 
129. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Boyd M, Cresswell K, et al. 
PINCER trial: a cluster randomised trial comparing the effectiveness and cost-effectiveness of 
a pharmacist-led IT based intervention with simple feedback in reducing rates of clinically 
important errors in medicines management in general practices.  Patient Safety Research 
Portfolio. Birmingham: Department of Health.2010. 
130. QRESEARCH 2018 [Available from: https://www.qresearch.org/. 
131. Wolrd Health Organization. The conceptual framework for the international 
classification for patient safety. Final Technical report. Geneva: World Health Organization; 
2009. 
132. King G, Zeng L. Logistic Regression in Rare Events Data. Political Analysis. 
2001;9(2):137-63. 
133. Alsulami Z, Conroy S, Choonara I. Medication errors in the Middle East 
countries: a systematic review of the literature. European Journal of Clinical Pharmacology. 
2013;69(4):995-1008. 
134. Karthikeyan M, Balasubramanian T, Khaleel MI, Sahl M, Rashifa. A 
systematic review on medication errors. International Journal of Drug Development and 
Research. 2015;7(4):9-11. 
135. Olaniyan JO, Ghaleb M, Dhillon S, Robinson P. Safety of medication use in 
primary care. International Journal of Pharmacy Practice. 2015;23(1):3-20. 
186 
 
136. Panesar SS, deSilva D, Carson-Stevens A, Cresswell KM, Salvilla SA, Slight 
SP, et al. How safe is primary care? A systematic review. BMJ Quality and Safety. 2015;0:1-
10. 
137. Akbarov A, Kontopantelis E, Sperrin M, Stocks SJ, Williams R, Rodgers S, et 
al. Primary Care Medication Safety Surveillance with Integrated Primary and Secondary Care 
Electronic Health Records: A Cross-Sectional Study. Drug Safety. 2015;38(7):671-82. 
138. Hippisley-Cox J, Pringle M, Cater R, Wynn A, Hammersley V, Coupland C, et 
al. The electronic patient record in primary care—regression or progression? A cross sectional 
study. British Medical Journal. 2003;326(7404):1439-43. 
139. Rodgers S. New PINCER Query Library tool to support safer prescribing. 
Prescriber. 2013;24:11-4. 
140. Improving prescribing and medicine use. Journal of Health Services Research 
and Policy. 2016;21(4):272-8. 
141. A Dictionary of Epidemiology. Fourth ed: New York Oxford University Press; 
2001. 
142. Cochrane community (beta). Glossary  [Available from: 
http://community.cochrane.org/glossary. 
143. AlSekait MA, Bamgboye EA, AlNasser AN. Sampling in epidemiological 
research: a case study of the prevalence of brucellosis in Saudi Arabia. Journal of the Royal 
Society of Health. 1992;112(4):172-6. 
144. UCL Databases  [Available from: http://www.ucl.ac.uk/ion/library/databases. 
145. Bibliographic databases  [Available from: 
http://guides.lib.ucdavis.edu/content.php?pid=492203&sid=4040883  










Appendix 1: Terminology and definitions 
 
Adverse drug event (ADE): Definition of Bates DW et al., an “injury resulting from medical 
intervention related to a drug”.(5) ADEs are caused by medication errors. 
 
Bias: “Systematic deviation of results or inferences from truth”.(106) 
 
Case control study: “(Synonym: case comparison study, case compeer study, case history 
study, case referent study, retrospective study). The observational epidemiologic study of 
persons with the disease (or other outcome variable) of interest and a suitable control 
(comparison, reference) group of persons without the disease”.(106) 
 
Cohort study: “(Synonym: concurrent, follow-up study, incidence, longitudinal, panel, 
prospective study) The analytic epidemiological study in which subsets of a defined 
population can be identified who are, have been, or in the future may be exposed or not 
exposed—or exposed in different degrees—to a factor or factors hypothesized to influence the 
occurrence of a given outcome”.(106) 
 
Confidence Interval (CI): “The computed interval with a given probability, e.g., 95%, that 
the true value of a variable such as a mean, proportion, or rate is contained within the 
interval”.(141)  
 
Content validity: “The extent to which the measurement incorporates the domain of the 
phenomenon under study”.(106) 
 
Cross-sectional study: “(Synonym: disease frequency survey, prevalence study) A study that 
examines the relationship between diseases (or other health outcomes) and other variables of 
interest as they exist in a defined population at one particular time. The presence or absence 
of disease and the presence or absence of the other variables (or, if they are quantitative, 
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their level) are determined in each member of the study population or in a representative 
sample at one particular time”.(106) 
 
Descriptive study: “A study concerned with and designed only to describe the existing 
distribution of variables without much regard to causal relationships or other 
hypotheses”.(106) 
 
Follow-up: “Observation over a period of time of an individual, group, or an initially defined 
population whose relevant characteristics have been assessed in order to observe changes in 
health status or health-related variables”.(106) 
 
Harm: “Impairment of the physical, emotional, or psychological function or structure of the 
body and pain or injury resulting therefrom”. (NCC-MERP) 
 
Heterogeneity: “In a meta-analysis, the variability in the intervention effects being evaluated 
in the different studies. It may be a consequence of clinical diversity (sometimes called 
clinical heterogeneity) or of methodological diversity (methodological heterogeneity), or 
both, among the studies”.(106) 
 
Home setting: This is setting for which care is provided or individuals live in which a person 
is not considered an inpatient in a hospital. 
 
High-alert medications: “High-alert medications are drugs that bear a heightened risk of 
causing significant patient harm when used in error. Although mistakes may or may not be 
more common with these drugs, the consequences of an error are clearly more devastating to 
patients”.(32)  
 
Imputation: “The process of replacing some missing values in a large-scale epidemiological 
or social research study, when all other relevant parameters and values are known for an 
individual, by inserting an average or other plausible value. The process may be subject to 
biases and errors, and must be disclosed in reporting the results”.(106) 
 
Incidence: “(Synonym: incidence number) the number of new health-related events in a 
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defined population within a specified period of time. It may be measured as a frequency 
count, a rate, or a proportion”.(106) 
 
Kappa index: “a measure of the degree of nonrandom agreement between observers or 
measurements of the same categorical variable. Kappa coefficients are measures of 
correlation between categorical variables often used as reliability or validity 
coefficients”.(106) 
 
Logistic model: “(logistic regression model) A statistical model for the probability that a 
binary variable Y equals 1 as a function of a covariate x, typically used when Y is an 
individual’s disease indicator and x is the value of a risk factor or risk indicator”.(106) 
 
Meta-analysis: “A statistical analysis of results from separate studies, examining sources of 
differences in results among studies, and leading to a quantitative summary of the results if 
the results are judged sufficiently similar or consistent to support such synthesis”.(106) 
 
Narrow therapeutic index (NTI-drugs): “Drugs with narrow therapeutic index (NTI-drugs) 
are drugs with small differences between therapeutic and toxic doses”.(33) 
 
Non-prescription drugs: Medicines that can be sold legally without a drug prescription. 
 
Odds ratio (OR): “(Synonym: cross-product ratio, relative odds) the ratio of two odds. The 
term odds is defined differently according to the situation under discussion”.(106) 
 
Outcome: “The result of interest in a study or experiment. A component of a participants 
clinical and functional status after an intervention has been applied, that is used to assess the 
effectiveness of an intervention”.(142)  
 
Over-the-counter (OTC) drug: The Food and Drug Administration FDA defines OTC drugs 
as “drugs that have been found to be safe and appropriate for use without the supervision of 
a health care professional such as a physician, and they can be purchased by consumers 




Period prevalence: “the proportion of individuals with the condition at any time during a 
specified time period or interval”.(106)  
 
Pilot study: “A small-scale test of the methods and procedures to be used on a larger scale if 
the pilot study demonstrates that these methods and procedures 
can work”.(106) 
 
Population: “In sampling, the whole collection of units (the “universe”) from which a sample 
may be drawn; not necessarily a population of persons—the units may be institutions, 
records, or events. The sample is intended to give results that are representative of the whole 
population; it may deviate from that goal owing to random and systematic errors”.(106) 
 
Prescription drug: Drugs that cannot be sold legally without a prescription. 
 
Prevalence: “The total number of individuals who have the condition (e.g., disease, exposure, 
attribute) at a particular time (or during a particular period) divided by the population at risk 
of having the condition at that time or midway through the period”.(106) 
 
Probability sample: “a sample in which the probability of each subject in the parent 
population being included in the sample is known”(143)  
 
Prospective study: “In evaluations of the effects of healthcare interventions, a study in which 
people are identified according to current risk status or exposure, and followed forwards 
through time to observe outcome”.(142) 
 
Protocol: “The plan or set of steps to be followed in a study”.(106, 142) “A Protocol for a 
systematic review should describe the rationale for the review, the objectives, and the 
methods that will be used to locate, select, and critically appraise studies, and to collect and 




Reliability: “a measurement is reliable when it is stable; i.e. when repetition of an experiment 
or measurement gives the same results”.(106) 
 
Relative risk: “The ratio of the RISK of disease or death among the exposed to the risk 
among the unexposed; this usage is synonymous with RISK RATIO”.(141)  
 
Retrospective study: “A study in which the outcomes have occurred to the participants 
before the study commenced.  Case- Control studies are usually retrospective, cohort studies 
sometimes are, randomised controlled trials never are”.(142)  
 
Risk factor: “(Synonym: determinant) a factor that is causally related to a change in the risk 
of a relevant health process, outcome, or condition”.(106)  
 
Sample: “A selected subset of a population. A sample may be random or nonrandom and may 
be representative or non-representative”.(106) 
 
Simple random sampling: is one type of the probability or (random) sampling defined as: 
“each person has an equal chance of being selected out of the entire population”.(106)  
 
Systematic sample: “The procedure of selecting according to some simple, systematic rule, 
such as all persons whose names begin with specified alphabetic letters, born on certain 
dates, or located at specified points on a master list”.(106) 
 
Search strategy: “The combination of terms used to identify studies in an electronic database 
such as: MEDLINE”.(142)  
  
Standard deviation: “A measure of dispersion or variation. It is the most widely used 
measure of dispersion of a frequency distribution. It is equal to the positive square root of the 
variance. The mean tells where the values for a group or for an estimator are centered in 
terms of the overall mass of their distribution. The standard deviation is a summary of how 




Statistics: “The science of collecting, summarising, analysing data. Data may or may be not 
subject to random variation”.(106) 
 
STATA (version14): Data analysis and statistical software. 
 
Systematic review: “A review of the scientific evidence, which applies strategies that limit 
bias in the assembly, critical appraisal, and synthesis of all relevant studies on the specific 
topic. Systematic reviews differ from traditional narrative reviews, which tend to be mainly 
descriptive, do not involve a systematic search of the literature, and thus can suffer from 
selection bias”.(106) 
 




























Appendix 4: Systematic review level 1 ethics  
 
Level 1 ethical application form 
University of Edinburgh, 
Centre for Population Health Sciences 
RESEARCH ETHICS SUBGROUP 
Self-Audit Checklist for Level 1 Ethical Review for PGR projects 
See Intra website for further information: 
http://www.cphs.mvm.ed.ac.uk/intra/research/ethicalReview.php  
NOTE to student:  Completion of this form should be under the oversight of your 
supervisor.  A good strategy would be to complete a draft as best you can, then discuss 
with your supervisor before completing a final copy for your supervisor to sign.  
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1. Bringing the University into disrepute 
Proposed Project (State research question and topic area, and briefly describe method/ data. Specify also 
countries in which data will be collected.): 
Title : Investigating the Epidemiology of Medication Errors and Error-Related Adverse Drug Events 
(ADEs) in Primary Care, Ambulatory Care and Home Settings: A Systematic Review Protocol 
Review question/Objective: what is the incidence/prevalence of and risk factors for medication errors and 
error-related ADEs in community (i.e. primary care, ambulatory and home) settings. 
Patient safety is a public concern in healthcare systems across the world. The National Coordinating 
Council for Medication Error Reporting and Prevention (NCC-MERP) defines a medication error as any 
preventable event that may cause or lead to inappropriate medication use or patient harm, while the 
medication is in the control of the health care professional, patient, or consumer. Medication errors are 
therefore any mistakes at any stage of the medication use process. Adverse drug events (ADEs) on the 
other hand are the result of an injury to a drug-related intervention, regardless of whether an error has 
occurred.  
Prior to undertaking further primary work in this area, it is important to take stock of the current evidence 
base, reflect on the quality of the evidence, distil key findings that have the potential to provide both 
estimates on the frequency of medication errors and error-related ADEs, and understand the factors 
underpinning this important source of preventable harm.  I am therefore undertaking a systematic review 
investigating the incidence and prevalence of and risk factors for medication errors and error-related ADEs 
in community (i.e. primary care, ambulatory and home) settings. 
I will perform a systematic review on the incidence and prevalence of medication errors and error related 
ADEs including prescribed and non-prescribed medications (over the counter medication) in community 
(i.e. primary care, ambulatory and home) settings using the following databases:  MEDLINE, CINAHL, 
EMBASE, PsycINFO, EMRO (IMEMR), Google Scholar and Web of science. Experts in the field will be 
contacted. Search will be done on human studies only, from 1990 until Oct 2015 and including studies 
globally. Excluding studies on illegal substance abuse, herbal products, home health care, nursing home, 
any supported home care, hospitalised in-patients or those managed in ED settings, and paediatrics (<18 





Is there any aspect of the proposed research which might bring the University into 
disrepute? NO 
2. Data protection and consent 
Are there any issues of DATA PROTECTION or CONSENT which are NOT adequately  
dealt with via established procedures? NO  
These include well-established sets of undertakings. For example, a ‘No’ answer is 
justified only if: 
(a) There is compliance with the University of Edinburgh’s Data Protection procedures (see   
       www.recordsmanagement.ed.ac.uk); 
(b) Respondents give consent regarding the collection, storage and, if appropriate, 
archiving and destruction of data; 
(c) Identifying information (e.g. consent forms) is held separately from data; 
(d) There is Caldicott Guardian approval for (or approval will be obtained 
prior to) obtaining/ analysing NHS patient-data. 
(e) There are no other special issues arising about confidentiality/consent. 
3. Study participants  
Will a study researcher be in direct contact with participants to collect data, 
whether face-to-face, or by telephone, electronic means or post, or by 
observation? (eg interviews, focus groups, questionnaires, assessments)  NO 
 
4. Duty to disseminate research findings  
Are there issues which will prevent all relevant stakeholders* having access 
to a clear, understandable and accurate summary of the research findings if 
they wish? NO 
* If, and only if, you answered ‘yes’ to 3 above, ‘stakeholders’ includes participants 
in the research  
5. Moral issues and Researcher/Institutional Conflicts of Interest 
Are there any SPECIAL MORAL ISSUES/CONFLICTS OF INTEREST? NO 
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(a)  An example of conflict of interest for a researcher would be a financial or non-
financial benefit for him/herself or for a relative of friend. 
(b)  Particular moral issues or concerns could arise, for example where the purposes 
of research are concealed, where respondents are unable to provide informed 
consent, or where research findings could impinge negatively/ differentially 
upon the interests of participants.  
(c)  Where there is a dual relationship between researcher and participant (eg where 
research is undertaken by practitioners so that the participant might be unclear 
as to the distinction between ‘care’ and research) 
 
6. Potential physical or psychological harm, discomfort or stress 
(a) Is there a FORSEEABLE POTENTIAL for PSYCHOLOGICAL HARM or 
 STRESS for participants? NO 
(b) Is there a FORSEEABLE POTENTIAL for PHYSICAL HARM or  
 DISCOMFORT for participants?  NO 
(c) Is there a FORSEEABLE RISK to the researcher? NO 
Examples of issues/ topics that have the potential to cause psychological harm, 
discomfort or distress and should lead you to answer ‘yes’ to this question include, 
but are not limited to:  
relationship breakdown; bullying; bereavement;   mental health difficulties; trauma / 
PTSD; violence or sexual violence; physical, sexual or emotional abuse in either 
children or adults. 
7. Vulnerable participants 
Are any of the participants or interviewees in the research considered to be 
vulnerable?                  e.g. children and young people under age of 16, people 
who are in custody or care, marginalised/stigmatised groups NO 
8. Protection of research subject confidentiality 
Are there any issues of CONFIDENTIALITY which are NOT adequately handled by  
normal tenets of confidentiality for academic research?                    NO 
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These include well-established sets of undertakings that should be agreed with 
collaborating and participating individuals/organisations. For example, a ‘No’ 
answer is justified only if: 
(a) There will be no attribution of individual responses;  
(b) Individuals (and, where appropriate, organisations) are anonymised 
in stored data, publications and presentation;  
(c) There has been specific agreement with respondents regarding 
feedback to collaborators and publication.  
Overall assessment 
➢ If every answer above is a definite NO, the self-audit has been conducted and confirms the  
ABSENCE OF REASONABLY FORESEEABLE ETHICAL RISKS – please tick box 
This means that regarding this study, as currently self-audited, no further 
ethical review actions   are required within CPHS.  However, if in the coming 
weeks/months there is any change to the research plan envisaged now (and 
outlined above), the study should be re-audited against a Level 1 form, because 
it may be that the change made negates the absence of ethical risks signed off 
here. 
➢ If one or more answers are YES, then risks have been identified and 
prior to commencing any data collection formal ethical review is 
required - either: 
 by NHS REC (NB copy of ethics application and decision letter to be sent 
to CPHS Ethics); or  
 if not to be formally reviewed by NHS REC, then CPHS level 2/3 
ethical review  required.           [If either of  5 or 7 are answered ‘yes’ 
then almost certainly level 3 is required.] 
Two copies of this form should be taken for inclusion in the final dissertation 
and the original should be returned to the CPHS Ethics administrator.  
 





                Student Name                       Supervisor Name 
                                          
         Student Signature     Supervisor Signature * 
* NOTE to supervisor: The CPHS Ethics Subgroup will not check this form (the light 
touch Level 1 form means we have insufficient detail to do so).  By counter-signing this 
check-list as truly warranting all ‘No’ answers, you are taking responsibility, on behalf 
of CPHS and UoE, that the research proposed truly poses no potential ethical risks. 
Therefore, if there is any doubt on any issue, it would be a wise precaution to mark it as 
‘uncertain’ and contact the Ethics Subgroup as to whether a level 2 form might be 
required as well. (See Intra Ethics website – URL at top of form).
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Appendix 5: Description of databases definitions 
CINAHL: The Cumulative Index to Nursing and Allied Health. “References and abstracts on 
nursing, biomedical, allied health and consumer health literature. Also includes health care 
books, nursing dissertations, selected conference proceedings, standards of practice, 
educational software, audiovisuals and book chapters, as well as Evidence-Based care sheets. 
Coverage: 1982-present”.(144) 
 
EMBASE: “Bibliographic database which gives access to online version of Excerpta 
Medica. It is produced by Elsevier Science Publishers B.V. and offers international coverage 
of the drug-related literature (drugs and toxicology, clinical medicine, biotechnology and 
bioengineering, health affairs, psychiatry, forensic medicine.  The database includes data 
from 3500 biomedical journals, dating back to 1974.  It is updated monthly”.(145)  
 
EMRO: “The Eastern Mediterranean Regional office of the World Health Organization, 
also known as EMRO, is the regional office of the World Health Organization that serves 22 
countries and territories in the Middle East, the North Africa, the Horn of Africa and Central 
Asia. It is one of the WHO's six regional offices around the world”.(146)  
 
Google scholar: Search for scholarly literature on the web, including "peer-reviewed papers, 
theses, books, preprints, abstracts and technical reports” from a variety of academic 
publishers, professional societies, preprint repositories and universities. 
 
MEDLINE: “Medline is a bibliographic database produced by the US National Library of 
Medicine.  It covers worldwide literature published since 1966.  Over 4000 journal titles are 
indexed, in the fields of medicine, nursing, dentistry, veterinary medicine, and health care 
system and pre-clinical sciences. 70% of the references have an abstract. The Medline 




PsycINFO: “PsycINFO is a department of the American Psychological Association (APA). It 
provides citations to articles in professional journals, conference proceedings, books, reports, 
dissertations and even important internet sites in psychology and related disciplines, most 
with abstracts and some citations. Coverage: 1840-present”.(144) 
 
Web of Science: “Provides access to the content from three Thomson Reuters ISI (Institute 
for Scientific Information) Citation Databases: Science Citation Index Expanded; Social 
Sciences Citation Index; Arts & Humanities Citation Index. 




Appendix 6: Systematic review search strategy 
 
 
A. MEDLINE  
 1. Medication Errors/ae, cl, mt [Adverse Effects, Classification, Methods] 
2. "Drug-Related Side Effects and Adverse Reactions"/ 
3. adverse drug event*.mp. 
4. medication error*.mp. 
5. Patient Safety/ 
6. drug safety.mp. 
7. medication safety.mp. 
8. prescribed medication*.mp. 
9. prescribed drug*.mp. 
10. Nonprescription Drugs/ 
11. over the counter medication*.mp.  
12. patient error*.mp. 
13. medication management.mp. 
14. Medication Therapy Management/ 
15. drug related problem*.mp. 
16. medication related problem*.mp. 
17. preventable adverse drug event*.mp. 
18. preventable adverse event*.mp. 
19. potential adverse event*.mp. 
20. ((medic* or drug*) adj3 (error* or problem* or event* or safety)).mp.  
21. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
or 19 or 20 
22. household*.mp.  
23. residence*.mp.  
24. residential home.mp.  
25. ambulatory care.mp.  
26. Outpatients/ 
27. self care/ or self medication/ or self manage*.mp. 
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28. After-Hours Care/ 
29. out of hours medical care.mp. 
30. Homebound Persons/ 
31. home visit.mp. 
32. face to face home interview.mp. 
33. face to face interview.mp. 
34. Primary Health Care/ 
35. General Practice/ 
36. Family Practice/ 
37. Patient-Centered Care/ 
38. ((home* or house* or community or ambulatory or primary or family or outpatient) adj3 
(setting* or context*)).mp.  
39. ((after or post) adj2 hospital discharge).mp. 
40. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 




44. risk factor*.mp. 
45. follow up.mp. 
46. cross sectional.mp. 
47. cohort.mp. 
48. case control.mp. 
49. observational.mp. 
50. 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 
51. 21 and 40 and 50 
52. limit 51 to (humans and yr="1990 -2015") 
 
B. EMBASE   
1. adverse drug event*.mp. 
2. medication error/ 
3. patient safety/ 
4. drug safety/ 
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5. medication safety.mp. 
6. prescription drug/ 
7. prescribed medication*.mp. 
8. non prescription drug/ 
9. over the counter medication*.mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
10. patient error*.mp. 
11. medication therapy management/ 
12. medication management.mp. 
13. drug related problem*.mp. 
14. medication related problem*.mp. 
15. preventable adverse drug event*.mp. 
16. preventable adverse event*.mp. 
17. potential adverse drug event*.mp. 
18. ((medic* or drug*) adj3 (error* or problem* or event* or safety)).mp.  
19. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20. household*.mp. 
21. residence*.mp. 
22. ambulatory care/ 
23. outpatient care/ or outpatient/ 
24. self care/ 
25. self medication/ 
26. self manage*.mp. 
27. after hours care.mp. 
28. out of hours medical care.mp. 
29. home visit.mp. 
30. interview/ or face to face interview.mp. 
31. primary health care/ 
32. general practice/ 
33. patient centered care.mp. or patient care/ 
34. family practice.mp. 
35. ((after or post) adj2 hospital discharge).mp.  
36. ((home* or house* or community or ambulatory or primary or family or outpatient) adj3 
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(setting* or context*)).mp.  





41. risk factor*.mp. 
42. follow up/ 
43. observational method/ 
44. cross-sectional study/ or cross sectional.mp. 
45. cohort.mp. 
46. case control study/ or case control.mp. 
47. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 
48. 19 and 37 and 47 
49. limit 48 to (human and yr="1990 -2015") 
 
 
C. PsycINFO  
1. medication error*.mp. 
2. adverse drug event*.mp. 
3. drug related adverse event*.mp. 
4. patient safety.mp. 
5. drug safety.mp. 
6. medication safety.mp. 
7. exp Prescription Drugs/ or exp "Prescribing (Drugs)"/ 
8. prescribed medication*.mp. 
9. exp Nonprescription Drugs/ 
10. over the counter medication*.mp.  
11. patient error*.mp. 
12. medication management.mp. 
13. medication therapy management.mp. 
14. drug related problem*.mp. 
15. medication related problem*.mp. 
213 
 
16. preventable adverse event*.mp. 
17. preventable adverse drug event*.mp. 
18. potential adverse event*.mp. 
19. ((medic* or drug*) adj3 (error* or problem* or event* or safety)).mp.  




23. residential home.mp. 
24. ambulatory care.mp. 
25. exp Outpatients/ 
26. self care.mp. 
27. exp Self Medication/ 
28. exp Self Management/ 
29. after hours care.mp. 
30. home visit.mp. 
31. exp Home Visiting Programs/ 
32. exp Interviews/ or face to face interview.mp. 
33. exp Primary Health Care/ 
34. exp General Practitioners/ or general practice.mp. 
35. family practice.mp. 
36. patient centered care.mp. 
37. ((after or post) adj2 hospital discharge).mp.  
38. ((home* or house* or community or ambulatory or primary or family or outpatient) adj3 
(setting* or context*)).mp.  
39. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 
or 37 or 38 
40. exp Epidemiology/ 
41. incidence.mp. 
42. prevalence.mp. 
43. risk factor*.mp. 
44. follow up.mp. 
45. exp Observation Methods/ 
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46. cross sectional.mp. 
47. cohort.mp. 
48. case control.mp. 
49. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 
50. 20 and 39 and 49 
51. limit 50 to (human and yr="1990 -2015") 
 
D. Web of Science  
#5 #4 AND #3 AND #2 AND #1  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, 
BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=1990-2015 
#4 TS=(follow up) OR TS=(cross sectional) OR TS=(cohort) OR 
TS=(case control) OR TS=(observational study)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, 
BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=1990-2015 
#3 TS=(epidemiology) OR TS=(incidence) OR TS=(prevalence) OR 
TS=(risk factor*)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, 
BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=1990-2015 
#2 TOPIC: (household) OR TOPIC: (residence) OR TOPIC: 
(ambulatory) OR TOPIC: (community) OR TOPIC: (outpatient) 
OR TOPIC: (general practice) OR TOPIC: (family practice) OR 
TOPIC: (primary health care) OR TOPIC: (patient centered care) 
OR TOPIC: (self care) OR TOPIC: (self manage*) OR TOPIC: 
(self medication*) OR TOPIC: (after hours care) OR TOPIC: 
(after hospital discharge) OR TOPIC: (post hospital discharge)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, 
BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=1990-2015 
 
 
#1 TOPIC: (medication error*) OR TOPIC: (adverse drug event*) OR 
TOPIC: (drug related adverse event*) OR TOPIC: (medication 
related adverse event*) OR TOPIC: (patient safety) OR TOPIC: 
(drug safety) OR TOPIC: (patient error*) OR TOPIC: (drug 
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related problem*) OR TOPIC: (preventable adverse drug event*) 
OR TOPIC: (potential adverse drug event*)  
 Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, 




S25   S21 AND S22 AND S23   Limiters – Published Date: 
19900101-20151031  
 
S24  S21 AND S22 AND S23   
S23  S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR 
S20   
S22  S8 OR S9 OR S10 OR S11 OR S12 OR S13   
S21  S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7   
S20  (MH "Case Control Studies")   
S19  "cohort"   
S18  (MH "Cross Sectional Studies")   
S17  (MH "Prospective Studies")   
S16  (MH "Risk Factors")   
S15  (MH "Incidence")   
S14  (MH "Prevalence")   
S13  (MH "Family Practice") OR "general practice"   
S12  (MH "Primary Health Care")   
S11  (MH "Self Care")   
S10  (MH "Ambulatory Care")   
S9  (MH "Outpatients")   
S8  "household*"   
S7  "medication therapy management"   
S6  "drug related problem*"   
S5  "over the counter medication*"   
S4  "prescribed medication*"   
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S3  "drug safety"   
S2  (MH "Adverse Drug Event")   
S1  (MH "Medication Errors")   
 
 
F. Global Health Library (EMRO) 
(Adverse drug event* OR medication error* OR patient error*) AND (outpatient OR 
ambulatory OR general practice OR family practice OR household OR community OR home 
visit OR after hospital discharge) AND (prevalence OR incidence OR risk factor* OR cross 
sectional OR cohort OR case control) 
G. Google scholar 
(Medication error* OR adverse drug event*) AND (home* OR ambulatory OR community 
OR outpatient OR general practice OR after discharge) AND (prevalence OR incidence OR 
risk factor* OR Cross sectional OR cohort OR case control) 
 
2- Experts in the field was contacted by email:  
 Date  Replay or 
not  
Result  
1- Tahir M khan 
from Malaysia  
11/8/2015 Yes (Medication error in the Southeast Asian 
countries ) systematic review study 
2- Azmi Hassali from 
Malaysia  
11/8/2015 Yes Referred to Tahir M khan 
3- Izham M Ibrahim 
from Malaysia  
11/8/2015 No - 
4- David Bates  11/8/2015 No - 
5- Tejal Gandhi  11/8/2015 No - 




Appendix 7: Outcome measures and their associated ADEs 
 Clinically important 











Primary outcome measures  
1 Patient with a history of 
peptic ulcer receiving a non-










2a Patient with a history of 
asthma who has been 







3 Patient aged 75 years and 
older who has been 
prescribed an angiotensin 
converting enzyme inhibitor 
(ACEI) or a loop diuretic 
long-term who has not had a 
recorded check of their renal 
function and electrolytes in 










Secondary outcome measures  
2b Patient with a history of 
asthma [and no history of 





High risk  
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(CHD)] who has been 
prescribed a beta-blocker 
 
4 Woman with a past medical 
history of venous or arterial 
thrombosis who has been 













methotrexate for at least 
three months who has not 
had a recorded full blood 
count and / or liver function 







or liver problem  
High risk 
6 Patient receiving warfarin 
for at least three months 
who has not had a recorded 
check of their international 
normalised ratio (INR) 







high INR, or 
thromboembolic 
event associated 
with low INR 
Extreme risk 
7 Patient receiving lithium for 
at least 3 months who has 
not had a recorded check of 
their lithium levels within 
Inadequate 
monitoring 
Lithium toxicity  High risk 
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the previous 3 months 
 
8 Patient receiving 
amiodarone for at least 6 
months who has not had a 
thyroid function test within 




Thyrotoxicosis  High risk 
9 Patient receiving 
prescriptions of 
methotrexate without 
instructions that the drug 








10 Patient receiving 
prescriptions of amiodarone 
for at least one month 
without instructions to take 









Composite secondary outcome measures   
11 Patients with at least one 
prescription problem (a 
combination of outcome 
measures 1, 2, or 4) 
 
   
12 Patients with at least one 
monitoring problem (a 
combination of outcome 
measures 3, 5, 6, 7, and 8) 
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Additional revised updated outcome measures   
13 Prescription of an oral 
NSAID, without co-
prescription of an ulcer-
healing drug, to a patient 




GI bleed  
14 Prescription of an anti-
platelet drug without co-
prescription of an ulcer-
healing drug, to a patient 





GI bleed High risk 
15 Prescription of warfarin or 
New Oral Anti-Coagulant 
(NOAC) in combination 




GI bleed High risk 
16 Prescription of warfarin or 
NOAC and an anti-platelet 
drug in combination without 





GI bleed  
17 Prescription of aspirin in 
combination with another 
anti-platelet drug without 








18 Prescription of a long-acting 
beta-2 agonist inhaler 
(excluding combination 
products with inhaled 
corticosteroid) to a patient 
with asthma who is not also 








19 Prescription of an oral 





Heart failure  High risk 
20 Prescription of 
antipsychotics for >6weeks 
in a patient aged ≥ 65 years 





Stroke High risk 
21 Prescription of an oral 
NSAID to a patient with 
estimated Glomerular 
Filtration Rate (eGFR) < 45 
Prescribing- 
contraindication 
Kidney Injury Extreme risk  
 (85, 99, 107)
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Appendix 8: Pilot and Cohort studies Kappa coefficient agreements between 
two independent data extractors 
 
Phase 3: Pilot study 
The number of positive (error or risk) in the pilot study dataset is 196 in 200 patients. To 
be able to calculate the kappa coefficient, the data were entered as a two-way table. 
To know the result of the kappa coefficient the following command was entered in 
STATA (version 14):  
. kap rater1 rater2 [freq=pop], tab 
Where kap is the interrater agreement for two unique raters, freq is frequency, pop is the 
number assessed by both raters and tab is to show the table of assessment. 
 
Where GA’s is Ghadah Assiri (rater 1), SK is Salma Al-khani (rater 2). 
The agreement between the two independent data extractors in the pilot study was 
substantial (Kappa 0.69). All discrepancies were resolved by discussion and by double-






Phase 4: Cohort study 
The number of observations with positive (error or risk) in the cohort study dataset is 48 
in 200 Patients. The data were entered as a two-way table. 
To know the result of the kappa coefficient the following command was entered in 
STATA (version 14):  
. kap rater1 rater2 [freq=pop], tab 
Where kap is the interrater agreement for two unique raters, freq is frequency, pop is the 
number assessed by both raters and tab to show the table of assessment. 
 
Where GA’s is Ghadah Assiri (rater 1), SH is Sarah Al-hathlool (rater 2). 
The agreement between the two independent data extractors in the cohort study for 200 
records was substantial (Kappa 0.8). All discrepancies were resolved by discussion and 





Appendix 9: Feasibility and pilot study ethics (The Clinical Research 




























      
                                                                      Office of Research Affairs  
          24528  27894   MBC 03             
INTERNAL MEMORANDUM  
  
  
TO:   Abdallah Alkhenizan, MD  DATE:  06 Sha’ban 1438  
  Chairman  02 May 2017  
  Department of Family Medicine/Poly Clinics   
 
THRU:     Afshan Ali, MD, MBA  REF:  ORA/0817/38  
  Chairperson, Research Ethics Committee  
  Office of Research Affairs  
 





Rana Moslimany, Pharm D, CCRP  
Member, Research Ethics Committee  
Office of Research Affairs    
  
SUBJECT:  Project # 2171 060  
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  Protocol for a Feasibility Study to Inform the Development of a Pilot 
Retrospective Cohort Study Investigating the Epidemiology of Medication 
Errors Using Electronic Health Records in Riyadh, Saudi Arabia  
  
 
Further to ORA’s email (dated 19 April 2017), your reply/Waiver of Informed 
Consent Form (email dated 20 April 2017) was reviewed by the Research Ethics 
Committee (REC) on 25 April 2017.  It is my pleasure to inform you that the 
REC has accepted the reply as submitted and recommended the proposal, Data 
Collection Sheet and the Waiver of Informed Consent for approval; and I would 
like to take this opportunity to congratulate you on behalf of the Research 
Advisory Council.  
  
Please be informed that in conducting this proposal, the Investigators are 
required to abide by the rules and regulations of the Government of Saudi 
Arabia, KFSH&RC, and the RAC.  Further, you are required to submit a 
Progress/Final Report by 25 March 2018; so it can be reviewed by the 
Committees without lapse of approval. The approval of this proposal will 
automatically be suspended 25 April 2018, pending the acceptance of the 
Report.  You also need to notify the ORA as soon as possible in the case of:  
  
6. Any amendments to the project,   
7. Termination of the study,   





ORA    E-Mail: ora@kfshrc.edu.sa  
                                                           0817 2171 060 Dr. Abdullah Al Khenizan Approve reply REC   
  A         





Please observe the following:  
  
5 Personally identifying data should only be collected when necessary for 
research.  
6 The data collected should only be used for this proposal.  
7 Data should be stored securely so that only a few authorised users are 
permitted access to the database.  
8 Secondary disclosures of personally identifiable data are not allowed.  
9 Should there be a need to contact the research subjects for follow-up 
information, you will       Need to seek the authorisation of the RAC prior to 
such contact.  
We wish you every success in your research endeavours.  
  
   
 cc:   Clinical Research Coordinator, Department of Family 
Medicine/Poly Clinics         RAC File
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Appendix 10: Pilot study data collection form 
A: demographic and basic information  
Patient code  
Age ____ Years 
Gender  M F 
Nationality  Saudi  Non-Saudi  
Diagnosis or past medical history  
  Anaemia  Back pain  
 Allergic rhinitis  Osteoporosis 
 Benign prostatic hypertrophy 
(BPH) 
 Osteoarthritis 
 Bronchial Asthma  Type 1 diabetes mellitus 
 Chronic Obstructive 
Pulmonary Disease (COPD) 
 Type 2 diabetes mellitus 
 Coronary artery disease 
(CAD) 
 Vitamin D deficiency 
 Depression   Hypertriglyceridemia 
 Essential primary 
hypertension (HTN) 
 Hyperlipidaemia 
 Gastroesophageal reflux 
disease (GERD) 
Other: 
 Heart failure (HF)  
 Hyperthyroidism  
 Hypothyroidism  
 
Polypharmacy at 
any point (≥ 5 
medications) 
Yes No 




If the patient had a history of the 
following:  
If the patient was on the following 
medications 
Peptic ulcer – see (outcome 1 and 14) 
Asthma – see (outcome 2a, 18) 
OR Asthma and not coronary heart disease 
(CHD)—see (outcome 2b, 18) 
A female with venous or arterial 
thromboembolism and arterial thrombosis 
– see (outcome 4) 
Patient aged ≥ 65 years – see (outcome 13) 
Patient aged ≥ 65 years with dementia – 
see (outcome 20) 
Heart failure – see (outcome 19) 
estimated Glomerular Filtration Rate 
(eGFR) < 45 – see (outcome 21) 
Aged ≥ 75 years and on angiotensin 
converting enzyme (ACE) inhibitors or 
diuretics – see (outcome 3) 
 
Methotrexate – see (outcome 5a, 5b & 9) 
 
Warfarin – see (outcome 6, 15 & 16) 
New Oral Anti-Coagulant (NOAC) – see 
(outcome 15 & 16) 
 
Lithium – see (outcome 7) 
 
Amiodarone – see (outcome 8 &10) 
 

















Primary, secondary and composite outcome measures 
1 History of peptic ulcer 
prescribed an non-steroidal 
anti-inflammatory drug 
(NSAID) without a proton-
pump inhibitor (PPI) 
 History of peptic ulcer 
without a PPI 
  
2a Asthma prescribed a β-
blocker 
 Asthma    
2b Asthma and not CHD 
prescribed a β-blocker 
 Asthma and not CHD    
 3   Aged ≥75 on long term ACE 
inhibitors or diuretics 
without urea and electrolyte 
monitoring in the previous 15 
months  
 Aged ≥75 on long term 
ACE inhibitors or 
diuretics 
  
4 History of venous or 
arterial thromboembolism 
and arterial thrombosis 
prescribed combined oral 
contraceptives (Female) 






5a Methotrexate for ≥ 3 
months without a full blood 
count in last 3 months  
 Methotrexate for ≥ 3 
months  
  
5b Methotrexate for ≥ 3 
months without an liver 
function test in last 3 months  
 Methotrexate for ≥ 3 
months  
  
6 Warfarin for ≥ 3 months 
without an international 
normalised ratio (INR) in last 
3 months  
 Warfarin for ≥ 3 months    
7 Lithium for ≥ 3 months 
without a lithium level in last 
3 months  
 Lithium for ≥ 3months    
8 Amiodarone for ≥ 6 months 
without a thyroid function 
test in the last 6 months  
 Amiodarone for ≥ 6 
months 
  
9 Methotrexate without 
instructions to take weekly 
 Patient prescribed 
methotrexate  
  
10 Amiodarone for ≥ 1 month 
at a dose of more than 
200mg/day 
 Amiodarone for ≥ 1 
month  
  
11 Patients with at least one 
prescription problem (a 
combination of outcome 
measures 1, 2, or 4) 
    
12 Patients with at least one 
monitoring problem (a 
combination of outcome 
measures 3, 5, 6, 7, and 8) 
 
 
   
Revised updated outcome measures  
13 Patients aged ≥65 years 
prescribed an oral NSAID 
without co-prescription of an 
ulcer-healing drug 
 Patients aged ≥65 years 
without co-prescription 
of an ulcer-healing drug 
  
14 History of peptic ulcer 
prescribed an anti-platelet 
drug without co-prescription 
of an ulcer-healing drug 
 History of peptic 
ulceration without co-
prescription of an ulcer-
healing drug 
  
15 Prescribed warfarin or 
NOAC in combination with 
an oral NSAID 
 Prescribed warfarin or 
NOAC 
  
16 Prescribed warfarin or 
NOAC and an anti-platelet 
drug in combination without 
co-prescription of an ulcer-
healing drug 
 Prescribed warfarin or 
NOAC without co-
prescription of an ulcer-
healing drug 
  
17 Prescribed aspirin in 
combination with another 
anti-platelet drug without co-
prescription of an ulcer-
healing drug 
 Prescribed aspirin 
without co-prescription 
of an ulcer-healing drug 
  
18 Asthma prescribed a long-
acting beta-2 agonist inhaler 
who is not also prescribed an 
inhaled corticosteroid  




19 Heart failure prescribed an 
oral NSAID  
 Heart failure   
20 Patients aged ≥65 years with 
dementia but not psychosis 
prescribed antipsychotic 
drugs for >6weeks  
 Patients aged ≥65 years 
with dementia but not 
psychosis 
  
21 Patients with an eGFR <45 
prescribed an oral NSAID  
 Patients with an eGFR 
<45 
  
Abbreviations: NSAID=non-steroidal anti-inflammatory drug. PINCER=pharmacist-led information 
technology intervention. ACE=angiotensin converting enzyme. PPI=proton-pump inhibitor. CHD=coronary 




Appendix 11: The RECORD statement – checklist of items, extended from the STROBE statement that should be 
reported in observational studies using routinely collected health data. (Pilot study) 
 Item 
No. 










Title and abstract  
 1 (a) Indicate the study’s design with 
a commonly used term in the title 
or the abstract (b) Provide in the 
abstract an informative and 
balanced summary of what was 
done and what was found 
102 RECORD 1.1: The type of data used 
should be specified in the title or 
abstract. When possible, the name of 
the databases used should be 
included. 
RECORD 1.2: If applicable, the 
geographic region and timeframe 
within which the study took place 
should be reported in the title or 
abstract. 
RECORD 1.3: If linkage between 




study, this should be clearly stated in 




2 Explain the scientific background 
and rationale for the investigation 
being reported 
102   
Objectives 3 State specific objectives, including 
any prespecified hypotheses 
47   
Methods 
Study Design 4 Present key elements of study 
design early in the paper 
103   
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, 
and data collection 
103   
Participants 6 (a) Cohort study - Give the 
eligibility criteria, and the sources 
and methods of selection of 
participants. Describe methods of 
follow-up 
Case-control study - Give the 
103 RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) 
should be listed in detail. If this is not 





eligibility criteria, and the sources 
and methods of case ascertainment 
and control selection. Give the 
rationale for the choice of cases 
and controls 
Cross-sectional study - Give the 
eligibility criteria, and the sources 
and methods of selection of 
participants 
 
(b) Cohort study - For matched 
studies, give matching criteria and 
number of exposed and unexposed 
Case-control study - For matched 
studies, give matching criteria and 
the number of controls per case 
RECORD 6.2: Any validation studies 
of the codes or algorithms used to 
select the population should be 
referenced. If validation was 
conducted for this study and not 
published elsewhere, detailed 
methods and results should be 
provided. 
RECORD 6.3: If the study involved 
linkage of databases, consider use of 
a flow diagram or other graphical 
display to demonstrate the data 
linkage process, including the 
number of individuals with linked 
data at each stage. 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 
Give diagnostic criteria, if 
applicable. 
105 RECORD 7.1: A complete list of 
codes and algorithms used to classify 
exposures, outcomes, confounders, 
and effect modifiers should be 
provided. If these cannot be reported, 






8 For each variable of interest, give 
sources of data and details of 
methods of assessment 
(measurement). 
Describe comparability of 
assessment methods if there is 
more than one group 
106   
Bias 9 Describe any efforts to address 
potential sources of bias 
107   
Study size 10 Explain how the study size was 
arrived at 
107   
Quantitative 
variables 
11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which 
groupings were chosen, and why 
109   
Statistical 
methods 
12 (a) Describe all statistical methods, 
including those used to control for 
confounding 
(b) Describe any methods used to 
examine subgroups and 
interactions 
(c) Explain how missing data were 




(d) Cohort study - If applicable, 
explain how loss to follow-up was 
addressed 
Case-control study - If applicable, 
explain how matching of cases and 
controls was addressed 
Cross-sectional study - If 
applicable, describe analytical 
methods taking account of 
sampling strategy 
(e) Describe any sensitivity 
analyses 
Data access and 
cleaning 
methods 
 ..  RECORD 12.1: Authors should 
describe the extent to which the 
investigators had access to the 
database population used to create the 
study population. 
 
RECORD 12.2: Authors should 
provide information on the data 




Linkage  ..  RECORD 12.3: State whether the 
study included person-level, 
institutional-level, or other data 
linkage across two or more databases. 
The methods of linkage and methods 




Participants 13 (a) Report the numbers of 
individuals at each stage of the 
study (e.g., numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in the 
study, completing follow-up, and 
analysed) 
(b) Give reasons for non-
participation at each stage. 
(c) Consider use of a flow diagram 
115 RECORD 13.1: Describe in detail the 
selection of the persons included in 
the study (i.e., study population 
selection) including filtering based on 
data quality, data availability and 
linkage. The selection of included 
persons can be described in the text 





14 (a) Give characteristics of study 
participants (e.g., demographic, 
clinical, social) and information on 
exposures and potential 




(b) Indicate the number of 
participants with missing data for 
each variable of interest 
(c) Cohort study - summarise 
follow-up time (e.g., average and 
total amount) 
Outcome data 15 Cohort study - Report numbers of 
outcome events or summary 
measures over time 
Case-control study - Report 
numbers in each exposure 
category, or summary measures of 
exposure 
Cross-sectional study - Report 
numbers of outcome events or 
summary measures 
117   
Main results 16 (a) Give unadjusted estimates and, 
if applicable, confounder-adjusted 
estimates and their precision (e.g., 
95% confidence interval). Make 
clear which confounders were 
124   
237 
 
adjusted for and why they were 
included 
(b) Report category boundaries 
when continuous variables were 
categorized 
(c) If relevant, consider translating 
estimates of relative risk into 
absolute risk for a meaningful time 
period 
Other analyses 17 Report other analyses done—e.g., 
analyses of subgroups and 
interactions, and sensitivity 
analyses 
124   
Discussion 
Key results  Summarise key results with 
reference to study objectives 
164   
Limitations 19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias 
167 RECORD 19.1: Discuss the 
implications of using data that were 
not created or collected to answer the 
specific research question(s). Include 
discussion of misclassification bias, 




data, and changing eligibility over 
time, as they pertain to the study 
being reported. 
Interpretation 20 Give a cautious overall 
interpretation of results 
considering objectives, limitations, 
multiplicity of analyses, results 
from similar studies, and other 
relevant evidence 
169   
Generalisability 21 Discuss the generalisability 
(external validity) of the study 
results 
168   
Other Information 
Funding 22 Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the present 
article is based 





   RECORD 22.1: Authors should 
provide information on how to access 
any supplemental information such as 




code programming code. 
From: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD 
Working Committee.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) 
Statement.  PLoS Medicine 2015; in press. *Checklist is protected under Creative Commons Attribution (CC BY) license.
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Appendix 12: Cohort study data collection sheet  
A: demographic and basic information  
Patient characteristics  
Patient code  
Age ____ Years 
Gender  M F 
Nationality  Saudi  Non-Saudi  
Diagnosis or past medical history  
  Anaemia  Back pain  
 Allergic rhinitis  Osteoporosis 
 Benign prostatic hypertrophy 
(BPH) 
 Osteoarthritis 
 Bronchial Asthma  Type 1 diabetes mellitus 
 Chronic Obstructive 
Pulmonary Disease (COPD) 
 Type 2 diabetes mellitus 
 Coronary artery disease 
(CAD) 
 Vitamin D deficiency 
 Depression   Hypertriglyceridemia 
 Essential primary 
hypertension (HTN) 
 Hyperlipidaemia 
 Gastroesophageal reflux 
disease (GERD) 
Other: 
 Heart failure (HF)  
 Hyperthyroidism  
 Hypothyroidism  
 
Polypharmacy at 
any point (≥ 5 
medications) 
Yes No 
OTC medication  Yes No 
 
Physician characteristics  
Physician code  





If the patient had a history of the 
following:  
If the patient was on the following 
medications 
Peptic ulcer – see (outcome 1 and 14) 
Asthma – see (outcome 2a, 18) 
OR Asthma and not coronary heart disease 
(CHD)—see (outcome 2b, 18) 
A female with venous or arterial 
thromboembolism and arterial thrombosis 
– see (outcome 4) 
Patient aged ≥ 65 years – see (outcome 13) 
Patient aged ≥ 65 years with dementia – 
see (outcome 20) 
Heart failure – see (outcome 19)  
eGFR < 45 – see (outcome 21) 
Aged ≥ 75 years and on angiotensin 
converting enzyme (ACE) inhibitors or 
diuretics – see (outcome 3) 
 
Methotrexate – see (outcome 5a, 5b & 9) 
 
Warfarin – see (outcome 6, 15 & 16) 
New Oral Anti-Coagulant (NOAC) – see 
(outcome 15 & 16) 
 
Lithium – see (outcome 7) 
 
Amiodarone – see (outcome 8 &10) 
 




B: outcome measures  




Primary, secondary and composite outcome measures 
1 History of peptic ulcer 
prescribed an non-steroidal 
anti-inflammatory drug 
(NSAID) without a proton-
pump inhibitor (PPI) 
 History of peptic 
ulcer without a PPI 
  
2a Asthma prescribed a β-blocker  Asthma    
2b Asthma and not CHD 
prescribed a β-blocker 
 Asthma and not 
CHD  
  
 3   Aged ≥75 on long term ACE 
inhibitors or diuretics without 
urea and electrolyte monitoring 
in the previous 15 months  





4 History of venous or arterial 
thromboembolism and 
arterial thrombosis prescribed 
combined oral contraceptives 
(Female) 







5a Methotrexate for ≥ 3 months 
without a full blood count in 
last 3 months  
 Methotrexate for ≥ 
3 months  
  
5b Methotrexate for ≥ 3 months 
without an liver function test in 
last 3 months  
 Methotrexate for ≥ 
3 months  
  
6 Warfarin for ≥ 3 months 
without an international 
normalised ratio (INR) in last 3 
months  
 Warfarin for ≥ 3 
months  
  
7 Lithium for ≥ 3 months 
without a lithium level in last 3 
months  
 Lithium for ≥ 
3months  
  
8 Amiodarone for ≥ 6 months 
without a thyroid function test 
in the last 6 months  
 Amiodarone for ≥ 
6 months 
  
9 Methotrexate without 
instructions to take weekly 
 Patient prescribed 
methotrexate  
  
10 Amiodarone for ≥ 1 month at 
a dose of more than 200mg/day 
 Amiodarone for ≥ 
1 month  
  
11 Patients with at least one 
prescription problem (a 
combination of outcome 
measures 1, 2, or 4) 
    
12 Patients with at least one 
monitoring problem (a 
combination of outcome 
measures 3, 5, 6, 7, and 8) 
 
 
   
Revised updated outcome measures  
13 Patients aged ≥65 years 
prescribed an oral NSAID 
without co-prescription of an 
ulcer-healing drug 
 Patients aged ≥65 
years without co-
prescription of an 
ulcer-healing drug 
  
14 History of peptic ulcer 
prescribed an anti-platelet drug 
without co-prescription of an 
ulcer-healing drug 






15 Prescribed warfarin or NOAC 






16 Prescribed warfarin or NOAC 
and an anti-platelet drug in 
combination without co-





prescription of an 
ulcer-healing drug 
  
17 Prescribed aspirin in 
combination with another anti-
platelet drug without co-
prescription of an ulcer-healing 
drug 
 Prescribed aspirin 
without co-
prescription of an 
ulcer-healing drug 
  
18 Asthma prescribed a long-
acting beta-2 agonist inhaler 
who is not also prescribed an 
inhaled corticosteroid  
 Asthma prescribed 
a long-acting beta-2 
agonist inhaler 
  
19 Heart failure prescribed an 
oral NSAID  
 Heart failure   
20 Patients aged ≥65 years with 
dementia but not psychosis 
prescribed antipsychotic drugs 
for >6weeks  
 Patients aged ≥65 
years with 
dementia but not 
psychosis 
  
21 Patients with an eGFR <45 
prescribed an oral NSAID  
 Patients with an 
eGFR <45 
  
Abbreviations: NSAID=non-steroidal anti-inflammatory drug. PINCER=pharmacist-led information technology intervention. 
ACE=angiotensin converting enzyme. PPI=proton-pump inhibitor. CHD=coronary heart disease. INR=international 
normalised ratio. E GFR=estimated Glomerular Filtration Rate. NOAC=New Oral Anti-coagulant.
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Appendix 14: The RECORD statement – checklist of items, extended from the STROBE statement that should be 
reported in observational studies using routinely collected health data. (Cohort study) 
 Item 
No. 










Title and abstract  
 1 (a) Indicate the study’s design with 
a commonly used term in the title 
or the abstract (b) Provide in the 
abstract an informative and 
balanced summary of what was 
done and what was found 
129 RECORD 1.1: The type of data used 
should be specified in the title or 
abstract. When possible, the name of 
the databases used should be 
included. 
RECORD 1.2: If applicable, the 
geographic region and timeframe 
within which the study took place 
should be reported in the title or 
abstract. 
RECORD 1.3: If linkage between 
databases was conducted for the 








2 Explain the scientific background 
and rationale for the investigation 
being reported 
129   
Objectives 3 State specific objectives, including 
any prespecified hypotheses 
47   
Methods 
Study Design 4 Present key elements of study 
design early in the paper 
129   
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, 
and data collection 
129   
Participants 6 (a) Cohort study - Give the 
eligibility criteria, and the sources 
and methods of selection of 
participants. Describe methods of 
follow-up 
Case-control study - Give the 
eligibility criteria, and the sources 
130 RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) 
should be listed in detail. If this is not 
possible, an explanation should be 
provided.  




and methods of case ascertainment 
and control selection. Give the 
rationale for the choice of cases 
and controls 
Cross-sectional study - Give the 
eligibility criteria, and the sources 
and methods of selection of 
participants 
 
(b) Cohort study - For matched 
studies, give matching criteria and 
number of exposed and unexposed 
Case-control study - For matched 
studies, give matching criteria and 
the number of controls per case 
of the codes or algorithms used to 
select the population should be 
referenced. If validation was 
conducted for this study and not 
published elsewhere, detailed 
methods and results should be 
provided. 
RECORD 6.3: If the study involved 
linkage of databases, consider use of a 
flow diagram or other graphical 
display to demonstrate the data 
linkage process, including the number 
of individuals with linked data at each 
stage. 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 
Give diagnostic criteria, if 
applicable. 
132 RECORD 7.1: A complete list of 
codes and algorithms used to classify 
exposures, outcomes, confounders, 
and effect modifiers should be 
provided. If these cannot be reported, 
an explanation should be provided. 
 
Data sources/ 8 For each variable of interest, give 132   
247 
 
measurement sources of data and details of 
methods of assessment 
(measurement). 
Describe comparability of 
assessment methods if there is 
more than one group 
Bias 9 Describe any efforts to address 
potential sources of bias 
133   
Study size 10 Explain how the study size was 
arrived at 
133   
Quantitative 
variables 
11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which 
groupings were chosen, and why 
134   
Statistical 
methods 
12 (a) Describe all statistical methods, 
including those used to control for 
confounding 
(b) Describe any methods used to 
examine subgroups and 
interactions 
(c) Explain how missing data were 
addressed 
134    
248 
 
(d) Cohort study - If applicable, 
explain how loss to follow-up was 
addressed 
Case-control study - If applicable, 
explain how matching of cases and 
controls was addressed 
Cross-sectional study - If 
applicable, describe analytical 
methods taking account of 
sampling strategy 
(e) Describe any sensitivity 
analyses 
Data access and 
cleaning 
methods 
 ..  RECORD 12.1: Authors should 
describe the extent to which the 
investigators had access to the 
database population used to create the 
study population. 
 
RECORD 12.2: Authors should 
provide information on the data 
cleaning methods used in the study. 
134 
Linkage  ..  RECORD 12.3: State whether the - 
249 
 
study included person-level, 
institutional-level, or other data 
linkage across two or more databases. 
The methods of linkage and methods 
of linkage quality evaluation should 
be provided. 
Results 
Participants 13 (a) Report the numbers of 
individuals at each stage of the 
study (e.g., numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in the 
study, completing follow-up, and 
analysed) 
(b) Give reasons for non-
participation at each stage. 
(c) Consider use of a flow diagram 
135 RECORD 13.1: Describe in detail the 
selection of the persons included in 
the study (i.e., study population 
selection) including filtering based on 
data quality, data availability and 
linkage. The selection of included 
persons can be described in the text 





14 (a) Give characteristics of study 
participants (e.g., demographic, 
clinical, social) and information on 
exposures and potential 
confounders 
135   
250 
 
(b) Indicate the number of 
participants with missing data for 
each variable of interest 
(c) Cohort study - summarise 
follow-up time (e.g., average and 
total amount) 
Outcome data 15 Cohort study - Report numbers of 
outcome events or summary 
measures over time 
Case-control study - Report 
numbers in each exposure 
category, or summary measures of 
exposure 
Cross-sectional study - Report 
numbers of outcome events or 
summary measures 
137   
Main results 16 (a) Give unadjusted estimates and, 
if applicable, confounder-adjusted 
estimates and their precision (e.g., 
95% confidence interval). Make 
clear which confounders were 
adjusted for and why they were 




(b) Report category boundaries 
when continuous variables were 
categorized 
(c) If relevant, consider translating 
estimates of relative risk into 
absolute risk for a meaningful time 
period 
Other analyses 17 Report other analyses done—e.g., 
analyses of subgroups and 
interactions, and sensitivity 
analyses 
151   
Discussion 
Key results 18 Summarise key results with 
reference to study objectives 
164   
Limitations 19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias 
168 RECORD 19.1: Discuss the 
implications of using data that were 
not created or collected to answer the 
specific research question(s). Include 
discussion of misclassification bias, 
unmeasured confounding, missing 




time, as they pertain to the study 
being reported. 
Interpretation 20 Give a cautious overall 
interpretation of results 
considering objectives, limitations, 
multiplicity of analyses, results 
from similar studies, and other 
relevant evidence 
170   
Generalisability 21 Discuss the generalisability 
(external validity) of the study 
results 
168   
Other Information 
Funding 22 Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the present 
article is based 






   RECORD 22.1: Authors should 
provide information on how to access 
any supplemental information such as 
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Appendix 16: Fieldwork figures  
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